Note: Descriptions are shown in the official language in which they were submitted.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
1
Dual mode radiotracer and -therapeutics
The present invention relates to compounds that bind to prostate-specific
membrane antigen
(PSMA) comprising a PSMA binding moiety, a linker group comprising a silicon-
fluoride
acceptor (SIFA) moiety and a chelator moiety, optionally containing a chelated
nonradioactive or radioactive cation, wherein the SIFA moiety comprises a
covalent bond
between a silicon and a fluorine atom which can be 18F.
BACKGROUND OF THE INVENTION
Prostate cancer
Prostate Cancer (PCa) remained over the last decades the most common malignant
disease
in men with high incidence for poor survival rates. Due to its overexpression
in prostate
cancer (Silver et al., Clinical Cancer Research 3, 81-85 (1997)), prostate-
specific membrane
antigen (PSMA) or glutamate carboxypeptidase II (GCP II) proved its
eligibility as excellent
target for the development of highly sensitive radiolabelled agents for
endoradiotherapy and
imaging of PCa (Afshar-Oromieh et al., European journal of nuclear medicine
and molecular
imaging 42, 197-209 (2015); Bene ova et al., Journal of Nuclear Medicine 56,
914-920
(2015); Robu et al., Journal of Nuclear Medicine, jnumed. 116.178939 (2016);
Weineisen et
al.; Journal of Nuclear Medicine 55, 1083-1083 (2014); Rowe et al., Prostate
cancer and
prostatic diseases (2016); Maurer et al., Nature Reviews Urology (2016)).
Prostate-specific
membrane antigen is an extracellular hydrolase whose catalytic center
comprises two
zinc(II) ions with a bridging hydroxido ligand. It is highly upregulated in
metastatic and
hormone-refractory prostate carcinomas, but its physiologic expression has
also been
reported in kidneys, salivary glands, small intestine, brain and, to a low
extent, also in
healthy prostate tissue. In the intestine, PSMA facilitates absorption of
folate by conversion
of pteroylpoly-y-glutamate to pteroylglutamate (folate). In the brain, it
hydrolyses N-acetyl-L-
aspartyl-L-glutamate (NAAG) to N-acetyl-L-aspartate and glutamate.
Prostate-specific membrane antigen (PSMA)
Prostate-specific membrane antigen (PSMA) is a type II transmembrane
glycoprotein that is
highly overexpressed on prostate cancer epithelial cells. Despite its name,
PSMA is also
expressed, to varying degrees, in the neovasculature of a wide variety of
nonprostate
cancers. Among the most common nonprostate cancers to demonstrate PSMA
expression
include breast, lung, colorectal, and renal cell carcinoma.
The general necessary structures of PSMA targeting molecules comprise a
binding unit that
encompasses a zinc-binding group (such as urea (Zhou et al., Nature Reviews
Drug
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
2
Discovery 4, 1015-1026 (2005)), phosphinate or phosphoramidate) connected to a
P1'
glutamate moiety, which warrants high affinity and specificity to PSMA and is
typically further
connected to an effector functionality (Machulkin et al., Journal of drug
targeting, 1-15
(2016)). The effector part is more flexible and to some extent tolerant
towards structural
modifications. The entrance tunnel accommodates two other prominent structural
features,
which are important for ligand binding. The first one is an arginine patch, a
positively
charged area at the wall of the entrance funnel and the mechanistic
explanation for the
preference of negatively charged functionalities at the P1 position of PSMA.
This appears to
be the reason for the preferable incorporation of negative charged residues
within the ligand-
scaffold. An in-depth analysis about the effect of positive charges on PSMA
ligands has
been, to our knowledge, so far not conducted. Upon binding, the concerted
repositioning of
the arginine side chains can lead to the opening of an Si hydrophobic
accessory pocket, the
second important structure that has been shown to accommodate an iodo-benzyl
group of
several urea based inhibitors, thus contributing to their high affinity for
PSMA (Barinka et al.,
Journal of medicinal chemistry 51, 7737-7743 (2008)).
Zhang et al. discovered a remote binding site of PSMA, which can be employed
for bidentate
binding mode (Zhang et al., Journal of the American Chemical Society 132,
12711-12716
(2010)). The so called arene-binding site is a simple structural motif shaped
by the side
chains of Arg463, Arg511 and Trp541, and is part of the GOP!! entrance lid.
The
engagement of the arene binding site by a distal inhibitor moiety can result
in a substantial
increase in the inhibitor affinity for PSMA due to avidity effects. PSMA l&T
was developed
with the intention to interact this way with PSMA, albeit no crystal structure
analysis of
binding mode is available. A necessary feature according to Zhang et al. is a
linker unit
(Suberic acid in the case of PSMA l&T) which facilitates an open conformation
of the
entrance lid of GOP!! and thereby enabling the accessibility of the arene-
binding site. It was
further shown that the structural composition of the linker has a significant
impact on the
tumor-targeting and biologic activity as well as on imaging contrast and
pharmacokinetics
(Liu et al., Bioorganic & medicinal chemistry letters 21, 7013-7016 (2011)),
properties which
are crucial for both high imaging quality and efficient targeted
endoradiotherapy.
Two categories of PSMA-targeting inhibitors are currently used in clinical
settings. On the
one side there are tracers with chelating units for radionuclide complexation
such as PSMA
l&T or related compounds (Kiess et al., The quarterly journal of nuclear
medicine and
molecular imaging 59, 241 (2015)). On the other side there are small
molecules, comprising
a targeting unit and effector molecules.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
3
The most often used agents for selective PSMA imaging are PSMA HBED-CC (Eder
et al.,
Bioconjugate chemistry 23, 688-697 (2012)), PSMA-617 (Bene ova et al., Journal
of Nuclear
Medicine 56, 914-920 (2015)) and PSMA l&T (Weineisen et al.; Journal of
Nuclear Medicine
55, 1083-1083 (2014)), which are predominantly labelled with 68Ga (88.9% fr,
E+, max = 1.89 MeV, t%= 68 min). Among these 68Ga-PSMA-HBED-CC (also known as
68Ga-
PSMA-11), is so far considered as the golden standard for PET imaging of PCa.
18F labelling
Recently, several groups have focused on the development of novel 18F-labelled
urea-based
inhibitors for PCa diagnosis. In contrast to the radiometal 68Ga, which can be
obtained from
commercially distributed 68Ge/68Ga radionuclide generators (68Ge;
= 270.8 d), the
radioisotope 18F-fluorine (96.7% fr, Ep+, mõ = 634 keV) requires an on-site
cyclotron for its
production. Despite this limitation, 18F offers due to its longer half-live
(t%= 109.8 min) and its
lower positron energy, significant advantages in terms of routine-handling and
image quality.
Additionally, there is the possibility for largescale production in a
cyclotron, which would be
beneficial for a higher patient throughput and reduction of production costs.
The 18F-labelled
urea-based PSMA inhibitor 18F-DCFPyl demonstrated promising results in the
detection of
primary and metastatic PCa (Rowe et al., Molecular Imaging and Biology, 1-9
(2016)) and
superiority to 68Ga-PSMA-HBED-CC in a comparative study (Dietlein et al.,
Molecular
Imaging and Biology 17, 575-584 (2015)). Based on the structure of PSMA-617,
the 18F-
labelled analogue PSMA-1007 was recently developed, which showed comparable
tumor-to-
organ ratios (Cardinale et al., Journal of nuclear medicine: official
publication, Society of
Nuclear Medicine 58, 425-431 (2017); Giesel et al., European journal of
nuclear medicine
and molecular imaging 43, 1929-1930 (2016)). A comparative study with 68Ga-
PSMA-H BE D-
CC revealed similar diagnostic accuracy of both tracers and a reduced urinary
clearance of
18F-PSMA-1007, enabling a better assessment of the prostate (Giesel et al.,
European
journal of nuclear medicine and molecular imaging 44, 678-688 (2017)).
An attractive approach for introducing 18F labels is the use of silicon
fluoride acceptors
(SI FA). Silicon fluoride acceptors are described, for example, in Lindner et
al., Bioconjugate
Chemistry 25, 738-749 (2014). In order to preserve the silicon-fluoride bond,
the use of
silicon fluoride acceptors introduces the necessity of sterically demanding
groups around the
silicone atom. This in turn renders silicon fluoride acceptors highly
hydrophobic. In terms of
binding to the target molecule, in particular to the target molecule which is
PSMA, the
hydrophobic moiety provided by the silicone fluoride acceptor may be exploited
for the
purpose of establishing interactions of the radio-diagnostic or -therapeutic
compound with
the hydrophobic pocket described in Zhang et al., Journal of the American
Chemical Society
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
4
132, 12711-12716 (2010). Yet, prior to binding, the higher degree of
lipophilicity introduced
into the molecule poses a severe problem with respect to the development of
radiopharmaceuticals with suitable in vivo biodistribution, i.e. low
unspecific binding in non-
target tissue.
Failure to solve the hydrophobicity problem
Despite many attempts, the hydrophobicity problem caused by silicon fluoride
acceptors has
not been satisfactorily solved in the prior art.
To explain further, Schirrmacher E. et al. (Bioconjugate Chem. 2007, 18, 2085-
2089)
synthesized different 18F-labelled peptides using the highly effective
labelling synthon p-(di-
tert-butylfluorosily1) benzaldehyde ([189SIFA-A), which is one example of a
silicon fluoride
acceptor. The SIFA technique resulted in an unexpectedly efficient isotopic
19F-18F
exchange and yielded the 18F-synthon in almost quantitative yields in high
specific activities
between 225 and 680 GBq/pmol (6081-18 378 Ci/mmol) without applying H PLC
purification.
[189SIFA-benzaldehyde was finally used to label the N-terminal amino-oxy (N-
AO)
derivatized peptides AO-Tyr3 -octreotate (AO-TATE), cyclo(fK(AO-N)RGD) and N-
AO-PEG2-
[D-Tyr-Gln-Trp-Ala-Val-Ala-His-Thi-Nle-NH2] (AO-BZH3, a bombesin derivative)
in high
radiochemical yields. Nevertheless, the labelled peptides are highly
lipophilic (as can be
taken from the HPLC retention times using the conditions described in this
paper) and thus
are unsuitable for further evaluation in animal models or humans.
In Wangler C. et al. (Bioconjugate Chem., 2009, 20 (2), pp 317-321), the first
SIFA-based
Kit-like radio-fluorination of a protein (rat serum albumin, RSA) has been
described. As a
labelling agent, 4-(di-tert-butyl[189fluorosily1)benzenethiol (Si[189FA-SH)
was produced by
simple isotopic exchange in 40-60% radiochemical yield (ROY) and coupled the
product
directly to maleimide derivatized serum albumin in an overall ROY of 12%
within 20-30 min.
The technically simple labelling procedure does not require any elaborated
purification
procedures and is a straightforward example of a successful application of Si-
18F chemistry
for in vivo imaging with PET. The time-activity cureves and pPET images of
mice showed
that most of the activity was localized in the liver, thus demonstrating that
the labelling agent
is too lipophilic and directs the in vivo probe to hepatobiliary excretion and
extensive hepatic
metabolism.
Wangler C. et al. (see Bioconjug Chem. 2010 Dec 15;21(12):2289-96)
subsequently tried to
overcome the major drawback of the SIFA technology, the high lipophilicity of
the resulting
radiopharmaceuticals, by synthesizing and evaluating new SI FA-octreotate
analogues
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
(SI FA-Tyr3-octreotate, SI FA-Asn(AcNH-8-G1c)-Tyr3-octreotate and SI FA-
Asn(AcNH-8-G1c)-
PEG-Tyr3-octreotate). In these compounds, hydrophilic linkers and
pharmacokinetic
modifiers were introduced between the peptide and the SIFA-moiety, i.e. a
carbohydrate and
a PEG linker plus a carbohydrate. As a measure of lipophilicity of the
conjugates, the log
5 P(ow) was determined and found to be 0.96 for SIFA-Asn(AcNH-8-G1c)-PEG-
Tyr3-octreotate
and 1.23 for SIFA-Asn(AcNH-8-G1c)-Tyr3-octreotate. These results show that the
high
lipophilicity of the SIFA moiety can only be marginally compensated by
applying hydrophilic
moieties. A first imaging study demonstrated excessive hepatic clearance
/liver uptake and
thus has never been transferred into a first human study.
Bernard-Gauthier et al. (Biomed Res Int. 2014;2014:454503) reviews a great
plethora of
different SIFA species that have been reported in the literature ranging from
small prosthetic
groups and other compounds of low molecular weight to labelled peptides and
most recently
affibody molecules. Based on these data the problem of lipophilicity of SIFA-
based
prosthetric groups has not been solved sofar; i.e. a methodology that reduces
the overall
lipophilicity of a SIFA conjugated peptide to a log D lower than approx. -2,0
has not been
described.
In Lindner S. et al. (Bioconjug Chem. 2014 Apr 16;25(4):738-49) it is
described that
PEGylated bombesin (PESIN) derivatives as specific GRP receptor ligands and
RGD (one-
letter codes for arginine-glycine-aspartic acid) peptides as specific av83
binders were
synthesized and tagged with a silicon-fluoride-acceptor (SIFA) moiety. To
compensate the
high lipophilicity of the SIFA moiety various hydrophilic structure
modifications were
introduced leading to reduced logD values. SIFA-Asn(AcNH-8-G1c)-PESIN, SIFA-
Ser(8-
Lac)-PESIN, SIFA-Cya-PESIN, SIFA-LysMe3-PESIN, SIFA-y-carboxy-d-Glu-PESIN,
SIFA-
Cya2-PESIN, SI FA-LysMe3-y-carboxy-d-Glu-PESI N, SI FA-(y-carboxy-d-Glu)2-
PESIN, SI FA-
RG D, SI FA-y-carboxy-d-Glu-RGD, SI FA-(y-carboxy-d-Glu)2-RGD, SI FA-LysM e3-y-
carboxy-
d-Glu-RGD. All of these peptides ¨ already improved and derivatized with the
aim to reduce
the lipophilicity ¨ showed a logD value in the range between +2 and -1.22.
In Niedermoser S. et al. (J Nucl Med. 2015 Jul;56(7):1100-5), newly developed
18F-SIFA-
and 18F-SIFAlin- (SIFA = silicon-fluoride-acceptor) modified TATE derivatives
were
compared with the current clinical gold standard 68Ga-DOTATATE for high-
quality imaging of
somatostatin receptor-bearing tumors. For this purpose, 18F-SIFA-TATE and two
quite
complex analogues, 18F-SIFA-Glc-PEG1-TATE, 18F-SIFAlin-Glc-Asp2-PEG1-TATE were
developed. None of the agents showed a logD <-1.5.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
6
In view of the above, the technical problem underlying the present invention
can be seen in
providing radio-diagnostics and radio-therapeutics which contain a silicone
fluoride acceptor
and which are, at the same time, characterized by favourable in-vivo
properties.
W02019/020831 and W02020/157184 disclose ligand-SIFA-chelator conjugates.
In the present invention a proof-of-principle has been established using
specific conjugates
which bind with high affinity to prostate-specific membrane antigen (PSMA) as
target.
Accordingly, a further technical problem underlying the present invention can
be seen in
providing improved radio-therapeutics and ¨diagnostics for the medical
indication which is
cancer, preferably prostate cancer.
THE INVENTION
The present disclosure relates to compounds of Formula (la), (lb), (1c) or
(1d):
0 0 0 0
H H H H
N N N N
OH OH
Z R 0 Z R S
0 LCM (la); 0 L __ CM b);
0 H 0
0
0 X yNOH N 0)-LOH
Z R 0 Z R 0
0 L ________ CM (14 OL __ CM (id);
or a pharmaceutically acceptable salt thereof, wherein;
L represents a linker group comprising a silicon-fluoride acceptor (SIFA)
moiety which
comprises a covalent bond between a silicon and a fluorine atom;
CM represents a chelator moiety, optionally containing a chelated
nonradioactive or
radioactive cation;
R1 is H or a 01-3 alkyl group optionally substituted with 1 to 3 fluorine
atoms;
X is selected from OH and an amino acid group;
Z is selected from -V-CO2H, -V-NH2, -V-P03H2, -V-COY, -V-W and a 01-6
saturated or
unsaturated hydrocarbon group optionally substituted with 1 to 3 fluorine
atoms, where Y is
an amino acid, W is a 5- or 6-membered heterocyclic ring, and V is a bond or a
01-3 alkyl
group optionally substituted with 1 to 3 fluorine atoms;
and when the compound is a compound of formula (la) and X is OH, Z is not
CH2002H.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
7
Also provided is a pharmaceutical or diagnostic composition comprising or
consisting of one
or more compounds of Formula (la), (1b), (1c) or (1d). The compounds of the
invention may
be for use as a cancer diagnostic or imaging agent. Accordingly also provided
is a method of
imaging and/or diagnosing cancer comprising administering a compound of
Formula (la),
(lb), (1c) or (1d) or a composition comprising a compound of Formula (la),
(1b), (1c) or (1d).
The compounds or compositions of the invention may be for use in the treatment
of cancer.
The compounds or compositions of the invention may be for use in the
diagnosis, imaging or
prevention of neoangiogenesis/angiogenesis. The compounds or compositions of
the
invention may be for use as a cancer diagnostic or imaging agent or for use in
the treatment
of cancer. The compounds or compositions of the invention may be for use as a
cancer
diagnostic or imaging agent or for use in the treatment of cancer wherein the
cancer is
prostate, breast, lung, colorectal or renal cell carcinoma.
DETAILED DESCRIPTION OF THE INVENTION
The present disclosure relates to compounds of Formula (la), (1b), (1c) or
(1d):
0 0 0 0
H H H H
N N N N
OH OH
Z R 0 Z R S
_________________________________ CM (la); 0 L __ CM b);
0 H 0
0
0 X yNOH N 0)-LOH
Z R 0 Z R 0
0 L __ CM (14 OL __ CM (id);
or a pharmaceutically acceptable salt thereof, wherein;
L represents a linker group comprising a silicon-fluoride acceptor (SIFA)
moiety which
comprises a covalent bond between a silicon and a fluorine atom;
CM represents a chelator moiety, optionally containing a chelated
nonradioactive or
radioactive cation;
R1 is H or a 01-3 alkyl group optionally substituted with 1 to 3 fluorine
atoms;
X is selected from OH and an amino acid group;
Z is selected from -V-CO2H, -V-NH2, -V-P03H2, -V-COY, -V-W and a 01-6
saturated or
unsaturated hydrocarbon group optionally substituted with 1 to 3 fluorine
atoms, where Y is
an amino acid, W is 5- or 6-membered heterocyclic ring, and V is a bond or a
01-3 alkyl
group optionally substituted with 1 to 3 fluorine atoms;
and when the compound is a compound of formula (la) and X is OH, Z is not
CH2002H.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
8
The invention relates to compounds of Formula (la):
0 0
H H 11
N N
xy OH
Z R 0
OL __ CM (la);
or a pharmaceutically acceptable salt thereof, wherein;
L represents a linker group comprising a silicon-fluoride acceptor (SIFA)
moiety which
comprises a covalent bond between a silicon and a fluorine atom;
CM represents a chelator moiety, optionally containing a chelated
nonradioactive or
radioactive cation;
R1 is H or a 01-3 alkyl group optionally substituted with 1 to 3 fluorine
atoms;
X is selected from OH and an amino acid group;
Z is selected from -V-CO2H, -V-NH2, -V-P03H2, -V-COY, -V-W and a C1-6
saturated or
unsaturated hydrocarbon group optionally substituted with 1 to 3 fluorine
atoms, where Y is
an amino acid, W is 5- or 6-membered heterocyclic ring, and V is a bond or a
C1-3 alkyl
group optionally substituted with 1 to 3 fluorine atoms;
and when X is OH, Z is not CH2CO2H.
The compounds of the invention comprise three separate moieties. The three
separate
moieties are a PSMA binding moiety, a linker group (L) comprising a silicon-
fluoride acceptor
(SIFA) moiety and a chelator moiety (CM), optionally containing a chelated
nonradioactive or
radioactive cation, wherein the SIFA moiety comprises a covalent bond between
a silicon
and a fluorine atom which can be 18F.
For diagnostic imaging, the fluorine atom on the SIFA moiety may be 18F. The
18F can be
introduced by isotopic exchange with 19F.
The compounds of the invention require a hydrophilic chelator moiety (CM) in
addition to the
PSMA binding moiety. The hydrophilic chelator moiety (CM) is required to
reduce the
hydrophobic nature of the compounds caused by the presence of the SIFA moiety.
A key
aspect of the invention is the combination, within a single molecule, of a
silicon fluoride
acceptor and a chelator moiety or a chelate. These two structural elements,
SIFA and the
chelator, exhibit a spatial proximity. Preferably, the shortest distance
between two atoms of
the two elements is less or equal 25 A, more preferably less than 20 A and
even more
preferably less than 15 A. Alternatively or in addition, it is preferred that
not more than 25
covalent bonds separate an atom of the SIFA moiety and an atom the chelator,
preferably
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
9
not more than 20 chemical bonds and even more preferably not more than 15
chemical
bonds.
The cation which may be optionally chelated to the chelator moiety may be a
radioactive or
non-radioactive cation. It is preferably a non-radioactive metal cation.
Examples of suitable
cations are provided below.
The compounds of the invention may be radioactively labelled at the SIFA
moiety. Also
included are molecules which are not radiolabelled at all. The chelator moiety
may be either
a complex of a cold (non-radioactive) ion or may be devoid of any ion.
The present inventors surprisingly discovered that placement of the silicone
fluoride acceptor
in the neighbourhood of a hydrophilic chelator such as, but not limited to,
DOTAGA or
DOTA, shields or compensates efficiently the lipophilicity of the SIFA moiety
to an extent
which shifts the overall hydrophobicity of compound in a range which renders
the compound
suitable for in-vivo administration.
A further advantage of the compounds of the present invention is their
surprisingly low
accumulation in the kidneys of mice when compared to other PSMA targeted
radiopharmaceuticals, such as PSMA l&T. Without wishing to be bound by a
particular
theory, it seems to be the combination of the structural element SIFA with a
chelator which
provides for the unexpected reduction of accumulation in the kidneys.
In terms of lipophilicity/hydrophilicity, the logP value (sometimes also
referred to as logD
value) is an art-established measure.
The term "lipophilicity" relates to the strength of being dissolved in, or be
absorbed in lipid
solutions, or being adsorbed at a lipid-like surface or matrix. It denotes a
preference for lipids
(literal meaning) or for organic or apolar liquids or for liquids, solutions
or surfaces with a
small dipole moment as compared to water. The term "hydrophobicity" is used
with
equivalent meaning herein. The adjectives lipophilic and hydrophobic are used
with
corresponding meaning to the substantives described above.
The mass flux of a molecule at the interface of two immiscible or
substantially immiscible
solvents is governed by its lipophilicity. The more lipophilic a molecule is,
the more soluble it
is in the lipophilic organic phase. The partition coefficient of a molecule
that is observed
between water and n-octanol has been adopted as the standard measure of
lipophilicity. The
partition coefficient P of a species A is defined as the ratio P = [A]n-
octanol / [A]water. A figure
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
commonly reported is the logP value, which is the logarithm of the partition
coefficient. In
case a molecule is ionizable, a plurality of distinct microspecies (ionized
and not ionized
forms of the molecule) will in principle be present in both phases. The
quantity describing the
overall lipophilicity of an ionizable species is the distribution coefficient
D, defined as the
5 ratio D = [sum of the concentrations of all microspecies]n_octand / [sum
of the concentrations of
all microspecies]water. Analogous to logP, frequently the logarithm of the
distribution
coefficient, logD, is reported. Often, a buffer system, such as phosphate
buffered saline is
used as alternative to water in the above described determination of logP.
10 If the lipophilic character of a substituent on a first molecule is to
be assessed and/or to be
determined quantitatively, one may assess a second molecule corresponding to
that
substituent, wherein said second molecule is obtained, for example, by
breaking the bond
connecting said substituent to the remainder of the first molecule and
connecting (the) free
valence(s) obtained thereby to hydrogen(s).
Alternatively, the contribution of the substituent to the logP of a molecule
may be
determined. The contribution 7cx x of a substituent X to the logP of a
molecule R-X is defined
as 7cxx = logPR_x¨ logPR_H, wherein R-H is the unsubstituted parent compound.
Values of P and D greater than one as well as logP, logD and 7cx x values
greater than zero
indicate lipophilic/hydrophobic character, whereas values of P and D smaller
than one as
well as logP, logD and 7cx x values smaller than zero indicate hydrophilic
character of the
respective molecules or substituents.
The above described parameters characterizing the lipophilicity of the
lipophilic group or the
entire molecule according to the invention can be determined by experimental
means and/or
predicted by computational methods known in the art (see for example Sangster,
Octanol-
water Partition Coefficients: fundamentals and physical chemistry, John Wiley
& Sons,
Chichester. (1997)).
The logP value of compounds of the invention may be between -5 and -1.5. It is
particularly
preferred that the logP value is between -3.5 and -2Ø
The compounds are preferably high affinity PSMA ligands with preferable
affinity, expressed
as IC50, being below 50 nM, below 20 nM or below 5 nM.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
11
The compounds of the invention may be compounds of Formula (2a), (2b), (2c) or
(2d):
O 0 0 0
H H H H
X
NvN-C XOH NvN-COH
, ,
Z R 0 Z R S
_________________________________ CM (2a); 0 L ______ CM(2b);
O 0 0 0
0 X INIJ-LOH 0j-LOH
Z y
R 0 Z R 0
_________________________________ CM (2c); 0 L ______ CM(2d);
or a pharmaceutically acceptable salt thereof, wherein X, Z, L, CM and R1 are
as defined
herein.
In the compounds herein, R1 can be H or a 01-3 alkyl group optionally
substituted with 1 to 3
fluorine atoms. R1 can be H or a 01-3 alkyl group. R1 can be H or methyl. R1
can be H. R1 can
be methyl.
The compounds of the invention may be compounds of Formula (3a), (3b), (3c) or
(3d):
O 0 0 0
H H H H
Ny N.COH Ny N.COH
0 z2s
OL __ CM (3a); OL _____ CM (3b);
O 0 0 0
0y INI y
,AOH 0j-LOH
0 z20
OL __ CM (3c); OL _____ CM (3d);
or a pharmaceutically acceptable salt thereof, wherein X, Z, L and CM are as
defined herein.
In the compounds herein, X can be OH or an amino acid group. X can be OH. X
can be OH
or -NHCH(06H13)CO2H. X can be -NHCH(06H13)CO2H.
In the compounds herein, Z can be selected from -V-CO2H, -V-NH2, -V-P03H2, -V-
COY, -V-
W and a C1-6 saturated or unsaturated hydrocarbon group optionally substituted
with 1 to 3
fluorine atoms, where Y is an amino acid, W is 5- or 6-membered heterocyclic
ring, and V is
a bond or a C1-3 alkyl group optionally substituted with 1 to 3 fluorine
atoms.
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
12
In the compounds herein, V can be a bond. V can be a 01-3 alkyl group
optionally substituted
with 1 to 3 fluorine atoms. V can be a 01-3 alkyl group. V can be -CH2-. V can
be -CHF-. V
can be -CH2CH2-. V can be -CH2CH2CH2-.
In the compounds herein, W can be a 5-membered heterocyclic ring. W can be a 6-
membered heterocyclic ring. W can be a 5- or 6-membered heterocyclic ring
containing 1 to
4 heteroatom ring members selected from N, 0 and S. W can be a tetrazole ring.
W can be
a furan ring.
In the compounds herein, Y can be an amino acid. Y can be -NHCH(06H13)CO2H. Y
can be -
NHCH(CH2CH3SCH3)CO2H.
In the compounds herein of Formula (la), when X is OH, Z is not CH2002H.
In the compounds herein, X can be -NHCH(06H13)CO2H. X can be -NHCH(06H13)CO2H
and
Z can be CH2002H.
Z can be -CHFCO2H, -CH200NH2, -CH2P03H2, n-butyl, acetylene, furan, -CH2-
tetrazole, -
NHCH(06H13)CO2H, CH2002H or -NHCH(CH2CH2SCH3)CO2H.
The term amino acid or amino acid group as used in relation to groups X and Y,
includes any
amino acid, i.e. any group of formula -NHCHRscCO2H, where Rsc is any amino
acid
sidechain. The amino acid group may be an essential or non-essential amino
acid. The
amino acid group may be arginine, histidine, isoleucine, leucine, lysine,
methionine,
phenylalanine, threonine, tryptophan, valine, alanine, asparagine, aspartic
acid, cysteine,
glutamic acid, glutamine, glycine, proline, serine, tyrosine, or any
derivative thereof.
The compounds of the invention may be compounds of Formula (4a), (4b), (4c),
(4d), (4e),
(4f), (4g), (4h), (4i), (4j), (4k) or (41):
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
13
0 0
O 0 0 H H
H H u
111 11-\LA NyNA0H HO NyNOH
HO y i OH HO E 0
F 0 0
HO 0 LM( 4a); HO 0 o LCM (4b); 0LCM (4c);
0 0
HO
H H H H
O 0 0 0
111y 11- OH
\11
u 11 i
HOyNyNOH Hp Ny 1\1
_ OH 0
0 0
HN NN 0L_CM
CM \ 0
1--CM
0 (4e); µ1\1=1\I
(4f);
O 0 0 H (ii 0 H 0
1 1A ii
HO11 y11 i OH HO yN -OH HO Nycoi-i
s o o
M ,CM
O OH 07.--Lcm (4g); o OH oL
(4h); 0 OH 07.--L (40;
o o
)511 ril 0 0
HO y _ OH NI 1 1- \11
0 HO y i OH
0
oNH CM
-
O 0 NH 0L_CM /0 H H
0 L ?I
0, N Ny N-
OH
OH 0)1 i-
OH H ,
0
OH
S cm
(4j); 1 (4k); 0 OH 0 L- (41);
or a pharmaceutically acceptable salt thereof, wherein L and CM are as defined
herein.
In the compounds herein, the silicon-fluoride acceptor (SIFA) moiety may have
the structure
represented by formula (5):
F
,is / m2S
R
SI
I 3S
R
HNLit'
(5),
wherein Ris and R2s are independently a linear or branched C3_10 alkyl group;
R3s is a C1-20 hydrocarbon group comprising one or more aromatic and/or
aliphatic units;
q is 0 to 3;
and wherein the SIFA moiety is attached to L via the bond marked by AmAmA^ .
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
14
Rls and R2s are independently a linear or branched 03_10 alkyl group.
Preferably Rls and R2s
are selected from isopropyl and tert-butyl, and are more preferably Rls and
R2s are tert-butyl;
R3s is a 01-20 hydrocarbon group comprising one or more aromatic and/or
aliphatic units,
preferably R3s is a 06_10 hydrocarbon group which comprises an aromatic ring;
more
preferably R3s comprises a phenyl ring, and most preferably, R3s is a phenyl
ring wherein the
Si-containing substituent and the amide group are in a para-position. q may be
0, 1, 2 or 3.
Preferably q is 1. The SIFA moiety is attached to the remainder of the
conjugate via the bond
marked by wom.v. in formula (5).
The silicon-fluoride acceptor (SIFA) moiety may have the structure represented
by formula
(5a):
FIVI
Si
HN 0
c?.<6c
(5a),
wherein q is 0 to 3.
The silicon-fluoride acceptor (SIFA) moiety may have the structure represented
by formula
(5b):
)S1)<
HN 0
(7-( (5b).
In the compounds and moieties represented structurally herein F is to be
understood to
encompass both 19F and 18F. The fluorine atom of the silicon-fluoride acceptor
(SIFA) moiety
may be 18F.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
In the compounds herein, a preferred chelating group comprises at least one of
the following
(i), (ii) or (iii):
(i) A macrocyclic ring structure with 8 to 20 ring atoms of which 2 or more,
more preferably 3
or more, are selected from oxygen atoms or nitrogen atoms. Preferably, 6 or
less ring atoms
5 are selected from oxygen atoms or nitrogen atoms. Especially preferred is
that 3 or 4 ring
atoms are nitrogen atoms or oxygen atoms. Among the oxygen and nitrogen atoms,
preference is given to the nitrogen atoms. In combination with the macrocyclic
ring structure,
the preferred chelating group may comprise 2 or more, such as 2 to 6,
preferably 2 to 4,
carboxyl groups and/or hydroxyl groups. Among the carboxyl groups and the
hydroxyl
10 groups, preference is given to the carboxyl groups.
(ii) An acyclic, open chain chelating structure with 8 to 20 main chain (back
bone) atoms of
which 2 or more, more preferably 3 or more are heteroatoms selected from
oxygen atoms or
nitrogen atoms. Preferably, 6 or less back bone atoms are selected from oxygen
atoms or
nitrogen atoms. Among the oxygen and nitrogen atoms, preference is given to
the nitrogen
15 atoms. More preferably, the open chain chelating structure is a
structure which comprises a
combination of 2 or more, more preferably 3 or more heteroatoms selected from
oxygen
atoms or nitrogen atoms, and 2 or more, such as 2 to 6, preferably 2 to 4,
carboxyl groups
and/or hydroxyl groups. Among the carboxyl groups and the hydroxyl groups,
preference is
given to the carboxyl groups.
(iii) A branched chelating structure containing a quaternary carbon atom.
Preferably the
quaternary carbon atom is substituted with 3 identical chelating groups in
addition to the
SIFA/ligand moiety. The substituted chelating groups can comprise an amide.
The
substituted chelating groups can comprise an aromatic group. The substituted
chelating
groups can comprise a hydroxypyridinone.
The chelator moiety may comprise at least one of:
(i) a macrocyclic ring structure with 8 to 20 ring atoms of which 2 or more
are
heteroatoms selected from oxygen atoms and nitrogen atoms;
(ii) an acyclic, open chain chelating structure with 8 to 20 main chain
atoms of which 2 or
more are heteroatoms selected from oxygen atoms and nitrogen atoms; or
(iii) a branched chelating structure containing a quaternary carbon atom.
In preferred specific examples, the chelating group is a residue of a
chelating agent selected
from bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CBTE2a),
cyclohexyl-
1,2-diaminetetraacetic acid (CDTA), 4-(1,4,8,11-tetraazacyclotetradec-1-yI)-
methylbenzoic
acid (C PTA), N'45-[acetyl(hydroxy)amino]penty1]-N45-[[445-aminopentyl-
(hydroxy)amino]-4-
oxobutanoyl]amino]pentyl]-N-hydroxybutandiamide (DFO),
4,11-bis(carboxymethyl)-
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
16
1,4, 8, 11-tetraazabicyclo[6 .6 .2]hexadecan (DO2A) 1,4, 7, 10-
tetracyclododecan-N , N', N", Nm-
tetraacetic acid (DOTA),
a-(2-carboxyethyl)-1,4, 7, 10-tetraazacyclododecane-1, 4 ,7, 10-
tetraacetic acid (DOTAGA), 1,4,7,10 tetraazacyclododecane N, N', N", N"
1,4,7,10-
tetra(methylene) phosphonic acid (DOTMP), N, N'-dipyridoxylethylendiamine-N,
N'-diacetate-
5,5'-bis(phosphat) (DPDP), diethylene triamine N,N',N" penta(methylene)
phosphonic acid
(DTMP), diethylenetriaminepentaacetic acid (DTPA), ethylenediamine-N, N'-
tetraacetic acid
(EDTA), ethyleneglycol-0,0-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid
(EGTA), N,N-
bis(hydroxybenzy1)-ethylenediamine-N,N'-diacetic acid (H BED),
hydroxyethyldiaminetriacetic
acid (HEDTA), 1-(p-n itrobenzyI)-1, 4 ,7, 10-tetraazacyclodecan-4,7,10-
triacetate (HP-D0A3),
6-hydrazinyl-N-methylpyridine-3-carboxamide (HYN IC), tetra 3-hydroxy-
N-methy1-2-
pyridinone chelators
(44(4-(3-(bis(2-(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridine-4-
carboxamido)ethyl)amino)-2-((bis(2-(3-hydroxy-1-methyl-2-oxo-1,2-
dihydropyridine-4-
carboxamido)ethyl)amino)methyl)propyl)phenyl)amino)-4-oxobutanoic acid),
abbreviated as
Me-3,2-HOPO, 1,4,7-triazacyclononan-1-succinic acid-4,7-diacetic acid
(NODASA), 1-(1-
carboxy-3-carboxypropyI)-4,7-(carbooxy)-1,4,7-triazacyclononane (NODAGA),
1,4,7-
triazacyclononanetriacetic acid (NOTA),
4, 11-bis(carboxymethyl)-1, 4 ,8, 11-
tetraazabicyclo[6 .6.2]hexadecane (TE2A),
1,4,8, 11-tetraazacycl ododecane-1, 4 ,8, 11-
tetraacetic acid (TETA), tris(hyd roxypyridi none)
(THP), terpyridin-
bis(methyleneamintetraacetic acid (TMT),
7-tris[methylene(2-
phosphi n ic acid] (TRAP), 1,4,7, 10-tetraazacyclotridecan-N, N', N", N"-
tetraacetic
acid (TRITA), 34[4,7-bis[[2-carboxyethyl(hydroxy)phosphoryl]methy1]-1,4,7-
triazonan-1-
yl]methyl-hydroxy-phosphoryl]propanoic acid, and
triethylenetetraaminehexaacetic acid
(TTHA), which residue is provided by covalently binding a carboxyl group
contained in the
chelating agent to the remainder of the conjugate via an ester or an amide
bond.
The chelator moiety may be 1,4,7,10-tetracyclododecan-N,N',N",N"-tetraacetic
acid (DOTA)
or a-(2-carboxyethyl)-1,4, 7, 10-tetraazacyclododecane-1, 4 ,7, 10-tetraacetic
acid (DOTAGA).
Particular chelators are shown below:
HO
f." OH HO 0
N N'Th( HO / \)
o C CNN
)L
,NN 0 C
HO N
oS-\ \4
OH
OH OH
DOTA
DOTAGA
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
17
/COON
HO(.
o) ) ,r)
OOP¨OH 0 /.40H
0
"P
õ¨A-1s
( 'OH
N N I
OH C
5A-1 CN I N N OH
p-1 HO j¨ ____
H HO > OOC¨rg HO¨Pi H=0 0
0
1/4.'"'".-
COON OH
TRAP
DOTPI
HO-
0O2H
=
(We)
N
HO2C N L--.1 \--CO2H
NOTA
THP
Of
HBED Me-3,2-HOPO
Among the above exemplary chelating agents, particular preference is given to
a chelating
agent selected from TRAP, DOTA and DOTAGA.
Metal- or cation-chelating macrocyclic and acyclic compounds are well-known in
the art and
available from a number of manufacturers. While the chelating moiety in
accordance with the
present invention is not particularly limited, it is understood that numerous
moieties can be
used in an off-the-shelf manner by a skilled person without further ado.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
18
The chelating group may comprise a chelated cation which may be radioactive or
non-
radioactive, preferably a chelated metal cation which may be radioactive or
non-radioactive.
The chelating group may comprise a chelated cation which is radioactive. The
chelating
group may comprise a chelated cation which is non-radioactive.
Especially preferred is that CM represents a chelating agent selected from
DOTA and
DOTAGA bound with one of its carboxylic groups via an amide bond to the
remainder of the
conjugate.
In order to be used in PET imaging, the compounds require a positron emitting
atom. The
compounds include 18F for medical use. Most preferred compounds of the
invention are
wherein F includes 18F and CM comprises a nonradioactive metal cation.
Preferred examples of cations that may be chelated by the chelating group are
the non-
radioactive cations of Sc, Cr, Mn, Co, Fe, Ni, Cu, Ga, Zr, Y, Tc, Ru, Rh, Pd,
Ag, In, Sn, te,
Pr, Pm, Tb, Sm, Gd, Tb, Ho, Dy, Er, Yb, Tm, Lu, Re, Pt, Hg, Au, Pb At, Bi, Ra,
Ac, Th; more
preferably the cations of Sc, Cu, Ga, Y, In, Tb, Ho, Lu, Re, Pb, Bi, Ac, Th
and Er. The cation
may be Ga. The cation may be Lu.
The chelator moiety may contain a chelated cation or cationic species selected
from the
cations of 435c, 445c, 475c, 51Cr, 52mMn, 58Co, 52Fe, 56Ni, 57Ni, 62Cu, 64Cu,
67Cu, 66Ga, 67Ga
68Ga, 89Zr, 90Y, 89Y, <Tc, 99mTc, 97Ru, 105Rh, 109pd, iiiAgliomin, 1111n,
3min, 4min, 117msn,
1215n, 127Te, 142pr, 143pr, 149pm, 151pm, 149Tb, 152Tb, 155Tb, 161Tb, 1535m,
157Gd, 161Tb, 166H0,
165Dy, 169E1-, 169yb, 175yb, 172Tm, 177Lu, 186Re, 188Re, 191 Pt, 197Fig,
198Au, 199Au, 212pb, 203pb,
2iiAt,212Bi,213Bi, 223Ra, 225Ab,
n a cationic molecule comprising 18F or a cation such as
187
.
I- [A192+; more preferably the cations of 445c, 475c, 64Cu, 67Cu, 68Ga, 90Y,
ln, 161Tb, 166H0,
177Lu, 188Re, 212pb,212Bi,213Bi, 225/AC. -,
and 227Th or a cationic molecule comprising 18F.
The chelator moiety may contain a chelated cation selected from the cations of
435c, 445C,
475C, 64CU, 67CU, 67Ga, 68Ga, 90Y, ln,
149Tb, 1521-b, 1551-b, 161-b, 166H0, 177Lu, 186Re,
188Re,212pb,212Bi,213Bi, 225/AC. -,
and 227Th or a cationic molecule comprising 18F. The chelator
moiety may contain a chelated cation selected from the cations of 68Ga or
177Lu. The chelator
moiety may contain a chelated 68Ga cation. The chelator moiety may contain a
chelated
177Lu cation.
In the compounds herein, the group -L-CM may be:
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
19
SIFA
I B 2
N-Q-R-u-uM
wherein Q1 is a divalent linking group with a structure selected from an
oligoamide, an
oligoether, an oligothioether, an oligoester, an oligothioester, an oligourea,
an oligo(ether-
amide), an oligo(thioether-amide), an oligo(ester-amide), an oligo(thioester-
amide),
oligo(urea-amide), an oligo(ether-thioether), an oligo(ether-ester), an
oligo(ether-thioester),
an oligo ether-urea), an oligo(thioether-ester), an oligo(thioether-
thioester), an
oligo(thioether-urea), an oligo(ester-thioester), an oligo(ester-urea), and an
oligo(thioester-
urea), wherein Q1 is optionally substituted with one or more substituents
independently
selected from ¨OH, -OCH3, -CH2OH, -CO2H, ¨CO2CH3, -N H2, -CH2NH2 and -
NHC(NH)NH2;
Q2 is selected from an amide bond, an ether bond, a thioether bond, an ester
bond, a
thioester bond, a urea bridge, an amine bond and linking groups of the
formula:
0
0
1LINH
N \C NH
= =
RB is a trivalent coupling group;
and SI FA is the silicon-fluoride acceptor moiety.
In the compounds herein, -Q1- can be selected from:
-R8-NH-C(0)-R9-C(0)-NH-R19-NH-C(0)-
-R8-NH-C(0)-R9-N H-C(0)-R19-N H-C(0)-R11-N H-C(0)-
wherein R6, R7, R8, R9, R19 and R11 are independently Ci_io alkyl, which alkyl
groups
may each be substituted by one or more substitutents independently selected
from ¨
OH, -OCH3, -CH2OH, -CO2H, ¨CO2CH3, -N H2, -CH2NH2 and -NHC(NH)NH2.
-Q1- can be selected from:
-CH(000H)-R13-NH-C(0)-R14-C(0)-NH-R16-CH(000H)-NH-C(0)-
-CH(000M-R13-NH-C(0)-R14-NH-C(0)-R15-NH-C(0)-CH(CH2OH)-NH-C(0)-
wherein R13, R14 and R15 are independently 01-6 alkyl.
In the compounds herein, -Q2- can be -NH-, -NH-C(0)-, -NH-C(0)-CH2-, -NH-C(0)-
CH2CH2-
or -NH-C(0)-CH2CH2-CH(000H)-. -Q2- can be -NH-.
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
In the compounds herein RB may be:
SIFA
_______________________________________________________ (CH 2)a A (CH2)b
wherein:
A is selected from N, CR16, wherein R16 is H or 01_6 alkyl, and a 5 to 7
membered carbocyclic
5 or heterocyclic group; preferably A is selected from N and CH, and more
preferably A is CH;
the bond marked by AmAmA^ at (CH2), is formed with Q1, and a is an integer of
0 to 4,
preferably 0 or 1, and most preferably 0; and
the bond marked by AmAmA^ at (CH2)b is formed with Q2, and b is an integer of
0 to 4,
preferably of 0 to 2, and most preferably 0.
RB can be:
SIFA
In the compounds herein, the group L-CM may be selected from:
0 0
OH 0
0
>Si
NH
HO 0
0 011 H
1\1y)LNI\12.NI.chA
H =
OH 0
0
>Si
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
21
rrNH 0 HO 0
On H
H
0,õ. 1\1y)LNI\12.N.chii
1 =
OH 0 H HHI\I
0
S iI.
F18 =
,
rrNH 01-8
H H H H
N
I\1)N'CM
H
OH 0 0 0
HI\I
>)Si I. 0
F
'
rrNH 01-8
H H Iiily( _ H
I\1)N'CM
1 H =
OH 0 0 0
HI\I
>Si I. 0
F =
,
rrNH 01-8
H H Iiily( _ H
I\1)N'CM
1 H =
OH 0 0 0
HI\I
S i
0
18 I.
F
=
In the compounds herein, CM may be selected from:
HO,...õ;,0 Fici HO 0 Fici
HO 0
\)
's.d \N 's.d \N rrY.1\1/ N
0 C 0 C 0 C
N NiC4) N NiC4) N NiC4)
oS'" OH
oS'O" OH
. oS'" OH
OH H OH
= =
, ,
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
22
HOO 071 HOO 0.-lo
N/ \N NI/ \N (1\1/ \N
0 C Lu3+ 0 C Lu3+ 0 C Lu3+
N N-\11.1? N N-\11.1? N N-\1114)
oS: - / 0
. S-\ / 0-
0 0 o 0
=
' .
In the compounds herein, the group L-CM may be selected from:
HOO 0 HO-- 0
`s(NH
H 0 E II 1:1. /--\ )
N
H H ) o(
OH 0 HN ) 0
(N N\
\I 0 0
().- OH OH
F
= ,
o----.0
HOO n
`s(NH H 0 ri H
(:),..1\11.r.ANNNIr= /--\ )
N
OH 0 HN
N
. 0 0
s, ?- -
F
.
,
HOO 0 1 HO-40
`s(NH 0
E )LF1
(Dy'..7\71i\11)HLI\IN : N N..,õi
H H ) o(
OH 0 HN ) 0
N N\___/4
)L i c \/ OH
0 0,0H
S
F184..
= ,
o----.0
HOO n
`s(NH H 0 ri H
(:),..1\11.r.ANNNIr= /--\ )
N
OH 0 HN O L LU3+ ) 0
N N\___/4
C \__/ _
. 0
s, ?-0-
F184..
,
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
23
HOO HOO H04)
NH 0 H
H)LI\INN- N/ ____________________________________________________ \NL
1 H
OH 0 H i 0 C
FINK
N 0
0
S...._\ / N\-----OH
-Si 0 OH
F
= ,
HOO HOO 0.:,
riNH 0 '-- Om H
H - / 0
1 H
OH 0 HI-INKi 0 C Lu3+
N N /5)
0 0
S: - / \-----j* -
0
>Si I O
F
= ,
HOO HOO H04)
NH 0 H
Hy)LNINN- N/ ____________________________________________________ \NL
1 H
OH 0 H i 0 C
FMK
N N /5)
0
S...._\ / \--j*OH
-Si 0 OH
F 1 8/
= ,
HOO HOO 0.:,
riNH 0 '-- Om H
H - / 0
1 H
OH 0 HI-INKi 0 C Lu3+
N N /5)
0 0
S: - / \-----j* -
0
>Si I O
F18
1 8/
=
,
A NH OF-8 HO10
H H H )111ii N I\H
Oy..N1.(NI.rk11.(CN z
OH 0 0 0 H ) HN o(
) 0
N N\____k
oOH
/
OH
s'
S
, 1
F"
.
,
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
24
010
ANH 011)
H H H )11-\II
N
OH 0 0 0 H ) HN Lu 0 C 3+
D 0
N N\ __14
\I 0 0
(-IC \¨/ - 0-
F
,
0
ANH 0110 HO1
H H H i H
oy=Ls,,,--..,,,,N...i.r..õ,-N.I.Ny( N
N z )r=N N
OH 0 0 0 H ) 0 C
HN ) 0
N N\ __J4
C \__/
)L ' 0 "-OH OH
F184....
,
o-10
ANH 011)
N N
OH 0 0 0 H ) 0 C +
HN Lu3 D 0
s...N N\_/4
' . o
o-
0
0
?8L1
F .
The term "oligo" as used in oligoamide, oligoether, oligothioether,
oligoester, oligothioester,
oligourea, oligo(ether-amide), oligo(thioether-amide), oligo(ester-amide),
oligo(thioester-
amide), oligo(urea-amide), oligo(ether-thioether), oligo(ether-ester),
oligo(ether-thioester),
oligo (ether-urea), oligo(thioether-ester), oligo(thioether-thioester),
oligo(thioether-urea),
oligo(ester-thioester), oligo(ester-urea), and oligo(thioester-urea) is
preferably to be
understood as referring to a group wherein 2 to 20, more preferably wherein 2
to 10 subunits
are linked by the type of bonds specified in the same terms. As will be
understood by the
skilled reader, where two different types of bonds are indicated in brackets,
both types of
bonds are contained in the concerned group (e.g. in "oligo (ester-amide)",
ester bonds and
amide bonds are contained).
It is preferred that L1 comprises a total of 1 to 5, more preferably a total
of 1 to 3, and most
preferably a total of 1 or 2 amide and/or ester bonds, preferably amide bonds,
within its
backbone.
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
The term oligoamide therefore describes a moiety having a chain of CH2 or CHR
groups
interspersed with groups selected from NHCO or CONH. Each occurrence of the R
moiety is
an optional substituent selected from ¨OH, -OCH3, -CH2OH, -CO2H, ¨CO2CH3, -
NH2, -
CH2NH2and -NHC(NH)NH2.
5 In the compounds herein, the chelated nonradioactive or radioactive
cation of the chelator
moiety may be chelated to one or more coa groups. The chelated nonradioactive
or
radioactive cation of the chelator moiety may be chelated to one or more N
atoms. The
chelated nonradioactive or radioactive cation of the chelator moiety may be
chelated to one
or more N atoms or one or more COO- groups. The chelated nonradioactive or
radioactive
10 cation of the chelator moiety may be chelated to one or more N atoms and
one or more
COO- groups. Where the chelated nonradioactive or radioactive cation is shown,
the acid
groups to which it is chelated are merely representatively shown as COO-.
The compound may be selected from:
0 0
HO5)\IIy 11¨\LA
i OH
F 0
0
HO 0 HO--
HOO ONH 0
1-11(A 0 H
On
NI\r !N)rN N
is H H i 0 C
OH 0 HIV' ) 0
)Lsi. 0 0
OH
OH
0
F
,
0 0
HOc11 11¨\11JL
y i OH
0
0
HO 0 HO--
HCAO ONH 0
1-11(A 0 H
NI\r !N)rN N
is H H i 0 C
OH 0 HIV' ) 0
)L 0 (N\ 7\ j4 si. 0
OH
'--.
0 0H
F
,
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
26
oH I-1 0i[
HO NyNOH
0
O NH H 0 HO O0 0
H HO--o
NN)cN
1' H -
H ) 0 CN
Ns'i
OH 0 HN
N N\")
Si
4 0 C \__/c
OH
rOH
F ;
OH H 0
HO,NyN 1[N, OH
0
0
HO O0
HO--
O NH H 0 .. 0 H
NN)cN
= 1' H
H ) 0 CN
Ns'i
OH 0 HN
N N\")
Si
4 0 C \__/c
OH
rOH
F ;
O El H 0
HO NyNN.,AOH
c----. it'
\ 0 0 HO 0 HO --e
O NH H 0 0 H
O,..NI.r..ANNI)cNNi--\N)
1' H H ) 8 C
OH 0 HN
N N.j"
Si
4 0
OH
crOH
F ;
O 0
INI INJL
HO y OH
0
HN NN 0 NH H 0 HO0 0 H HO--e
: i--\ )
N=N N )N, /N
N.,..1
1' N
H H , If
OH 0 ) 0 C
HN
N N\")
Si
4 0 C \__/c
OH
rOH
F
;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
27
ON 0
INI
HO y JL OH
S
O OH 0 NH H 0 HO 0 0 H HO--e
: i--\ )
(3',===/\/1\11r\ANN)L/N
Is H H N N-.1
OH 0 ) 0 C
HN
N N")
Si
4 0 C \__/o
"OH
OH
OH
F ;
ON
0
C31A
HO y OH
0
O OH 0 NH H 0 HO 0 0 H HO--e
: i--\ )
(3',===/\/N1r\ANN)L/N
Is H H N N-.1
OH 0 ) 0 C
HN
N N")
Si
4 0 C \__/o
"OH
OH
OH
F ;
O H 0 1\
0 k.
HO y 11OH
0
O OH 0 NH H 0 HO 0 0 H HO--e
: i--\ )
(3',===/\/N1r\ANN)L/N
Is H H N N-.1
OH 0 ) 0 C
HN
N N")
Si
4 0 ( \__/o
"OH
OH
OH
F ;
ON 0
INI
HO y JL OH
0
O NH 0 NH 0 HO 0 0 H HO--e
H --\
C) (3',===/\/N1r\ANN i )
H
)L/N
Is H N N-.1
OH OH 0 ) 0 C
HN
N N")
4 C /
o".-OH OH
Si
F ;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
28
H 0
1 11-\11JL
HO y i OH
0
HO 0 HO--o
0 NH ONH H 0 0 H
C) NN N N.
).N
1' H H
OH OH 0 HN
S N N\_/4)
I
)LS=I = o oS-OH OH
FA
,
/
/
0 H 0
0 ' ENI Nj-
N y , OH
OHH r 0
0
HO, 0 HO
0NH 0 --- Foi H 1 \I
00H H
/
, N N-___
I H H E 6 C
OH 0 1-11\I
N <14)
0
S-\0H _____________________________________________________________ / OH
>Si Si 0
F
;
or a pharmaceutically acceptable salt thereof, wherein the fluorine atom is
optionally 18F and
wherein the chelator moiety is optionally coordinated to Lu3+.
The compound may be selected from:
0 0
lil 11-\11JL
HO y i OH
F 0
o-...0
HO 0 ONH H HO 00 0 H
)
0.,..1...,......--...õ.õ,N,Irjt,Nw...c...N,Ntr..,Nr-\N
-1. H H :
OH 0 HN O
Si = N N\
C /
1- -
0
0 0
F .
'
CA 03207132 2023-07-04
PCT/EP2022/050090 WO 2022/144467
29
0
0
INIJL y E OH
HO
0
HO 0 0---)
HO 0 0 NH H 0 0 H
O ,..t.,õ,.0-..õõ...Nt,NN,...IL:õ..Ny-..õ
is H
N N
OH 0 0 L
LU3+ )
HN 0
_ 4 N N \___/4
= 0
Si
F .
,
0
H H 011
HO NH NyNOH
0
O H 0 HO 0
0 H 0---)
0.,..t.,õ.õõ...Nt.N,...c.N,ir.õ
is H H : N N
HN N
OH 0 Si 0 L
LU3+ )
0
4
= 0
F ;
0
H H 011
O,NyNOH
H
0
/,,..
HO 00 H
0---f
O NH H 0
O.,..t.,õ.õõ...Nt.N,...c.N,ir.õ
is H N N
OH 0 " % L
Lu3+ )
HN 0
4 N
= 0
Si
F .
,
0
H H 0
HO NyN11OH
---..
\ 0 0
HO,s0 0 0-
O NH H 0 ___ H __ / \I
0,,.1...õ.......---..õ,.NI.Ht.N ...-ww-LN.,,c.----., /
H N N....,
1 H H = :!. r
O 0 He u LU3+
N
H
0 ___________________ / \---j'ko_
>Si 0
F--- 0
,
CA 03207132 2023-07-04
PCT/EP2022/050090 WO 2022/144467
O 0
,Ill INIJL y OH
HO
0
HO 0 0----,)
0 NH 0 0 H
H
i\I=N1 0.,..,N11.r.ANN)cNI.r=
1. H H : N N
HN NN
OH 0 0 L LU3+ )
HN
N
4 S
Si 0
0 0-
F .
,
O 0
,Ill INIJL
HO y OH
S
HO 0 0----,)
)
O OH 0 NH H 0 0 H
0. ,..icNy-..õ /--\
1. H H : N N
LU3+ )
HN
N
4 S
Si 0
0 0-
F .
,
O H 0
)5,N 0.A
y OH
HO
0
HO 0 0----,)
)
O OH 0 NH H 0 0 H
,...c.N,ir..õ /--\
1. H H : N N
LU3+ )
HN
N
4 S
Si 0
0 0-
F ;
O H 0
)5,0 1\1=A
y OH
HO
0
HO 0 0----,)
O OH 0 NH H 0 0 H
)
0.,..L.,,,,-,....õNõTHLN.,---õ,,.--N,...c.N,ir..õ /--\
1. H H : N N
LU3+ )
HN
N
4 S
Si 0
0 0-
F ;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
31
H 0
1 11-\11JL
HO y i OH
0
0=4
O NH ONH H HO 0 0 0 H
O) I\i N N
N).(Ny
1' H H :
OH OH 0 HN 0 L Lu" ) 0
N N\
= = o
o0- 0
)LSI
FA
,
0 0
111 11-\11JL
HO y i OH
0
o:40
O NH ONH H HO 00 0 H
C) NNN I\i N N
).(Ny
1' H H :
OH OH 0 HN L Lu" ) 0
S
I
= = o N N\
0-
)LSI ?-. _
FA
,
H H 0
N y i OH
' H
OH 0
O
HO 0
0 OH NH
O H 0 0 H
)
0),.===N)HLNilli i ) TNN N
H
OH 0 HN 0
)LS= =
N\_/4 _
I
F-A
,
or a pharmaceutically acceptable salt thereof, wherein the fluorine atom is
optionally 18F.
5
Preferred labelling schemes for these most preferred compounds are as defined
herein
above.
Also provided is a compound [177Lu]Lu-PSMA-1 0 ([177Lu]Lu-1 below),
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
32
0 0
HOtj-\1y1 11-\LA
OH
0
HO 00
O ONH 0 LH
)
OH 0 H 0
71\j4
)LS. = 0
I 0
Compound [177Lu]Lu-PSMA-10 is the Lutetium 177 chelate of PMSA 10 shown below,
(D) 0
1 iSiL
)
HC OH
0
HO 0
0 OH C "NH 0 0
CL(19
N N Irsht )
On 0 0 (
µ-'14
HO
HO
0
PSMA-10 (1)
Also provided is a pharmaceutical imaging composition comprising or consisting
of one or
more compounds of the invention as disclosed herein above.
Also provided is a diagnostic composition comprising or consisting of one or
more
compounds of the invention as disclosed herein above.
The pharmaceutical composition may further comprise pharmaceutically
acceptable carriers,
excipients and/or diluents. Examples of suitable pharmaceutical carriers,
excipients and/or
diluents are well known in the art and include phosphate buffered saline
solutions, water,
emulsions, such as oil/water emulsions, various types of wetting agents,
sterile solutions etc.
Compositions comprising such carriers can be formulated by well-known
conventional
methods. These pharmaceutical compositions can be administered to the subject
at a
suitable dose. Administration of the suitable compositions may be effected in
different ways,
e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical,
intradermal,
intranasal or intrabronchial administration. It is particularly preferred that
said administration
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
33
is carried out by injection and/or delivery, e.g., to a site in the pancreas
or into a brain artery
or directly into brain tissue. The compositions may also be administered
directly to the target
site, e.g., by biolistic delivery to an external or internal target site, like
the pancreas or brain.
The dosage regimen will be determined by the attending physician and clinical
factors. As is
well known in the medical arts, dosages for any one patient depends upon many
factors,
including the patient's size, body surface area, age, the particular compound
to be
administered, sex, time and route of administration, general health, and other
drugs being
administered concurrently. Pharmaceutically active matter may be present in an
effective
therapeutic amount, which may be between 0.1 ng and 10 mg/kg body weight per
dose;
however, doses below or above this exemplary range are envisioned, especially
considering
the aforementioned factors.
Also provided is one or more compounds of the invention as disclosed herein
above for use
in diagnostic medicine.
Preferred uses in medicine are in nuclear medicine such as nuclear diagnostic
imaging, also
named nuclear molecular imaging, and/or targeted radiotherapy of diseases
associated with
an overexpression, preferably of PSMA on the diseased tissue.
Also provided is a compound of the invention as defined herein above for use
in a method of
diagnosing and/or staging cancer, preferably prostate cancer. Prostate cancer
is not the only
cancer to express PSMA. Nonprostate cancers to demonstrate PSMA expression
include
breast, lung, colorectal, and renal cell carcinoma. Thus, any compound
described herein
having a PSMA binding moiety can be used in the diagnosis, imaging or
treatment of a
cancer having PSMA expression.
Preferred indications are the detection or staging of cancer, such as, but not
limited high
grade gliomas, lung cancer and especially prostate cancer and metastasized
prostate
cancer, the detection of metastatic disease in patients with primary prostate
cancer of
intermediate-risk to high-risk, and the detection of metastatic sites, even at
low serum PSA
values in patients with biochemically recurrent prostate cancer. Another
preferred indication
is the imaging and visualization of neoangiogensis.
Also provided is a compound of the invention as defined herein above for use
in a method of
diagnosing and/or staging cancer, preferably prostate cancer.
Also provided is a pharmaceutical or diagnostic composition comprising or
consisting of one
or more compounds of Formula (la), (1b), (1c) or (1d). The compounds of the
invention may
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
34
be for use as a cancer diagnostic or imaging agent. Accordingly also provided
is a method of
imaging and/or diagnosing cancer comprising administering a compound of
Formula (1a),
(lb), (1c) or (1d) or a composition comprising a compound of Formula (1a), (1
b), (1c) or (1d).
The compounds or compositions of the invention may be for use in the treatment
of cancer.
The compounds or compositions of the invention may be for use in the
diagnosis, imaging or
prevention of neoangiogenesis/angiogenesis. The compounds or compositions of
the
invention may be for use as a cancer diagnostic or imaging agent or for use in
the treatment
of cancer. The compounds or compositions of the invention may be for use as a
cancer
diagnostic or imaging agent or for use in the treatment of cancer wherein the
cancer is
prostate, breast, lung, colorectal or renal cell carcinoma.
The term "treatment", in relation to the uses of any of the compounds
described herein,
including those of Formula (1a), (1 b), (1c) and (1d) is used to describe any
form of
intervention where a compound is administered to a subject suffering from, or
at risk of
suffering from, or potentially at risk of suffering from the disease or
disorder in question.
Thus, the term "treatment" covers both preventative (prophylactic) treatment
and treatment
where measurable or detectable symptoms of the disease or disorder are being
displayed.
The term "effective therapeutic amount" (for example in relation to methods of
treatment of a
disease or condition) refers to an amount of the compound which is effective
to produce a
desired therapeutic effect.
Terms such as "alkyl", "hydrocarbon" and "heterocyclic" are all used in their
conventional
sense (e.g. as defined in the IUPAC Gold Book), unless indicated otherwise.
"optionally
substituted" as applied to any group means that the said group may if desired
be substituted
with one or more substituents, which may be the same or different.
To the extent that any of the compounds described have chiral centres, the
present invention
extends to all optical isomers of such compounds, whether in the form of
racemates or
resolved enantiomers. The invention described herein relates to all crystal
forms, solvates
and hydrates of any of the disclosed compounds however so prepared. To the
extent that
any of the compounds disclosed herein have acid or basic centres such as
carboxylates or
amino groups, then all salt forms of said compounds are included herein. In
the case of
pharmaceutical uses, the salt should be seen as being a pharmaceutically
acceptable salt.
Salts or pharmaceutically acceptable salts that may be mentioned include acid
addition salts
and base addition salts as well as salt forms arising due to the presence of
the chelated
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
nonradioactive or radioactive cation. Such salts may be formed by conventional
means, for
example by reaction of a free acid or a free base form of a compound with one
or more
equivalents of an appropriate acid or base, optionally in a solvent, or in a
medium in which
the salt is insoluble, followed by removal of said solvent, or said medium,
using standard
5 techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may
also be prepared by
exchanging a counter-ion of a compound in the form of a salt with another
counter-ion, for
example using a suitable ion exchange resin.
Beyond the suitable chelated nonradioactive or radioactive cations described
herein above,
10 further examples of pharmaceutically acceptable salts include acid
addition salts derived
from mineral acids and organic acids, and salts derived from metals such as
sodium,
magnesium, potassium and calcium.
Examples of acid addition salts include acid addition salts formed with
acetic, 2,2-
15 dichloroacetic, adipic, alginic, aryl sulfonic acids (e.g.
benzenesulfonic, naphthalene-2-
sulfonic, naphthalene-1,5-disulfonic and p-toluenesulfonic), ascorbic (e.g. L-
ascorbic), L-
aspartic, benzoic, 4-acetamidobenzoic, butanoic, (+) camphoric, camphor-
sulfonic, (+)-(15)-
camphor-10-sulfonic, capric, caproic, caprylic, cinnamic, citric, cyclamic,
dodecylsulfuric,
ethane-1,2-disulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, formic,
fumaric, galactaric,
20 gentisic, glucoheptonic, gluconic (e.g. D-gluconic), glucuronic (e.g. D-
glucuronic), glutamic
(e.g. L-glutamic), a-oxoglutaric, glycolic, hippuric, hydrobromic,
hydrochloric, hydriodic,
isethionic, lactic (e.g. (+)-L-lactic and ( )-DL-lactic), lactobionic, maleic,
malic (e.g. (-)-L-
malic), malonic, ( )-DL-mandelic, metaphosphoric, methanesulfonic, 1-hydroxy-2-
naphthoic,
nicotinic, nitric, oleic, orotic, oxalic, palmitic, pamoic, phosphoric,
propionic, L-pyroglutamic,
25 salicylic, 4-amino-salicylic, sebacic, stearic, succinic, sulfuric,
tannic, tartaric (e.g.(+)-L-
tartaric), thiocyanic, undecylenic and valeric acids.
Also encompassed are any solvates of the compounds and their salts. Preferred
solvates
are solvates formed by the incorporation into the solid state structure (e.g.
crystal structure)
30 of the compounds of the invention of molecules of a non-toxic
pharmaceutically acceptable
solvent (referred to below as the solvating solvent). Examples of such
solvents may include
water, alcohols (such as ethanol, isopropanol and butanol) and
dimethylsulfoxide. Solvates
can be prepared by recrystallising the compounds of the invention with a
solvent or mixture
of solvents containing the solvating solvent. Whether or not a solvate has
been formed in
35 any given instance can be determined by subjecting crystals of the
compound to analysis
using well known and standard techniques such as thermogravimetric analysis
(TGA),
differential scanning calorimetry (DSC) and X-ray crystallography.
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
36
The solvates can be stoichiometric or non-stoichiometric solvates. Particular
solvates may
be hydrates, and examples of hydrates include hemihydrates, monohydrates and
dihydrates.
For a more detailed discussion of solvates and the methods used to make and
characterise
them, see Bryn et al, Solid-State Chemistry of Drugs, Second Edition,
published by SSCI,
Inc of West Lafayette, IN, USA, 1999, ISBN 0-967-06710-3.
The compounds of the invention may contain one or more isotopic substitutions,
and a
reference to a particular element includes within its scope all isotopes of
the element. For
example, a reference to hydrogen includes within its scope 1H, 2H (D), and 3H
(T). Similarly,
references to carbon and oxygen include within their scope respectively 120,
130 and 140
and 160 and 180. In an analogous manner, a reference to a particular
functional group also
includes within its scope isotopic variations, unless the context indicates
otherwise. For
example, a reference to an alkyl group such as an ethyl group or an alkoxy
group such as a
methoxy group also covers variations in which one or more of the hydrogen
atoms in the
group is in the form of a deuterium or tritium isotope, e.g. as in an ethyl
group in which all
five hydrogen atoms are in the deuterium isotopic form (a perdeuteroethyl
group) or a
methoxy group in which all three hydrogen atoms are in the deuterium isotopic
form (a
trideuteromethoxy group). The isotopes may be radioactive or non-radioactive.
PREPARATION OF THE COMPOUNDS OF THE INVENTION
Some compounds of Formula (la), (1 b), (1c) and (1d) and derivatives or
synthetic
intermediates thereof can be prepared in accordance with synthetic methods
known to the
skilled person. In some embodiments, the invention provides a process for the
preparation of
a compound as defined in Formula (la), (1 b), (1c) and (1d). Certain compounds
of the
invention may be prepared according to the methods described below.
PSMA ligands containing modified binding motifs (Figure 1) were synthesized
according to
known or modified organic chemical synthesis procedures. On-resin synthesis of
binding
motifs was established and adjusted in individual cases. Peptide chain
elongation was
performed according to standard solid phase peptide synthesis protocols for
PSMA
derivatives and optimizations concerning (radio)metal complexation reactions
were
performed if necessary. The following sections cover the syntheses of
compounds 2 to 11,
highlighting special synthetic aspects, improvements to already described
procedures as
well as methods for preservation of the mandatory L-configuration of the PSMA-
binding motif
during inhibitor modification.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
37
General Information
All reagents were purchased from Merck KGaA (Darmstadt, Germany), Sigma-
Aldrich
Chemie GmbH (Steinheim, Germany), VWR International GmbH (Darmstadt, Germany),
TCI
(Eschborn, Germany), Iris Biotech (Marktredwitz, Germany) and Carbolution (St.
Ingbert,
Germany) in the quality grade "for synthesis". Racemic 2-PMPA was purchased
from
Bio-Techne GmbH (Wiesbaden-Nordenstadt, Germany). Chematech (Dijon, France)
delivered the chelator DOTA and derivatives thereof. Cell culture media and
buffer solutions
were purchased from Merck KGaA (Darmstadt, Germany) and Sigma Aldrich Chemie
GmbH
(Steinheim, Germany). ([1251]Nal was purchased from Hartmann Analytic
(Braunschweig,
Germany), n.c.a. [177Lu]LuCI3 was delivered by ITG (Garching, Germany).
Solvents were
purchased from VWR International GmbH (Darmstadt, Germany) in the quality
grade "HPLC
grade" and used for column chromatography or liquid-liquid extraction. Dry
solvents were
purchased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany), Alfa Aesar
(Karlsruhe,
Germany) and VWR International GmbH (Darmstadt, Germany). Silica gel (high
purity
grade, 60 A, 0.040 - 0.063 particle size) used for column chromatography was
purchased
from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). Solid phase synthesis of
the
peptides was carried out by manual operation using an Intelli-Mixer syringe
shaker (Neolab,
Heidelberg, Germany).
Materials
Analytical and preparative RP-HPLC were performed using Shimadzu gradient
systems
(Shimadzu Deutschland GmbH, Neufahrn, Germany), each equipped with a SPD-20A
UV/Vis detector (220 nm, 254 nm). All systems were operated by the
LabSolutions software.
Prior to quality control acquisitions, a control run was performed, in which
only
water/acetonitrile (1/1) was injected. Thereby, the system was checked for
impurities in the
injection port or on the column.
As different eluents and flow rates have been used for several compounds, the
used
methods are cited in the text and described as follows:
Method A: solvent A = water + 0.1% TFA, solvent B = acetonitrile + 2% water +
0.1% TFA
Method B: solvent A = water + 0.1% TFA, solvent B = acetonitrile + 5% water +
0.1% TFA
Method C: solvent A = water, solvent B: acetonitrile + 5% water
Method D: solvent A = water, solvent B: acetonitrile
Analytical RP-HPLC was performed on a Nucleosil 100-C18 (5 pm, 125 mm x 4.6
mm)
.. column (CS GmbH, Langerwehe, Germany) applying different linear solvent
gradients
(Method A) and a constant flow rate of 1 mL/min. Both, specific gradients and
the
corresponding retention times tR as well as capacity factor k are cited in the
text. The
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
38
capacity factor was calculated from the experimentally determined dead time
(to = 1.6 min) of
the HPLC system and the respective retention time tR:
k = tR ¨ to
to
Preparative RP-HPLC was performed on a Multospher 100 RP 018 (5 pm, 250 x 20
mm)
column (CS GmbH, Langerwehe, Germany) applying different linear solvent
gradients
(Method B or C) and different constant flow rates of 5, 8, 9 or 10 mlimin.
Flash chromatography was performed with a Biotage gradient HPLC system
(Biotage
Europe, Uppsala, Sweden), using HP-Sphere 018-25 catridges (micron spherical
silica,
Biotage SNAP Ultra 018, 12 g). The compounds were eluted applying different
solvent
gradients (Method D).
Radio-RP-HPLC was performed on a Nucleosil 100-018 (5 pm, 125 mm x 4.6 mm)
column
(CS GmbH, Langerwehe, Germany) using a Shimadzu gradient system (Shimadzu
Deutschland GmbH, Neufahrn, Germany) with a linear solvent gradient (Method A)
and a
constant flow rate of 1 mL/min. For radioactivity detection, the outlet of the
UV detector was
connected to a HERM LB 500 Nal detector (Berthold Technologies, Bad VVildbad,
Germany).
For metabolite analysis a FlowStar2 LB 514 detector (Berthold Technologies,
Bad VVildbad,
Germany) was additionally connected to the HERM detector.
Mass spectra were acquired with an Advion expression L compact mass
spectrometer
(Advion Ltd., Harlow, UK) with electrospray ionization (positive ion mode) and
an orthogonal
ion sampling from the heated capillary. The system was operated by the Mass
Express
software and spectra were processed using the Data Express software.
All 1H- and 13C-NMR spectra were measured at room temperature in either DMSO-
d6 or
CDCI3 on Bruker (Rheinstetten, Germany) instruments (AHV HD-300, AHV HD-400).
Chemical shifts (5) are reported in parts per million (ppm) and calibrated on
the residual
solvent signal (DMSO-d6: 2.50 ppm for 1H and 39.5 ppm for 130, 0D0I3: 7.26 ppm
for 1H and
77.0 ppm for 130). Multiplicities are described as follows: s = singlet, d =
doublet, t = triplet, q
= quartet, br = broad singlet m = multiplet.
Analytical thin layer chromatography (TLC) was carried out on precoated silica
gel plates
form Merck KGaA (Darmstadt, Germany) (TLC plates silica gel 60 F254).
Substance spots
were visualized either via UV illumination at 254 nm or with a 0.75% (m/v)
potassium
permanganate stain solution.
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
39
Radio-thin layer chromatography (TLC) was carried out with a Scan-RAM detector
(LabLogic
Systems, Sheffield, United Kingdom). Cellulose strips were used for citrate-
buffer
(0.1 M disodium citrate sesquihydrate in H20). Normal-phase TLC plates (Silica
gel 60 RP-
18 F254s) were used for analyses in NH40Ac buffer (1.0 M NH40Ac in H20)/DMF
(1/1).
Activity measurements of the respective probes obtained from competitive
binding assays,
internalization assays, log D determinations, biodistribution or metabolism
studies were
measured by a 2480 VVizard2 automatic y-counter (PerkinElmer, Waltham, USA).
Methods
General remarks on peptide synthesis
The used equivalents of the reactants for the solid phase synthesis refer to
the calculated
load after attaching the first amino acid onto the resin. The specific loads
are cited in the
text. Prior to any reaction, dry resin was swelled in NM P for at least 30 min
and then filtered.
Unless otherwise indicated, the resin was washed with DMF (6x) after each
reaction step.
For storage, the resin was washed with DMF (3x) and DCM (3x) and dried in a
desiccator.
General procedure for loading the first amino acid onto 2-CTC resin (GP1)
The first amino acid (1.50 eq.) and DIPEA (1.33 eq.) were dissolved in DCM
(5.00 mL) and
stirred for 5 min at r.t. prior to addition of the resin (1.00 eq.). After 15
min further DIPEA
(2.67 eq.) was added and the reaction mixture was stirred for 75 min.
Afterwards, Me0H
(2 mL) was added and stirred for 15 min. The resin was washed successively
with Me0H
(4x), DMF (4x) and DCM (4x) and dried at least two hours or overnight in a
desiccator. The
load was calculated using the following formula:
(m2 ¨ m1) = 1000 [mmoll
load =
(Mw 1VIFic1) = m2 [ g
Mw = molecular weight of the amino acid [g/mol]
MHCI = molecular weight of HCI [g/mol]
mi = mass of dry 2-CTC resin before coupling [g]
m2= mass of dried resin after coupling [g]
General procedure for on-resin peptide bond formation (GP2)
To a solution of TBTU (2.00 eq.), HOAt (2.00 eq.) and the amino acid (2.00
eq.) in DMF
(-- 10 mlig resin), DIPEA (6.00 - 9.00 eq.) was added to adjust the pH value
to 9 - 10 and
the mixture was allowed to preactivate for five minutes. In the case of Fmoc-D-
Dap(Dde)-OH
sym-collidine (6.00 - 8.00 eq.) was added instead of DIPEA. Unless otherwise
noted, the
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
solution was added to the resin-coupled peptide and shaken for 2 h at room
temperature.
Afterwards the resin was washed with DMF (6x).
General procedure for the on-resin Fmoc-removal (GP3)
5 The resin was shaken 5 x 5 min in 20% piperidine in DMF (v/v) to remove
the Fmoc-
protective group and afterwards washed with DMF (7x). If Ornithin was the
first amino acid
bound to the resin, Fmoc-removal was performed 12 x 5min in 20% piperidine.
General procedures for the on-resin Dde-removal (GP4 & GP5)
10 GP4: If no Fmoc-group was present in the resin bound peptide, the resin
was treated with
2% hydrazine in DMF (10 mL) for 20 min and afterwards washed with DMF (7x).
GP5: If an Fmoc-group was present in the resin bound peptide, the resin was
treated with a
solution of imidazole (0.46 g/g resin) and hydroxylamine hydrochloride (0.63
g/g resin) in
NMP (5.0 mlig resin) and DMF (1.0 mlig resin) for 2 x 3 h. Afterwards, the
resin was
15 washed with DMF (7x).
General procedures for monitoring the reaction progress (GP6 & GP7)
For a test cleavage with TFA (GP6) a small aliquot of the resin was taken and
treated with
100 pL of TFA for 15 min at r.t. in an Eppendorf tube.
20 To avoid cleavage of tert-butyl groups or formation of other
unidentifiable by-products, test
cleavage with HFIP/DCM (GP7) was used. The resin aliquot was treated with 100
pL of
HFIP/DCM (1/4, v/v) for 30 min at r.t.
For both procedures the respective solution (without beads!) was transferred
into another
Eppendorf tube and the solvent was evaporated under a stream of nitrogen. The
residue
25 was dissolved in a mixture of H20 and MeCN (1/1, v/v), now ready for RP-
HPLC analysis.
Cleaving the peptide off the resin with simultaneous removal of all acid-
labile protective
groups (GP8)
The resin was treated with TFA/TIPS/DCM (95/2.5/2.5, 10.0 mL) twice for 30 min
at r.t. and
30 washed with DCM afterwards (3x). The solvent was evaporated under N2
flow and after
lyophilisation the crude product was obtained.
General procedure for reactions under air- and moisture free conditions (GP9)
The used Schlenk flask, further glassware as well as the agitator were heated
properly three
35 times under vacuum (2.0 x 10-3 - 8.0 x 10-3 mbar) prior to the reaction.
The apparatus was
flushed with argon after each heating cycle. Only dry solvents and dry
reagents were used
for the reactions. The addition of reagents or reactants to the reaction
mixture was only
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
41
performed under argon counterflow. Probes for HPLC control were also only
taken under
argon counterflow. If the reaction mixture was heated or evolution of gas was
expected, the
stop cock at the top of the apparatus was replaced by a balloon.
Abbreviations
2-Aha 2-aminoheptanoic acid
2-Aoc 2-aminooctanoic acid
2-CT 2-chlorotrityl
2-PM PA 2-(phosphonomethyl)pentane-1,5-dioic acid
Am molar activity
BOP (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium
hexafluorophosphate
BSA bovine serum albumin
BzI benzyl
CAN cerium(IV) ammonium nitrate
Cbz carbobenzoxy
CD! 1,1'-carbonyldiimidazole
CT computed tomography
Dap 2,3-diaminopropionic acid
DCE 1,2-dichloroethane
DCM dichloromethane
Dde N-1-(4,4-dimethy1-2,6-dioxocyclohex-1-ylidene)ethylamine
DIAD diisopropyl azodicarboxylate
DIPEA N,N-diisopropylethylamine
DMAP 4-dimethylaminopyridine
DMEM Dulbecco's Modified Eagle's Medium
DMF dimethylformamide
DMSO dimethyl sulfoxide
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
EDC N-(3-dimethylaminopropyI)-N'-ethylcarbodiimide
FWHM full width at half maximum
HBSS Hank's buffered salt solution
HFIP 1,1,1,3,3,3-hexafluoro-2-propanol
HOAt 1-hydroxy-7-azabenzotriazole
IC50 half maximal inhibitory concentration
ID/g injected dose per gram
MeCN acetonitrile
Me0H methanol
NHS N-hydroxysuccinimide
NMP N-methyl-2-pyrrolidone
01 optical imaging
PBS phosphate-buffered saline
PET positron emission tomography
PPh3 triphenylphosphane
PSMA prostate-specific membrane antigen
RCP radiochemical purity
RCY radiochemical yield
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
42
RIPA radioimmunoprecipitation assay
RP-HPLC reversed-phase high-performance liquid chromatography
r.t. room temperature
SiFA-BA silicon-based fluoride acceptor-benzoic acid
SPECT single-photon emission computed tomography
TBTU 2-(1H-benzotriazole-1-yI)-1,1,3,3-tetramethylam ini um
tetrafluoroborate
tBu tert-butyl
tBuOH tert-butanol
TEA triethylamine
TFA trifluoroacetic acid
TI PS triisopropylsilane
TLC thin layer chromatography
TMSN3 trimethylsilyl azide
Synthesis, cold complexation and radiolabeling of ligands with different
binding
motifs
Reference compound PSMA-10 (1) in its free chelator form was synthesized
according to a
previously published protocol (VVurzer A. et al. Journal of Nuclear Medicine
2020, 61(5), 735-
42). Preparation of natLu-1 and [177Lu]Lu-1 followed similar procedures to
those conducted in
the literature (VV02019/020831). Hence, their analytical data can be found
elsewhere and
are not again listed. ICso data for natLu-1 as well as internalization, log D,
biodistribution and
pSPECT/CT data of [177Lu]Lu-1 were not adopted from previously published
studies.
Instead, they were again determined to ensure a valid comparability of the
obtained results
and to investigate salivary gland uptake of the reference [177Lu]Lu-1 at 24 h
p.i.
Synthesis of PSMA derivatives containing modifications within the central Zn2+-
binding unit
Thioureate 2
Di-tert-butyl (1H-imidazole-1-carbonothioyI)-L-glutamate (12)
0 0 0 0
TEA
A DMAP
N N
_ S
DCM
- >(:)yNH2 = HCI C ¨> r.t., 24 h
>(:)Y --µN N \I\J
H
0 0
S-1 S-2 12
Exact Mass: 295,16 Exact Mass: 178,03 Exact Mass: 369,17
Molecular Weight: 295,81 Molecular Weight: 178,21
Molecular Weight: 369,48
Compound S-1 was dissolved in dry DCM (14.9 mL) and cooled to 0 C.
Triethylamine (1.79
mL, 12.8 mmol, 2.53 eq.) and DMAP (24.8 mg, 0.20 mmol, 0.04 eq.) were added
and stirred
for five minutes. Afterwards, 1,1'-thiocarbonyldiimidazole (S-2) (1.36 g, 7.61
mmol, 1.50 eq.)
was added, the solution was allowed to warm to room temperature and stirred
overnight.
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
43
The mixture was dissolved with - 15 mL DCM and washed with NaHCO3 (1x), H20
(1x) and
brine (1x). The organic layer was dried over Na2SO4, filtered and the solvent
removed under
reduced pressure. This afforded 1.67 g (89.2%) of crude product 12 as a yellow
oil, which
was used without further purification in the next step.
Chemical formula: C17H27N304.S
Molecular weight: 369.48 g/mol
Exact mass: 369.17 g/mol
tR-value: 13.0 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 6.2
ESI-MS: calculated monoisotopic mass (Ci7H27N304S): 369.17;
found: ESI (positive ion mode): m/z = 370.2 [M(12)+H], 411.2 [M(12)+MeCN+H];
1H-NMR (300 MHz, CDCI3) O(ppm): 8.45 (virt. d, 1H, H(1)), 7.65 (virt. 1H,
H(2)), 7.23 (s, 1H,
H(3)), 7.18 - 7.01 (m, 1H, H(4)), 4.83 (t, 3J = 5.7 Hz, 1H, H(5)), 2.56 - 2.44
(m, 2H, H(6)),
2.30 - 2.20 (m, 2H, H(7)), 1.48 (s, 9H, H(8, 8', 8")), 1.45 (s, 9H, H(9, 9',
9")).
8'
8
0 0
8 7 s
9 0 2
Nr"-N
3
4
12
L-G1u[D-Orn(Dde)-2-C-1]-0tBu (13)
H2NHOO
j<
1) TBTU
NH2 0 HOAt 0NH 0
H DI.PEA
or '
r.t 2 h
I 8 0
2) Fmoc-removal (GP3) 0 0
S-3 18 13
Exact Mass: 425,18 Exact Mass: 296,17 Exact Mass: 481,28
Molecular Weight: 425,48 Molecular Weight: 296,37 Molecular Weight:
481,59
Fmoc-D-Orn(Dde)-OH was coupled to 2-CTC resin according to GP1 (load: 0.71
mmol/g,
0.34 mmol, 1.00 eq.). After removal of the Fmoc protective group (GP3), Fmoc-L-
Glu-OtBu
(S-3) (294 mg, 0.69 mmol, 2.00 eq.) was coupled to 18 according to GP2 (2.00
eq. TBTU,
2.00 eq. HOAt, 9.00 eq. DIPEA). After two hours, the Fmoc group of the resin-
bound
dipeptide was cleaved off, again according to GP3. Some resin beads were taken
according
to GP6 and analyzed via RP-HPLC, which indicated nearly complete conversion to
13.
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
44
Chemical formula: C24.H39N307; -tBu: C201-131N307
Molecular weight: 481.59 g/mol; -tBu: 425.48 g/mol
Exact mass: 481.28 g/mol; -tBu: 425.22 g/mol
tR-value (-tBu): 8.47 min (10 - 90% B in 15 min, Method A)
Capacity factor k (-tBu): 4.6
ESI-MS: calculated monoisotopic mass (C24H39N307): 481.28, -tBu (C201-
131N307): 425.22;
found: ESI (positive ion mode): m/z = 426.0 [M(13)-tBu+H].
L-Glu(OtBu)2-(thiocarbony1)-L-Glu[D-Orn(Dde)-2-C-1]-0tBu (S-4)
H N zjEL. (s)"`ly'd 6-jLoJ<
0 2 0
g
S TEA
0 >r
0NH 0
r A OHL 10) CE¨> 40 C, 18 h 0 0 N_L,N
Argon
=
0 0 on 0
12 13 S-4
Exact Mass: 369,17 Exact Mass: 481,28 Exact Mass:
782,41
Molecular Weight: 369,48 Molecular Weight: 481,59 Molecular
Weight: 782,99
Reactant 12 (160 mg of crude product, contain - 60% of 12 (RP-HPLC), 0.26
mmol, 1.50
eq.) was dissolved in 2 mL DCM and cooled to 0 C. Triethylamine (59.6 pL,
0.43 mmol,
2.50 eq.) and the resin-bound dipeptide 13 (0.17 mmol, 1.00 eq) were added and
stirred for
five minutes at 0 C. The reaction mixture was heated to 40 C and stirred
overnight under
argon atmosphere. The resin was transferred to a syringe for peptide synthesis
(equipped
with a frit, pore size 25 pm) and washed with DCM (4x). Some resin beads were
taken
according to GP7 and analyzed via RP-HPLC, which indicated nearly complete
conversion
to S-4.
Chemical formula: C38H62N40115;
Molecular weight: 782.99 g/mol;
Exact mass: 782.41 g/mol;
tR-value: 12.7 min (40 - 100% B in 15 min, Method A)
Capacity factor k: 7.5
ESI-MS: calculated monoisotopic mass (C38H62N40115): 782.41;
found: ESI (positive ion mode): m/z = 783.2 [M(S-4)+H], 805.4 [M(S-4)+Na],
822.1 [M(S-
4)+K].
Thioureate 2
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
o 0
HO s ENlyEN0H .'L.
S =-.õ. 0
HO10 OH 0 NH HO 0H 0 H
0(/>==,,N NNAP-N Cr\I---)H,",
H
OH 0
FINN(
2 y 0 o (r-OH
Exact Mass: 1414,62 F Six 0
Molecular Weight: 1415,63
Further reactions on resin-bound compound S-4 were performed according to
standard
Fmoc-SPPS on 2-CT resin, applying the above-mentioned methods (GP2 - GP8). In
brief,
the Dde protective group was removed (GP4) and succinic anhydride (119 mg,
1.19 mmol,
5 7.00 eq.) was coupled (GP2) over a period of at least 2.5 h, only using
DIPEA (202 pL,
1.19 mmol, 7.00 eq.) and no further coupling reagents. The peptide was
elongated with
Fmoc-D-Lys-OtBu*HCI (157 mg, 0.34 mmol, 2.00 eq.). Therefore, the resin-bound
acid was
preactivated for five minutes using TBTU (109 mg, 0.34 mmol, 2.00 eq.), HOAt
(46.3 mg,
0.34 mmol, 2.00 eq.) and DIPEA (173 pL, 1.02 mmol, 6.00 eq.). The amino acid
was
10 dissolved in DMF, added to the preactivated resin and shaken for at
least 2.5 h. Fmoc-
removal was conducted (GP3) and Fmoc-D-Dap(Dde)-OH was coupled for at least
2.5 h
using TBTU (109 mg, 0.34 mmol, 2.00 eq.), HOAt (46.3 mg, 0.34 mmol, 2.00 eq.)
and sym-
collidine (158 pL, 1.19 mmol, 7.00 eq.) as coupling reagents. Afterwards, Dde-
removal was
performed according to GP5. The SiFA-BA moiety (73.4 mg, 0.26 mmol, 1.50 eq.)
was
15 attached using TBTU (109 mg, 0.34 mmol, 2.00 eq.), HOAt (46.3 mg, 0.34
mmol, 2.00 eq.)
and sym-collidine (158 pL, 1.19 mmol, 7.00 eq.) as coupling reagents. After an
incubation
time of at least 2 h, the Fmoc protective group was removed (GP3) and the DOTA
chelator
moiety was added to half of the resin. Therefore, DOTA*6 H20 (43.6 mg, 85.0
pmol,
1.00 eq.), TBTU (22.8 mg, 71.0 pmol, 0.84 eq.), HOAt (9.66 mg, 71.0 pmol, 0.84
eq.) and
20 sym-collidine (66.3 pL, 0.50 mmol, 5.88 eq.) were dissolved in a mixture
of DM F/DMSO (5/1,
v/v) and incubated with the resin-bound amine for 23 h. As RP-HPLC/MS analysis
(GP6)
revealed successful coupling, the peptide was cleaved off the resin with
TFA/TIPS/H20
(95/2.5/2.5, slightly modified to GP8) (2 x 30 min) and purified afterwards by
preparative RP-
HPLC (30- 50% B in 20 min, Method B). Subsequent lyophilization afforded 1.99
mg (1.65%
25 yield) of pure product 2 as a colorless powder.
Chemical formula: C601-195FN12022SSi;
Molecular weight: 1415.63 g/mol;
Exact mass: 1414.62 g/mol;
tR-value: 7.82 min (40 - 100% B in 15 min, Method A)
30 Capacity factor k: 4.2
ESI-MS: calculated monoisotopic mass (C601-195FN12022SSi): 1414.62;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
46
found: ESI (positive ion mode): m/z = 708.6 [M(2)+2H]2+, 1415.8 [M(2)+H].
natGa-thioureate 2 (natGa-2)
0 0
H H
H0 s Ny N s
)51-
S 0
Ce....OH 0 NH 0 C) 0 CrS
H =
OH 0 / Oil cfja=:'-N......./0
HN N
natGa-2 y = o
Exact Mass: 1481,53 FSI 0
Molecular Weight: 1483,33 X
Thioureate 2 (1.99 mg, 1.41 pmol, 1.00 eq.) was dissolved in 300 pL of tBuOH,
and
Ga(NO3)3*6 H20 (1.79 mg, 4.92 pmol, 3.50 eq.) dissolved in 100 pL H20 was
added. The
mixture was stirred for 30 min at 75 C and afterwards filtered through single
use syringe
filters (Sartorius Minisart ) to remove Ga(OH)3 precipitate. The natGa-complex
of thioureate 2
(= natGa_2) was purified by RP-HPLC (30 - 50% B in 20 min, Method B) and
afforded 70.0 pg
(3.35%) of pure product natGa-2 as a colorless powder after lyophilization.
Chemical formula: C601-193FGaN12022SSi;
Molecular weight: 1483.33 g/mol;
Exact mass: 1481.53 g/mol;
tR-value: 8.65 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 4.7
ESI-MS: calculated monoisotopic mass (C601-193FGaNi2022SSi): 1481.53;
found: ESI (positive ion mode): m/z = 742.5 [m(natGa-2)+2H]2+, 1483.0 [M(natGa-
2)+H],
1503.6 [M(natGa-2)+Nar.
Carbamate I (3)
Tert-butyl (S)-5-oxotetrahydrofuran-2-carboxylate (S-6)
tBuOH
DMAP
0 OH EDC*HCI . 0
DCM
0 0 C ¨> r.t., 17.3 h 0
Argon
S-5 S-6
Exact Mass: 130,03 Exact Mass: 186,09
Molecular Weight: 130,10 Molecular
Weight: 186,21
According to a slightly modified procedure by Zhang et al. (Tetrahedron. 2009,
65(48), 9997-
10001), (S)-5-oxotetrahydrofuran-2-carboxylic acid (S-5) (1.50 g, 11.5 mmol,
1.00 eq.) was
weighed in a 100 mL round bottom flask and dissolved in 36 mL dry DCM. DMAP on
polystyrene (1.60 mmol/g, 718 mg, 1.15 mmol, 0.10 eq.) and dry tBuOH (1.40 mL,
15.0
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
47
mmol, 1.30 eq.) were added and the reaction mixture was cooled to 0 C.
EDC*HCI (2.87 g,
15.0 mmol, 1.30 eq.) in 12 mL dry DCM was added slowly, the ice bath was
removed, the
solution was allowed to warm to room temperature and stirred under argon
atmosphere for
17.3 h. DMAP on polystyrene was filtered off, the organic layer was washed
once with H20
.. (spiked with some drops of brine), dried over Na2SO4 and the solvent was
removed under
reduced pressure. The crude product was purified by column chromatography
(toluene/Et0Ac = 3/2) to afford 928 mg (43%) of compound S-6 as a colorless,
crystalline
solid.
Chemical formula: C9H1404;
Molecular weight: 186.21 g/mol;
Exact mass: 186.09 g/mol;
tR-value: not detectable at 220/254 nm
Rrvalue: 0.58 (toluene/Et0Ac = 3/2)
1H-NMR (300 MHz, CDCI3) O(ppm): 4.83 ¨ 4.76 (m, 1H, H(1)), 2.68 ¨ 2.39 (m, 3H,
H(2, 3, 4)), 2.32 ¨2.14 (m, 1H, H(5)), 1.48 (s, 9H, H(6, 6', 6")).
13C-NMR (75 MHz, CDCI3) O(ppm): 176.32 (s, 1C, C(1)), 169.12 ((s, 1C, C(2)),
83.23 (s, 1C,
C(3)), 76.40 (s, 1C, C(4)), 28.03 (s, 3C, C(5, 5' 5")), 26.90 (s, 1C, C(6)),
26.00 (s, 1C, C(7)).
4,5 2.3
0.--At.ro 6
s
0 I
6"
6-7
0"-=1
0 5"
S-6
(S)-5-(tert-butoxy)-4-hydroxy-5-oxopentanoic acid (S-7)
HO 0
0 KOH
."-o-Ay '==< THF >(:)0H
r.t., 1 h 0
S-6 S-7
Exact Mass: 186,09 Exact Mass: 204,10
Molecular Weight: 186,21 Molecular Weight: 204,22
According to a slightly modified procedure by Zhang et al. (Tetrahedron. 2009,
65(48), 9997-
10001), tert-butyl (S)-5-oxotetrahydrofuran-2-carboxylate (S-6) (425 mg, 2.28
mmol,
1.00 eq.) was dissolved in 2.40 mL THF. At 0 C, a 1 M aqueous KOH solution
(2.64 mL,
2.64 mmol, 1.16 eq.) was added dropwise over five minutes. The solution was
allowed to
warm to room temperature and stirred for one hour. As reaction control via TLC
revealed
almost complete consumption of educt S-6, THF was removed under reduced
pressure and
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
48
the pH value of the remaining aqueous layer was adjusted to 3 by adding 2 M
HCI. The
aqueous residue was extracted with Et0Ac (3x), the combined organic phases
dried over
Na2SO4, filtered and the solvent removed under reduced pressure. This afforded
381 mg of
crude product S-7 as a colorless solid, which was used without further
purification in the next
step.
Chemical formula: C9H1605;
Molecular weight: 204.22 g/mol;
Exact mass: 204.10 g/mol;
tR-value: not detectable at 220/254 nm
Rrvalue: 0.0 (toluene/Et0Ac = 3/2)
Di-tert-butyl (S)-2-hydroxypentanedioate (14)
HO 0 0 0
>0
1\1"" N DCM
0 H reflux, 96 h 0
Argon
S-7 S-8 14
Exact Mass: 204,10 Exact Mass: 200,19 Exact Mass: 260,16
Molecular Weight: 204,22 Molecular Weight: 200,33 Molecular Weight:
260,33
Compound 14 was synthesized in analogy to a previously published procedure by
Bergmeier et al. (J Org Chem. 1993, 58(9), 2369-76) with some minor
modifications.
Glassware and reagents were handled under air- and moisture-free conditions
(GP9).
Lyophilized educt S-7 (crude product, -100 mg, 0.49 mmol, 1.00 eq.) was
dissolved in 5 mL
dry DCM and the first portion of 0-tert-butyl-N,N'-diisopropylisourea (S-8)
(162 pL,
0.73 mmol, 1.50 eq.) was added. The reaction mixture was stirred under reflux
(-42 C) and
argon atmosphere for 24 h. A second portion of S-8 (162 pL, 0.73 mmol, 1.50
eq.) was
added and also DCM, in order to keep the solvent amount constantly between 3
and 5 mL.
After stirring for further 72 h at reflux temperature and under argon
atmosphere, the reaction
was terminated by diluting the suspension with DCM. Solid by-products were
removed by
filtration and the solvent removed under reduced pressure. Purification by
column
chromatography (PE/Et0Ac = 9/1) provided 24.6 mg (19%) of compound 14 as a
colorless
liquid.
Chemical formula: C13H2405;
Molecular weight: 260.33 g/mol;
Exact mass: 260.16 g/mol;
tR-value: not detectable at 220/254 nm
Rrvalue: 0.65 (PE/Et0Ac = 9/1)
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
49
1H-NMR (300 MHz, CDC13) O(ppm): 4.07 (dd, 3J = 8.0, 4.1 Hz, 1H, H(1)), 2.88
(s, 1H, H(2)),
2.53 ¨ 2.24 (m, 2H, H(3)), 2.08 (virt. dddd, 1H, H(4)), 1.93¨ 1.73 (m, 1H,
H(5)), 1.49 (s, 9H,
H(6, 6', 6")), 1.44 (s, 9H, H(7, 7' 7")).
13C-NMR (75 MHz, CDC13) O(ppm): 174.22 (s, 10, 0(1)), 172.72 (s, 10, 0(2)),
82.80 (s, 10,
0(3)), 80.59 (s, 10, 0(4)), 69.89 (s, 10, C(5)), 31.13 (s, 10, 0(6)), 29.82
(s, 10, 0(7)), 28.25
(s, 30, 0(8, 8', 8")), 28.17 (s, 30, 0(9, 9', 9")).
8'
8,1,
38"
6'
a's1
0 0 6
7
3 4,5 4" -2 OH
g
z 9"
7 0 :1 0
>r
14
Di-tert-butyl (S)-2-((1H-imidazole-1-carbonyl)oxy)pentanedioate (S-10)
0 0
N N
_ 0
Dcm _______________________________________________
(DANN
>h-rrs>OH r.t., 20 h
0 Argon 0
14 S-9 S-10
Exact Mass: 260,16 Exact Mass: 162,05 Exact Mass: 354,18
Molecular Weight: 260,33 Molecular Weight: 162,15
Molecular Weight: 354,40
Compound S-10 was synthesized in analogy to a previously published procedure
by Yang et
al. (Journal of Medicinal Chemistry. 2016, 59(1), 206-18), with some minor
modifications. Di-
tert-butyl (S)-2-hydroxypentanedioate (14) (398 mg, 1.53 mmol, 1.00 eq.) was
dissolved in
25 mL dry DCM and stirred at room temperature. 1,1'-Carbonyldiimidazole (S-9)
(478 mg,
2.95 mmol, 1.93 eq.) was added to the solution, which was then stirred under
argon
atmosphere for 20 h at room temperature. The reaction mixture was diluted with
DCM and
washed once with H20. The aqueous layer was extracted two times with DCM, the
combined organic phases were dried over Na2SO4, filtered and the solvent
evaporated in
vacuo. This afforded 615 mg (>99%) of crude product as slightly yellow solid.
RP-HPLC/MS
control revealed nearly complete conversion to product S-10, which was used in
the next
step without further purification.
Chemical formula: 017H26N206;
Molecular weight: 354.40 g/mol;
Exact mass: 354.18 g/mol;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
tR-value: 10.2 min (40 - 100% B in 15 min, Method A)
Capacity factor k: 5.8
ESI-MS: calculated monoisotopic mass (Ci7H26N206): 354.18;
found: ESI (positive ion mode): m/z = 355.2 [M(S-10)+H], 396.2 [M(S-
10)+MeCN+H].
5
5-Benzyl 1-(tert-butyl) ((((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-
yl)oxy)carbonyI)-L-
glutamate (S-12)
0 ,4
HCI = H2NZYI....0j<
0 T
TEA
DCE 0
0 0 0 0 0 C ¨> 45 C, 41 h
C, 70.5 h
Argon
S-10 S-11 S-12
Exact Mass 354,18 Exact Mass 329,14 Exact Mass 579,30
Molecular Weight 354,40 Molecular Weight 329,82 Molecular Weight
579,69
Compound S-12 was synthesized in analogy to a previously published procedure
by
10 Weineisen et al. (EJNMMI Research. 2014, 4(1), 63). with some minor
modifications. Di-tert-
butyl (S)-2-((1H-imidazole-1-carbonyl)oxy)pentanedioate (S-10)
(542 mg, 1.53 mmol,
1.00 eq.) was dissolved in 7.29 mL DCE and cooled to 0 C. H-L-Glu(OBz1)-
0tBu*HCI (S-11)
(1.01 g, 3.06 mmol, 2.00 eq.) and triethylamine (531 pL, 3.83 mmol, 2.50 eq.)
were added
and stirred for further five minutes at 0 C. The reaction mixture was warmed
to 45 C and
15 stirred for 41 h under argon atmosphere. As RP-HPLC/MS analysis revealed
very low
conversion (4.4% S-12, 44% S-10), again, H-L-Glu(OBz1)-0tBu*HCI (S-11) (1.01
g,
3.06 mmol, 2.00 eq.) and triethylamine (531 pL, 3.83 mmol, 2.50 eq.) were
added and the
temperature was increased to 55 C. Complete consumption of educt S-10 was
observed
after 70.5 h at 55 C under argon atmosphere. DCM was added for dilution of
the reaction
20 mixture and washed once with H20 (+ 1 mL brine). The aqueous phase was
extracted two
times with DCM, the combined organic layers were dried over Na2SO4, filtered
and the
solvent was removed under reduced pressure. The obtained crude product was
purified by
preparative RP-HPLC (70 - 80% B in 20 min, Method B, 5 mL/min), which gave 277
mg
(31.3%) of compound S-12 as a colorless oil.
25 Chemical formula: C301-145N010;
Molecular weight: 579.69 g/mol;
Exact mass: 579.30 g/mol;
tR-value: 12.6 min (40 - 95% B in 15 min, Method A)
Capacity factor k: 7.4
30 ESI-MS: calculated monoisotopic mass (C301-145N010): 579.30;
found: ESI (positive ion mode): m/z = 412.3 [M(S-12)-3tBu+H], 468.3 [M(S-12)-
2tBu+H],
524.4 [M(S-12)-tBu+H], 580.5 [M (S-12)+H], 597.5 [M(S-12)+H2O+H],
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
51
602.5 [M(S-12)+Na], 618.5 [M(S-12)+K];
1H-NMR (300 MHz, CDCI3) O(ppm): 7.44 ¨ 7.30 (m, 5H, H(1, 1', 1", 1", 1"), 5.44
(d, 3J = 8.3
Hz, 1H, H(2)), 5.12 (s, 2H, H(3)), 4.84 (dd, 3J = 8.1, 4.6 Hz, 1H, H(4)), 4.27
(td, 3J = 8.2,
4.9 Hz, 1H, H(5)), 2.60 ¨ 2.41 (m, 2H, H(6)), 2.41 ¨2.28 (m, 2H, H(7)), 2.28¨
1.82 (m, 4H,
H(8, 9)), 1.46 (s, 9H, H(10, 10', 10")), 1.44 (s, 9H, H(11, 11', 11")), 1.44
(s, 9H,
H(12, 12', 12")).
13C-NMR (75 MHz, CDCI3) O(ppm): 172.69 (s, 20, 0(1, 2)), 171.94 (s, 10, 0(3)),
170.95 (s,
10, 0(4)), 155.22 (s, 10, C(5)), 136.02 (s, 10, 0(6)), 128.67 (s, 20, 0(7,
7')), 128.34 (s, 30,
0(8, 9, 9')), 82.71 (s, 10, 0(10)), 82.31 (s, 20, 0(11, 12)), 80.75 (s, 10,
0(13)), 66.57 (s, 10,
0(14)), 53.82 (s, 10, 0(15)), 31.24 (s, 10, 0(16)), 30.24 (s, 10, 0(17)),
28.23 (s, 30,
0(18, 18', 18")), 28.12 (s, 30, 0(19, 19', 19")), 28.09 (s, 30, 0(20, 20',
20")), 26.80 (s, 20,
0(21,22)).
19 0 0 18
19%.* 0 11 ii
11 19 10
0 2 0 19" 0 13 ."5- 1'8"
22 CI 2116
17
11" 0 4 0 1
6
12
0 0 0 0 20' l''20"
12 20' II
3 Ly-^--...1
12"
12' 1"
S-12
(S)-5-(tert-butoxy)-4-(((((S)-1, 5-d i-tert-butoxy-1, 5-d ioxopentan-2-
yl)oxy)carbonyl)am i no)-5-
oxopentanoic acid (15)
0
0 =õ 0
H2, Pd/C
D
0 0 0 0 CM 0 0 h 0 OH
r.t. 16
101
S-12 15
Exact Mass: 579,30 Exact Mass: 489,26
Molecular Weight: 579,69 Molecular Weight: 489,56
Compound S-12 (139 mg, 0.24 mmol, 1.00eq.) was dissolved in 12 mL DCM and the
solution was flushed 5 minutes with argon to remove dissolved oxygen. 25.5 mg
of palladium
on carbon (10% wt) (corresponds to 2.55 mg palladium, 24.0 pmol, 0.10 eq.)
were added
and the flask was sealed with a rubber septum. Remaining air was displaced
with argon and
subsequently replaced by hydrogen gas. The mixture was stirred under hydrogen
atmosphere at room temperature for 16 h. Palladium on carbon was filtered off,
and the
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
52
solvent was evaporated in vacuo. This afforded 59.2 mg (50.4%) of compound 15
as a
colorless clear oil, which was used in the next step without further
purification.
Chemical formula: C23H39N010;
Molecular weight: 489.56 g/mol;
Exact mass: 489.26 g/mol;
tR-value: 8.80 min (40 - 95% B in 15 min, Method A)
Capacity factor k: 4.9
ESI-MS: calculated monoisotopic mass (C23H39N010): 489.26;
found: ESI (positive ion mode): m/z = 304.2 [M(15)-3tBu-OH], 322.3 [M(15)-
3tBu+H],
378.3 [M(15)-2tBu +H], 434.3 [M(15)-tBu +H], 490.5 [M(15)+H],
507.5 [M(15)+H2O+H], 512.5 [M(15)+Na], 528.4 [M(15)+K].
[S-2-oxopentanedioic acid(OtBu)2]-(carbonyl)-L-Glu[D-Orn(Dde)-2-C-1]-0tBu (S-
13)
>L0 (s) ai.NIZY1,0.j< TBTU
HOAt
0
NH2 0 sym-collidine
DMF
0 0 0 NH
0 0 r.t 85 h
0 0
18 S-13
Exact Mass: 489,26 Exact Mass: 296,17 Exact Mass:
767,42
Molecular Weight 489,56 Molecular Weight 296,37 Molecular Weight
767,91
According to GP2, fragment 15 (59.2 mg, 0.12 mmol, 1.10 eq.) was coupled to
resin-bound
H-D-Orn(Dde) (18) (0.11 mmol 1.00 eq.), with TBTU (70.6 mg, 0.22 mmol, 2.00
eq.) and
HOAt (29.9 mg, 0.22 mmol, 2.00 eq.) as coupling reagents and sym-collidine
(131 pL,
0.99 mmol, 9.00 eq.) as base. After shaking for 85 h at room temperature,
formation of
product S-13 could be confirmed (GP7). Additionally, some resin beads were
taken, treated
for 20 minutes with 2% hydrazin/DMF (v/v) and analyzed via RP-HPLC/MS after a
test
cleavage according to GP7. Thus, stability of the carbamate moiety towards Dde-
removal
conditions was confirmed, as only one major peak (besides DMF) with the
expected m/z-
ratio of 604.6 occurred.
Chemical formula: C38H61N3013;
Molecular weight: 767.91 g/mol;
Exact mass: 767.42 g/mol;
tR-value: 9.21 min (40 - 95% B in 15 min, Method A)
Capacity factor k: 5.1
ESI-MS: calculated monoisotopic mass (C38H61N3013): 767.42;
found: ESI (positive ion mode): m/z = 768.7 [M(S-13)+H], 790.6 [M(S-13)+Na],
806.6 [M(S-13)+K];
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
53
Carbamate I (3)
0 H 0
HO s h-IOH
0
HO-IS
0 OH 0 NH H
H 0 ti
H
OH 0
HN' C--- N-----
1\1.,õ)
3 y a 0 HO,.) HO
0
0
Exact Mass: 1399,62 Si
Molecular Weight: 1400,55 F X
Further reactions on resin-bound compound S-13 were performed according to
standard
Fmoc-SPPS on 2-CT resin, applying the above-mentioned methods (GP2 - GP8). In
brief,
the Dde protective group was removed (GP4) and succinic anhydride (77.1 mg,
0.77 mmol,
7.00 eq.) was coupled (GP2) over a period of at least 2.5 h, only using DIPEA
(131 pL,
0.77 mmol, 7.00 eq.) and no further coupling reagents. The peptide was
elongated with
Fmoc-D-Lys-OtBu*HCI (101 mg, 0.22 mmol, 2.00 eq.). Therefore, the resin-bound
acid was
preactivated for five minutes using TBTU (70.6 mg, 0.22 mmol, 2.00 eq.), HOAt
(29.9 mg,
0.22 mmol, 2.00 eq.) and DIPEA (112 pL, 0.66 mmol, 6.00 eq.). The amino acid
was
dissolved in DMF, added to the preactivated resin and shaken for at least 2.5
h. Fmoc-
removal was conducted (GP3) and Fmoc-D-Dap(Dde)-OH was coupled for at least
2.5 h
using TBTU (70.6 mg, 0.22 mmol, 2.00 eq.), HOAt (29.9 mg, 0.22 mmol, 2.00 eq.)
and sym-
collidine (102 pL, 0.77 mmol, 7.00 eq.) as coupling reagents. Afterwards, Dde-
removal was
performed according to GP5. The SiFA-BA moiety (46.6 mg, 0.17 mmol, 1.50 eq.)
was
attached using TBTU (70.6 mg, 0.22 mmol, 2.00 eq.), HOAt (29.9 mg, 0.22 mmol,
2.00 eq.)
and sym-collidine (102 pL, 0.77 mmol, 7.00 eq.) as coupling reagents. After an
incubation
time of at least 2 h, the Fmoc protective group was removed (GP3) and the DOTA
chelator
moiety was added to the resin. Therefore, DOTA*6 H20 (56.4 mg, 0.11 mmol, 1.00
eq.),
TBTU (29.3 mg, 91.3 pmol, 0.83 eq.), HOAt (12.4 mg, 91.3 pmol, 0.83 eq.) and
sym-collidine
(102 pL, 0.77 mmol, 7.00 eq.) were dissolved in a mixture of DMF/DMSO (5/1,
v/v) and
incubated with the resin-bound amine for 19.5 h. As RP-HPLC/MS analysis (GP6)
revealed
no sufficient coupling, the resin was divided into two equivalent portions.
One portion was
again incubated with a freshly prepared DOTA-coupling mixture for 20 h. An
only low rise in
turnover led to a further DOTA-coupling step, now with DIPEA (101 pL, 0.59
mmol, 10.7 eq.)
instead of sym-collidine, in order to monitor and adjust the pH value to 9 -
10. After
incubation for 68 h an adequate conversion was achieved and the peptide was
cleaved off
the resin with TFA/TIPS/H20 (95/2.5/2.5, slightly modified to GP8) (2 x 30
min) and purified
afterwards by preparative RP-HPLC (20 - 70% B in 20 min, Method B, 5 mlimin).
Subsequent lyophilization afforded 6.30 mg (8.18%) of pure product 3 as a
colorless powder.
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
54
The second portion was cleaved off the resin with HFIP/DCM (1/4, v/v) at room
temperature
for 1 h in total (2 x 30 min). Thereby, all acid-labile protective groups were
retained. The
major portion of solvent was removed under a stream of nitrogen and the
residual crude
product additionally dried by lyophilization. Crude product (48.0 mg, 39.0
pmol, 1.00 eq.)
was dissolved in 3.00 mL DMF and DOTA-NHS (32.5 mg, 43.0 pmol, 1.10 eq.) as
well as
DIPEA (39.7 pL, 0.23 mmol, 6.00 eq.) was added. The mixture was stirred at
room
temperature for 18 h. Preparative RP-HPLC (35 - 95% B in 15min, Method B, 1
mL/min) and
subsequent lyophilization afforded 23.7 mg of the tert-butyl-functionalized
peptide.
Incubation with TFA/TIPS/DCM (95/2.5/2.5, slightly modified to GP8) at 0 C
for 1h in total
revealed 11.8mg (21.5%) of pure product 3 after RP-HPLC purification (30-50% B
in 15 min,
Method B, 1 ml/min) and lyophilization. This resulted in an overall yield of
18.1 mg (13.8 %
yield, chemical purity >98% of carbamate I (3).
Chemical formula: C601-194FN11024Si;
Molecular weight: 1400.55 g/mol;
Exact mass: 1399.62 g/mol;
tR-value: 8.58 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 4.72
ESI-MS: calculated monoisotopic mass (C601-194FN11024SO: 1399.62;
found: ESI (positive ion mode): m/z = 701.0 [M(3)+2H]2+,
1400.9 [M(3)+H],
1868.1 [M4(3)+3H]3+.
natGa-carbamate I (natGa-3)
0 H 0
HotyN-PA0H
0 0
OOH 0 NH H 0 H
H
Aa-N r\rirVI.--\ HO
OH 0 H 8 ( Giac
HN
\---N
natGa_3 io 0
Exact Mass: 1466,53 Fslµ 0
Molecular Weight: 1468,26 A
Carbamate I (3) (5.90 mg, 4.22 pmol, 1.00 eq.) was dissolved in 400 pL of
HEPES buffer
(pH = 3) and Ga(NO3)3*6 H20 (5.37 mg, 14.8 pmol, 3.50 eq.) dissolved in 444 pL
HEPES
buffer was added. The mixture was stirred for 30 min at 75 C and afterwards
filtered
through single use syringe filters (Sartorius Minisart ) to remove Ga(OH)3
precipitate. The
natGa-complex of carbamate I (3) (= natGa-3) was purified by RP-HPLC (25 - 45%
B in
15 min, Method A, 1 mL/min) which afforded 1.64 mg (26.5%) of pure product
natGa-3 as a
colorless powder after lyophilization.
Chemical formula: C601-192FGaN11024Si;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
Molecular weight: 1468.26 g/mol;
Exact mass: 1466.53 g/mol;
tR-value: 12.0 min (25 - 45% B in 15 min, Method A)
Capacity factor k: 7.0
5 ESI-MS: calculated monoisotopic mass (C601-192FGaNii024SO: 1466.53;
found: ESI (positive ion mode): m/z = 734.9 [M(natGa-3)+2H]2, 1468.0 [M(natGa-
3)+H],
1835.8 [M5(natGa-3)+4N4+, 1957.3 [M4(natGa-3)+3H]3.
natLu-carbamate I (natLu-3)
0 H 0
HotyN0H
0 0
OOH 0 NH H 0
HN y
natLu_3 y 0
Exact Mass: 1571,54 FSI 0
Molecular Weight: 1572,49 X
100 pL of the precursor (3) (2.00 mM in DMSO, 0.20 pmol, 1.00 eq.) were added
to 60.0 pL
of LuCI3 (20 mM in Tracepur -H20, 1.20 pmol, 6.00 eq.) and 40.0 pL Tracepur -
H20. The
reaction mixture was heated for 30 min at 70 C and afforded 1atLu-3 in 92.3%
chemical
purity (>99% yield), determined by RP-HPLC (220 nm). This natLu-3 solution
(now 1.00 mM)
was directly used as stock solution for affinity determination.
Chemical formula: C601-191FLuNii024Si;
Molecular weight: 1572.49 g/mol;
Exact mass: 1571.54 g/mol;
tR-value: 8.48 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 4.7
ESI-MS: calculated monoisotopic mass (C601-191FLuNii024SO: 1571.54;
found: ESI (positive ion mode): m/z = 787.1 [M(natLu-3)+2H]2+, 1573.2 [M(natLu-
3)+H],
1598.0 [M(natLu-3)+Nar.
[177Lu]Lu-carbamate I ([177Lu]Lu-3)
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
56
0
H
0 0
00H 0NH 0 C) 0 w
NA&H ,-0
OH 0
HNI/
177Lu-3 y o
Exact Mass: 1573,54
F SXi 0
Molecular Weight: 1574,47
5.00 pL of the precursor (3) (0.20 mM in DMSO, 1.00 nmol, 1.00 eq.) were added
to 10.0 pL
of 1 M Na0Ac buffer (aq.) (pH = 5.5). Subsequently, 22.3 to 62.2 MBq
[177Lu]LuCI3 (As >
3000 GBq/mg, 740 MBq/mL, 0.04 M HCI, ITG, Garching, Germany) were added and
the
mixture was filled up to 100 pL with 0.04 M HCI (in Tracepur -H20). 10.0 pL of
0.1 M sodium
ascorbate (aq.) (in Tracepur -H20) were added and the reaction mixture was
heated for
25 min at 70 C. Due to this lower temperature, removal of free [177Lu]Lu3+
via HLB cartridge
(30 mg) was required. This afforded [177Lu]Lu-3 in 69.7 18.2% (n = 6)
isolated
radiochemical yield (ROY) (decay corrected (d.c.) to the start of synthesis).
The apparent
molar activities (A,) were 12.5 to 21.9 GBq/pmol at the end of synthesis.
Radiochemical
purity (RCP) as determined by radio-RP-HPLC and radio-TLC was 96.9 2.1%.
Chemical formula: C601-191F177LuNii024Si;
Molecular weight: 1574.47 g/mol;
Exact mass: 1573.54 g/mol;
tR-value: 9.59 min (10 - 90% B in 15 min, Method A)
tR-value of co-injected cold standard: 9.49 min (10 - 90% B in 15 min, Method
A)
Capacity factor k: 5.4.
Carbamate 11(4)
5-benzyl 1-(tert-butyl) (S)-2-hydroxypentanedioate (16)
HO 0 1) Na2CO3
Me0H/H20
-> pH = 7
2) Bn-Br 0,
>i(jOH DMS0 >i r- OH
0 r.t., 4.5 h 0
Argon
S-7 16
Exact Mass: 204,10 Exact Mass: 294,15
Molecular Weight: 204,22 Molecular Weight: 294,35
According to a slightly modified procedure by Shin et al. (Journal of Organic
Chemistry.
2000, 65(22), 7667-75), (S)-5-(tert-butoxy)-4-hydroxy-5-oxopentanoic acid (S-
7) (crude
product, 381 mg, 2.28 mmol, 1.00 eq.) was dissolved in 20.7 mL Me0H/H20 (10/1,
v/v). The
solution was stirred during continuous addition of aqueous 10% Na2CO3, which
was
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
57
terminated as soon as a pH value of 7 was reached (1.10 mL of 10% Na2003 in
total). All
solvents were removed in vacuo, and the remaining residue was further dried by
lyophilization, which afforded a slightly yellow solid. For the subsequent
step, the used
glassware was pretreated as described in GP9 (air- and moisture-free
conditions) and also
handling of reactants proceeded by the described methods (GP9). Lyophilized
reactant S-7
was dissolved in 11.4 mL dry DMSO and 5.70 mL thereof (1.14 mmol, 1.00 eq.)
were
transferred into a Schlenk flask. Benzyl bromide (203 pL, 1.71 mmol, 1.50 eq.)
was added
and the reaction mixture was stirred at room temperature for 4.5 h under argon
atmosphere.
Afterwards, the reaction was quenched with H20, the mixture was extracted with
Et20 (3x).
.. The organic phase was washed once with H20, dried over Na2SO4, filtered and
the solvent
removed under reduced pressure. The obtained crude product was purified by
preparative RP-HPLC (20 - 80% B in 20 min, Method C, 5 mL/min). Subsequent
lyophilization afforded 178 mg (53.2%) of pure product 16 as a colorless
solid.
Chemical formula: C16H2205;
.. Molecular weight: 294.35 g/mol;
Exact mass: 294.15 g/mol;
tR-value: 15.7 min (10- 90% B in 15 min, Method A)
Capacity factor k: 9.5
ESI-MS: calculated monoisotopic mass (C16H2205): 294.15;
.. found: ESI (positive ion mode): m/z = 239.1 [M(16)-tBu+H], 262.2 [M(16)-
tBu+Na],
280.2 [M(16)-tBu+MeCN+H], 295.2 [M(16)+H], 317.2 [M(16)+Na], 333.2 [M(16)+K],
358.3 [M(16)+MeCN+Na];
1H-NMR (300 MHz, CDCI3) O(ppm): 7.38 ¨ 7.32 (m, 5H, H(1, 1', 1", 1", 1¨)),
5.13 (s, 2H,
H(2)), 4.09 (dd, 3J = 7.9, 4.1 Hz, 1H, H(3)), 2.87 (s, 1H, H(4)), 2.63 ¨ 2.39
(m, 2H, H(5)), 2.16
(virt. dddd, 1H, H(6)), 1.98 ¨ 1.81 (m, 1H, H(7)), 1.48 (s, 9H, H(8, 8', 8")).
13C-NMR (75 MHz, CDCI3) O(ppm): 174.04 (s, 1C, C(1)), 173.16 (s, 1C, C(2)),
136.06 (s, 1C,
C(3)), 128.69 (s, 2C, C(4, 4')), 128.36 (s, 1C, C(5)), 128.32 (s, 2C, C(6,
6')), 82.96 (s, 1C,
C(7)), 69.73 (s, 1C, C(8)), 66.49 (s, 1C, C(9)), 29.91 (s, 1C, C(10)), 29.63
(s, 1C, C(11)),
28.15 (s, 3C, C(12, 12', 12")).
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
58
5% 869
0 õ.0
2
1
67 72cm-i
_
12' I II
8 0 3 12" 0
rf" H
0
8" 16
5-benzyl 1-(tert-butyl) (S)-2-((1H-imidazole-1-carbonyl)oxy)pentanedioate (S-
14)
101
0 0 0 0 0
A
N N
, 0
+ N
>r
DCM
0 s (DOH r.t., 21.3 h
>r Niz-N
0 Argon 0
16 S-9 S-14
Exact Mass: 294,15 Exact Mass: 162,05 Exact Mass: 388,16
Molecular Weight: 294,35 Molecular Weight: 162,15 Molecular Weight:
388,42
5 Compound S-14 was synthesized in analogy to a previously published
procedure by Yang et
al. (Journal of Medicinal Chemistry. 2016, 59(1), 206-18) with some minor
modifications. 5-
benzyl 1-(tert-butyl) (S)-2-hydroxypentanedioate (16) (71.6 mg, 0.24 mmol,
1.00 eq.) was
dissolved in 4 mL dry DCM and stirred at room temperature. 1,1'-
Carbonyldiimidazole (S-9)
(74.5 mg, 0.46 mmol, 1.92 eq.) was dissolved in 1 mL dry DCM and added to the
solution,
which was stirred under argon atmosphere for 21.3 h at room temperature. The
reaction
mixture was diluted with DCM and washed once with H20 (+ 1 mL brine). The
aqueous
phase was extracted two times with DCM, the combined organic phases were dried
over
Na2SO4, filtered and the solvent evaporated in vacuo. This afforded 112 mg
(>99%) of crude
product as slightly yellowish oil. RP-HPLC/MS control revealed nearly complete
conversion
to product S-14, which was used in the next step without further purification.
Chemical formula: C201-124N206;
Molecular weight: 388.42 g/mol;
Exact mass: 388.16 g/mol;
tR-value: 10.1 min (40 - 100% B in 15 min, Method A)
.. Capacity factor k: 5.7
ESI-MS: calculated monoisotopic mass (C201-124N206): 388.16;
found: ESI (positive ion mode): m/z = 389.2 [M(S-14)+H], 839.5 [M2(S-
14)+MeCN+Na].
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
59
5-benzyl 1-(tert-butyl) (S)-2-((((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-
yl)carbamoyl)oxy)pentanedioate (S-15)
101 ID 0
(s) 0
6..z),..V.õ
, 0
TEA
,
, H DCE
0 0 NH2' HCI 0 C
¨> 40 C, 27 h 0 0
" 45 C, 96 h
0 0
Argon
S-1 S-14 S-15
Exact Mass: 295,16 Exact Mass: 388,16 Exact
Mass: 579,30
Molecular Weight: 295,81 Molecular Weight: 388,42 Molecular Weight:
579,69
Compound 5-15 was synthesized in analogy to a previously published procedure
by
5 Weineisen et al. (EJNMMI Research. 2014, 4(1), 63) with some minor
modifications. 5-
benzyl 1-(tert-butyl) (S)-2-((1H-imidazole-1-carbonyl)oxy)pentanedioate (S-14)
(93.2 mg,
0.24 mmol, 1.00 eq.) was dissolved in 2.50 mL DCE and cooled to 0 C.
H-L-Glu(OtBu)-0tBu*HCI (5-1) (142 mg, 0.48 mmol, 2.00 eq.) and triethylamine
(83.2 pL,
0.60 mmol, 2.50 eq.) were added and stirred for further five minutes at 0 C.
The reaction
10 mixture was warmed to 40 C and stirred for 27 h under argon atmosphere.
As
RP-HPLC/MS analysis revealed very low conversion (7% 5-15, 90.7% S-14), again,
H-L-Glu(OtBu)-0tBu*HCI (5-1) (284 mg, 0.96 mmol, 4.00 eq.) and triethylamine
(166 pL,
1.20 mmol, 5.00 eq.) were added and the temperature was increased to 45 C.
Complete
consumption of educt S-14 was observed after 96 h at 45 C under argon
atmosphere. DCM
15 was added for dilution of the reaction mixture and once washed with H20
(+ 1 mL brine). The
aqueous phase was extracted two times with DCM, the combined organic layers
were dried
over Na2SO4, filtered and the solvent was removed under reduced pressure. The
obtained
crude product was purified by flash chromatography (65 - 98% B in 10 min,
Method D,
12 mL/min), which gave 84.1 mg (60.5%) of compound 5-15 as a colorless viscous
oil.
20 .. Chemical formula: C301-145N010;
Molecular weight: 579.69 g/mol;
Exact mass: 579.30 g/mol;
tR-value: 16.9 min (40 - 100% B in 15 min, Method A)
Capacity factor k: 10.3
25 ESI-MS: calculated monoisotopic mass (C301-145N010): 579.30;
found: ESI (positive ion mode): m/z = 602.1 [M(S-15)+Na], 618.2 [M2(S-15)+K].
(S)-5-(tert-butoxy)-4-((((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2-
yl)carbamoyl)oxy)-5-
oxopentanoic acid (17)
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
6411y (s)
0 0
H2, Pd/C
DCM .====
00 0 0 4h 0 0 0 OH
S-15 17
Exact Mass: 579,30 Exact Mass: 489,26
Molecular Weight: 579,69 Molecular Weight: 489,56
Compound S-15 (84.1mg, 0.15 mmol, 1.00eq.) was dissolved in 6.20 mL DCM and
the
solution was flushed 5 minutes with argon to remove dissolved oxygen. 16.0 mg
of palladium
on carbon (10% wt) (corresponds to 1.60 mg palladium, 15.0 pmol, 0.10 eq.)
were added
5 .. and the flask was sealed with a rubber septum. Remaining air was
displaced with argon and
subsequently replaced by hydrogen gas. The mixture was stirred under hydrogen
atmosphere at room temperature for 24 h. Palladium on carbon was filtered off,
and the
solvent was evaporated in vacuo. This afforded 85.5 mg (>99%) of compound 17
as a
colorless clear oil, which was used in the next step without further
purification.
10 .. Chemical formula: C23H39N010;
Molecular weight: 489.56 g/mol;
Exact mass: 489.26 g/mol;
tR-value: 11.6 min (40- 100% B in 15 min, Method A)
Capacity factor k: 6.7
15 .. ESI-MS: calculated monoisotopic mass (C23H39N010): 489.26;
found: ESI (positive ion mode): m/z = 304.1 [M(17)-3tBu-OH], 322.1 [M(17)-
3tBu+H],
378.2 [M(17)-2tBu+H], 434.2 [M(17)-tBu+H], 490.4 [M(17)+H], 512.3 [M(17)+Na],
528.4 [M(17)+K].
20 .. L-Glu(OtBu)2-(carbonyl)-[(S)-2-oxopentanedioic acid-(D-Orn(Dde)-2-CT)-
0tBu] (S-16)
(S) N y 001,0,k TBTU
HOAt
0 0 0
NH2 DIPEA
T
0 0 0 OH 0 65.3 h 0 0 0 NH
HL
0
0 0 0
17 18 S-16
Exact Mass: 489,26 Exact Mass: 296,17 Exact Mass:
767,42
Molecular Weight: 489,56 Molecular Weight: 296,37 Molecular Weight:
767,91
According to GP2, fragment 17 (73.4 mg, 0.15 mmol, 1.00 eq.) was coupled to
resin bound
H-D-Orn(Dde) (18) with TBTU (110 mg, 0.34 mmol, 2.29 eq.) and HOAt (46.8 mg,
25 .. 0.34 mmol, 2.29 eq.) as coupling reagents and DIPEA (264 pL, 1.55 mmol,
10.3 eq.) as
base. After shaking for 65.3 h at room temperature, formation of product S-16
could be
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
61
confirmed (GP6). Additionally, some resin beads were taken, treated for 20
minutes with 2%
hydrazin/DMF (v/v) and analyzed via RP-HPLC/MS after test cleavage according
to GP7.
Thus, stability of the carbamate moiety towards Dde-removal conditions was
confirmed, as
only one major peak (besides DMF) with the expected m/z-ratio of 604 occurred.
Chemical formula: C381-161N3013, -3tBu: C26H37N3013;
Molecular weight: 767.91 g/mol, -3tBu: 599.59 g/mol;
Exact mass: 767.42 g/mol, -3tBu: 599.23 g/mol;
tR-value (-3tBu): 10.1 min (10 - 90% B in 15 min, Method A)
Capacity factor k (-3tBu): 5.7
ESI-MS: calculated monoisotopic mass (C38H6iN3013): 767.42, -3tBu
(C26H37N3013): 599.23;
found: ESI (positive ion mode): m/z =
600.5 [M(S-16)-3tBu+H],
662.3 [M (S-16)-3tBu+M eCN+ Na]'.
Carbamate 11 (4)
0 0
HO s ENly 4'S))LOH .?.
0 OH 0NH H HO-IS
0 ti
H
0..)-J==,,....."...õ-N.r...,--il--NNN'irrN--)
HI\l C---Nj----,
H
OH 0
4 y 0 0 HO\ j Ho 0
0
Exact Mass: 1399,62 F SI \
Molecular Weight: 1400,55 A
Further reactions on resin-bound compound S-16 were performed according to
standard
Fmoc-SPPS on 2-CT resin, applying the above-mentioned methods (GP2 - GP8). In
brief,
the Dde protective group was removed (GP4) and succinic anhydride (121 mg,
1.20 mmol,
7.00 eq.) was coupled (GP2) over a period of at least 2.5 h, only using DIPEA
(156 pL,
0.92 mmol, 5.33 eq.) and no further coupling reagents. The peptide was
elongated with
Fmoc-D-LysOtBu*HCI (159 mg, 0.34 mmol, 2.00 eq.). Therefore, the resin-bound
acid was
preactivated for five minutes using TBTU (110 mg, 0.34 mmol, 2.00 eq.), HOAt
(46.8 mg,
0.34 mmol, 2.00 eq.) and DIPEA (176 pL, 1.02 mmol, 6.00 eq.). The amino acid
was
dissolved in DMF, added to the preactivated resin and shaken for at least 2.5
h. Fmoc-
removal was conducted (GP3) and Fmoc-D-Dap(Dde)-OH was coupled for at least
2.5 h
using TBTU (110 mg, 0.34 mmol, 2.00 eq.), HOAt (46.8 mg, 0.34 mmol, 2.00 eq.)
and sym-
collidine (160 pL, 1.20 mmol, 7.00 eq.) as coupling reagents. Afterwards, Dde-
removal was
performed according to GP5. The SiFA-BA moiety (73.4 mg, 0.26 mmol, 1.50 eq.)
was
attached using TBTU (110 mg, 0.34 mmol, 2.00 eq.), HOAt (46.8 mg, 0.34 mmol,
2.00 eq.)
and sym-collidine (160 pL, 1.20 mmol, 7.00 eq.) as coupling reagents. After an
incubation
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
62
time of at least 2 h, the Fmoc protective group was removed (GP3) and the DOTA
chelator
moiety was added to the resin. Therefore, DOTA*6 H20 (87.1 mg, 0.17 mmol, 1.00
eq.),
TBTU (45.0 mg, 0.14 mmol, 0.83 eq.), HOAt (19.1 mg, 0.14 mmol, 0.83 eq.) and
sym-
collidine (160 pL, 1.20 mmol, 7.00 eq.) were dissolved in a mixture of
DMF/DMSO (5/1, V/V)
and incubated with the resin-bound amine for 19.5 h. As RP-HPLC/MS analysis
(GP6)
revealed successful coupling, the peptide was cleaved off the resin with
TFA/TIPS/DCM
(95/2.5/2.5, GP8) and purified afterwards by preparative RP-HPLC (35 - 45% B
in 20 min,
Method B, 5 mL/min). Subsequent lyophilization afforded 8.35 mg (3.51% yield)
of pure
product 4 as a colorless powder.
Chemical formula: C601-194FN11024Si;
Molecular weight: 1400.55 g/mol;
Exact mass: 1399.62 g/mol;
tR-value: 13.7 min (10- 90% B in 15 min, Method A)
Capacity factor k: 8.1
.. ESI-MS: calculated monoisotopic mass (C601-194FN11024SO: 1399.62;
found: ESI (positive ion mode): m/z = 701.1 [M(4)+2H]2+, 1400.6 [M(4)+H].
natGa-carbamate II (natGa-4)
0 0
HO s ENIIILOH
0
0 OH 0 NH
H 0 H C) 0 H ql
H
HN
natGa-4 y 6 0 rµµb
Exact Mass: 1466,53 si 0
Molecular Weight: 1468,26 ' X
Carbamate 11 (4) (3.22 mg, 2.30 pmol, 1.00 eq.) was dissolved in 200 pL of
HEPES buffer
(pH = 3) and 260 pL of Ga(NO3)3*6 H20 (2.93 mg, 8.05 pmol, 3.50 eq.) dissolved
in HEPES
buffer was added. The mixture was stirred for 30 min at 75 C and afterwards
filtered
through single use syringe filters (Sartorius Minisart ) to remove Ga(OH)3
precipitate. The
natGa-complex of carbamate II (4) (= natGa-4) was purified by RP-HPLC (20 -
60% B in
15 min, Method A, 1 mL/min) and afforded 0.53 mg (15.7%) of pure product natGa-
4 as a
colorless powder after lyophilization.
Chemical formula: C601-192FGaN11024Si;
Molecular weight: 1468.26 g/mol;
Exact mass: 1466.53 g/mol;
tR-value: 8.46 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 4.6
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
63
ESI-MS: calculated monoisotopic mass (C601-192FGaNii024SO: 1466.53;
found: ESI (positive ion mode): m/z = 734.3 [m(natGa_4)+2H]2+, 1468.2 [M(natGa-
4)+H],
1835.5 [M5(natGa-4)+4H]4, 1957.4 [M4(natGa-4)+3H]3+.
Synthesis of proinhibitors I, II & III Proinhibitor1(5)
Tert-butyl N5-((S)-1-(tert-butoxy)-4-(methylthio)-1-oxobutan-2-yI)-L-
glutaminate (19)
0
>,,c) )NH2
1) COMU
DIPEA
DMF
0 C, 2 h ¨> r.t., 42 h
0 NH
2) 20% piperidine (DMF)
0
HCI = H2N
H 0 r.t., 30 min
0
S-3 S-17 19
Exact Mass: 329,14 Exact Mass: 205,11 Exact Mass: 390,22
Molecular Weight: 329,82 Molecular Weight: 205,32 Molecular Weight:
390,54
Fmoc-L-Glu-OtBu (S-3) (3.00 g, 7.05 mmol, 1.10 eq.) was dissolved in 40.1 mL
DMF and
cooled to 0 C. COMU (3.02 g, 7.05 mmol, 1.10 eq) and DIPEA (5.27 mL, 31.0
mmol,
4.84 eq.) were added to reach a basic pH of 10. H-L-Met-OtBu*HCI (S-17)
(1.55g, 6.41
mmol, 1.00 eq.) was added and the reaction mixture was stirred for further 2 h
at 0 C. The
ice bath was removed and the solution was stirred at room temperature for 42
h. The
reaction was terminated by addition of H20 and diluted with Et20. The aqueous
phase was
extracted three times with Et20 and the combined organic phases were then
washed once
with saturated NaHCO3 and brine. The organic layer was dried over Na2SO4,
filtered and the
solvent was removed under reduced pressure. As RP-HPLC/MS analysis revealed
dipeptide
Fmoc-19 to be the main portion of the crude product, 5 mL of 20% piperidine
(DMF) were
added and stirred for 30 min at room temperature. As the dibenzofulvene-
piperidine by-
product could not be removed sufficiently by preparative RP-HPLC (35 - 60% B
in 20 min,
Method B), it was removed by column chromatography (n-Hex/Et0Ac = 3/2).
Afterwards, the
solvent was changed (DCM/Me0H/acetone = 5/1/1) by which a distinct separation
of product
19 from all remaining by-products was possible. This afforded 287 mg (11.5%)
of pure
product 19 as a clear, yellow oil.
Chemical formula: C18H34.N2055;
Molecular weight: 390.54 g/mol;
Exact mass: 390.22 g/mol;
tR-value: 9.37 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 5.2
Rrvalue: 0.64 (DCM/Me0H/acetone = 5/1/1)
ESI-MS: calculated monoisotopic mass (C18H34N2055): 390.22;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
64
found: ESI (positive ion mode): m/z = 391.5 [M(19)+H], 782.0 [M2(19)+H].
1-Carbonyl imidazole-Glu[D-Orn(Dde)-2-C-1]-0tBu (20)
0 0
H2Ns)-Lo<
Y 0
0 0
,.....
TEA
N./ N N \NN
,OTDc7:::( DCE ^ 0
0 NH
H 0 C-> 40 C, 16 h 0-NH
Argon
0-0 0 0 0
S-9 S-18 20
Exact Mass: 162,05 Exact Mass: 481,28 Exact Mass:
575,30
Molecular Weight: 162,15 Molecular Weight: 481,59 Molecular Weight:
575,66
Compound S-18 was transferred into a round bottom flask, where it was
dissolved in
3.81 mL DCE. At 0 C triethylamine (146 pL, 1.05 mmol,
2.50 eq.) and
1,1'-carbonyldiimidazole (S-9) (68.1 mg, 0.42 mmol, 1.00 eq.) were added and
the mixture
was stirred for further 5 min at 0 C. Afterwards, it was warmed to 40 C and
stirred for 16 h
under argon atmosphere. The resin was washed with DCM (4x) and again dried in
a
desiccator for 30 min. Some resin beads were taken and treated with HFIP/DCM
(1/4)
according to GP7. RP-HPLC/MS analysis revealed nearly complete conversion to
product
20.
Chemical formula: C28F141N508;
Molecular weight: 575.66 g/mol;
Exact mass: 575.30 g/mol;
tR-value: 8.24 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 4.5
ESI-MS: calculated monoisotopic mass (C28H41N508): 575.30;
found: ESI (positive ion mode):
m/z = 452.4 [M(20)-imidazole-tBu+H],
508.5 [M(20)-imidazole], 576.6 [M(20)+H].
L-Glu(L-Met-OtBu)-0tBu-(carbonyl)-L-Glu[D-Orn(Dde)-2-CT]-0tBu (S-19)
0
õ.>.,0 NH 2 L o7
kl
0
T ,
TEA
DCE
0 NH 0 0 NH 0 NH
0 NH 0 C -> 40 C, 16 h
(3) 0
0 Argon
>r,0
19 20 S-19
Exact Mass: 390,22 Exact Mass: 575,30 Exact Mass:
897,48
Molecular Weight 390,54 Molecular Weight 575,66 Molecular Weight
898,12
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
Compound S-19 was synthesized in analogy to a previously published procedure
by
Weineisen et al. (EJNMMI Research. 2014, 4(1), 63) with some minor
modifications. The H-
L-Glu(L-Met-OtBu)-0tBu dipeptide 19 (246 mg, 0.63 mmol, 1.50 eq.) was
dissolved in
3.81 mL DCE and added to compound 20 (0.42 mmol, 1.00 eq.). At 0 C
triethylamine
5 (146 pL, 1.05 mmol, 2.50 eq.) was added and the mixture was stirred for
further five minutes
at 0 C. The solution was warmed to 40 C and stirred for 16 h under argon
atmosphere.
The resin was transferred to a syringe for peptide synthesis (equipped with a
frit, pore size
25 pm) and washed with DCM (4x). Some resin beads were taken according to GP7
and
analyzed via RP-HPLC/MS, which indicated nearly complete conversion to S-19.
10 Chemical formula: C43H71 N50i3S;
Molecular weight: 898.12 g/mol;
Exact mass: 897.48 g/mol;
tR-value: 13.2 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 7.8
15 ESI-MS: calculated monoisotopic mass (C43H7iN5013S): 897.48;
found: ESI (positive ion mode): m/z = 450.2 [M(S-19)+2H]2+, 470.7 [M(S-
19)+MeCN+2H]2+,
899.2 [M(S-19)+H].
Proinhibitor I (5)
0 0
HO s [1 y [1 0 H
0 NH 0NH H H01
0 0 ti
apj....1,
N---------------R-N)LP---r---N N-)
H
OH OH 0
S H HN/
I N .s...)
6 y 0 0 0
HO)rr j Ho 0
Exact Mass: 1529,68 F SI
20 Molecular Weight: 1530,76 X
Further reactions on resin-bound compound S-19 were performed according to
standard
Fmoc-SPPS on 2-CT resin, applying the above-mentioned methods (GP2 - GP8). In
brief,
the Dde protective group was removed (GP4) and succinic anhydride (294 mg, 294
mmol,
7.00 eq.) was coupled (GP2) over a period of at least 2.5 h, only using DIPEA
(500 pL,
25 2.94 mmol, 7.00 eq.) and no further coupling reagents. The peptide was
elongated with
Fmoc-D-Lys-OtBu*HCI (290 mg, 0.63 mmol, 1.50 eq.). Therefore, the resin-bound
acid was
preactivated for five minutes using TBTU (270 mg, 0.84 mmol, 2.00 eq.), HOAt
(114 mg,
0.82 mmol, 2.00 eq.) and DIPEA (629 pL, 3.70 mmol, 8.81 eq.). The amino acid
was
dissolved in DMF, added to the preactivated resin and shaken for at least 2.5
h. Fmoc-
30 removal was conducted (GP3) and Fmoc-D-Dap(Dde)-OH (309 mg, 0.63 mmol,
1.50 eq.)
was coupled for at least 2.5 h using TBTU (270 mg, 0.84 mmol, 2.00 eq.), HOAt
(114 mg,
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
66
0.84 mmol, 2.00 eq.) and sym-collidine (490 pL, 3.70 mmol, 8.81 eq.) as
coupling reagents.
Afterwards, Dde-removal was performed according to GP5. Due to extensive
oxidation and
other side reactions, some test reactions were performed with a minor part
(0.09 mmol) of
the resin for optimization of SiFA-BA and DOTA coupling. Hence, further
reactions were
conducted on the remaining part (0.33 mmol) and all following equivalents
refer to this
amount of substance. The SiFA-BA moiety was attached via the Pfp-ester, which
was
generated previously by preactivation of SiFA-BA (93.1 mg, 0.33 mmol, 1.00
eq.) with
pentafluorophenol (104 pL, 0.99 mmol, 3.00 eq.), DIC (153 pL, 0.99 mmol, 3.00
eq.) and
pyridine (214 pL, 2.64 mmol, 8.00 eq.) in DMF for 1.5 h. The solution was
added to the
resin-bound peptide and incubated for 22 h prior to Fmoc protective group
removal (GP3).
For coupling of the DOTA moiety, DOTA-NHS (276 mg, 0.36 mmol, 1.10 eq.) and
DIPEA
(437 pL, 2.57 mmol, 7.79 eq.) were each dissolved in DMF. First, DIPEA in DMF
was added
to the resin for preactivation. After five minutes, DOTA-NHS in DMF was added
and
incubated with the resin-bound amine for 21 h. An adequate conversion (RP-
HPLC/MS after
GP7) was achieved and the peptide was cleaved off the resin under argon
atmosphere with
TFA/TIPS/DCM/dithiothreitol (95/2.5/2.5/0.5% wt, slightly modified to GP8) (3
x 30 min) and
purified afterwards by preparative RP-HPLC (30 - 60% B in 20 min, Method B and
33 - 40% B in 15 min, Method A). Subsequent lyophilization afforded 0.39 mg
(0.08% yield,
chemical purity 98.0%) of pure product 5 as a colorless powder.
Chemical formula: C65H104FN13024SSi;
Molecular weight: 1530.76 g/mol;
Exact mass: 1529.68 g/mol;
tR-value: 8.62 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 4.7
ESI-MS: calculated monoisotopic mass (C65H104FN13024SSi): 1529.68;
found: ESI (positive ion mode): m/z = 765.8 [M(5)+2H]2+, 1531.5 [M(5)+H].
natLu-proinhibitor I (natLu-5)
0 0
HO s ENlyENoH
2-'
91
o 0
0 NH 0NH HO0 0
r-),:',N
Oy..i..1 0.*'1) ==,,.....".õ-N,r,...--11,-N-N,-,&N.Tri....
µ,,,,,_Di-0
H
OH OH 0 / 0-- - \--- ---------
S HN
natLU-6 y 6 o rµb
Exact Mass: 1701,60 Si 0
Molecular Weight: 1702,70 F X
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
67
50 pL of the precursor (5) (2.00 mM in DMSO, 0.10 pmol, 1.00 eq.) were added
to 30.0 pL of
LuCI3 (20 mM in Tracepur -H20, 60.0 pmol, 6.00 eq.) and 20.0 pL Tracepur -H20.
The
reaction mixture was heated for 30 min at 70 C and afforded natLu-5 in >99%
chemical
purity (>99% yield), determined by RP-HPLC (220 nm). This natLu-5 solution
(now 0.50 mM)
was directly used as stock solution for affinity determination.
Chemical formula: C65H101FLuNi3024.SSi;
Molecular weight: 1702.70 g/mol;
Exact mass: 1701.60 g/mol;
tR-value: 8.62 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 4.7
ESI-MS: calculated monoisotopic mass (C65H101FLuNi3024SSi): 1701.60;
found: ESI (positive ion mode): m/z = 851.3 [M(natLu-5)+2H]2+, 1701.8 [M(natLu-
5)+H].
[177Lu]Lu-proinhibitor I ([177Lu]Lu-5)
0 0
HONyNOH
H H
o
0NH 0NH 0 C) 0 H
o
01 H OH 0
HN N
177Lu-6 y=
o
r/I-nbn
Exact Mass: 1703,60
Molecular Weight: 1704,68 F
X
5.00 pL of the precursor (5) (0.20 mM in DMSO, 1.00 nmol, 1.00 eq.) were added
to 10.0 pL
of 1 M Na0Ac buffer (aq.) (pH = 5.5). Subsequently, 14.0 to 35.9 MBq
[177Lu]LuCI3 (As >
3000 GBq/mg, 740 MBq/mL, 0.04 M HCI, ITG, Garching, Germany) were added and
the
mixture was filled up to 100 pL with 0.04 M HCI (in Tracepur -H20). 10.0 pL of
0.1 M sodium
ascorbate (aq.) (in Tracepur -H20) were added and the reaction mixture was
heated for
min at 80 C. After removal of free [177Lu]Lu3+ via HLB cartridge (30 mg),
[177Lu]Lu-5 was
purified by radio-RP-HPLC, which afforded [177Lu]Lu-5 in 44.0 7.6% (n = 4)
isolated RCY
(d.c. to the start of synthesis). Exact apparent A, of products, which were
purified by radio-
RP-HPLC could not be determined as the amount of cold precursor within the
product
25 fraction could only be estimated. In these cases, the amount of
substance was roughly
determined by the percentage of product, determined by radio-RP-HPLC. This
afforded
apparent A, of approximately 4.64 to 14.5 GBq/pmol. RCP as determined by
radio-RP-HPLC and radio-TLC was 89.3 1.9%. Higher RCP could not be achieved,
as right
after purification, quality control revealed up to 13% of oxidized byproduct
again.
Chemical formula: C65H101 F177LuNi3024SSi;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
68
Molecular weight: 1704.68 g/mol;
Exact mass: 1703.60 g/mol;
tR-value: 10.1 min (10- 90% B in 15 min, Method A)
tR-value of co-injected cold standard: 10.0 min (10 - 90% B in 15 min, Method
A)
Capacity factor k: 5.7.
Proinhibitor 11 (6)
(S)-2-((S)-5-(tert-butoxy)-4-(1H-imidazole-1-carboxamido)-5-oxopentanamido)
octanoic acid-[2-CT] (S-21)
0 H
1) Fmoc-removal (GP3) ,s, N
2) Fmoc-L-Glu-OtBu
TBTU, HOAt, DIPEA
3) Fmoc-removal (GP3)
4) COI
TEA 0
0 NH
DCE 0,7
aaremoc
0 C 40 C, 14 h
Argon 0 0
S-20 S-21
Exact Mass 381,19 Exact Mass 438,25
Molecular Weight 381,47 Molecular Weight 438,53
Fmoc-L-2-Aminooctanoic acid was coupled to 2-CTC resin according to GP1.
Further
reactions on compound S-20 (load: 0.72 mmol/g, 0.86 mmol, 1.00 eq.) were
performed
according to standard Fmoc-SPPS on 2-CT resin, applying the above-mentioned
methods
(GP2 & GP3). In brief, the Fmoc protective group was removed (GP3) and Fmoc-L-
Glu-OtBu
(549 mg, 1.29 mmol, 1.50 eq.) was coupled (GP2) over a period of 16 h using
TBTU
(552 mg, 1.72 mmol, 2.00 eq.), HOAt (234 mg, 1.72 mmol, 2.00 eq.) and DIPEA
(658 pL,
3.87 mmol, 4.50 eq.). After removal of the Fmoc protective group (GP3), the
resin was dried
in a desiccator for 30 min and transferred into a round bottom flask, where it
was dissolved
in 7.81 mL DCE. At 0 C, triethylamine (298 pL, 2.15 mmol, 2.50 eq.) and
1,1'-carbonyldiimidazole (154 mg, 0.95 mmol, 1.10 eq.) were added and the
mixture was
stirred for further 5 min at 0 C. Afterwards, it was warmed to 40 C and
stirred for 14 h
under argon atmosphere. The resin was washed with DCM (4x) and again dried in
a
desiccator for 30 min. Some resin beads were taken and treated with TFA
according to GP7.
RP-HPLC/MS revealed nearly complete conversion to product S-21.
Chemical formula: C21H34N406;
Molecular weight: 438.53 g/mol;
Exact mass: 438.25 g/mol;
tR-value: 9.61 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 5.4
ESI-MS: calculated monoisotopic mass (C21H34N406): 438.25;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
69
found: ESI (positive ion mode): m/z = 439.3 [M(S-21)+H], 480.4 [M(S-
21)+MeCN+H].
(6S,10S, 155)-6,10-bis(tert-butoxycarbony1)-15-hexy1-3, 8, 13-trioxo-1-phenyl-
2-oxa-7,9, 14-
triazahexadecan-16-oic acid (S-22)
0 p
11
0 y 1) TEA
0 DCE
0
0 C ¨>40 C, 4.3 h
0 NH Argon 0 NH 0 0
0 (s)
HCI
2) HFIP/DCM
NH2= OH
0 0 0
S-11 S-21 S-22
Exact Mass: 329,14 Exact Mass: 438,25 Exact Mass: 663,37
Molecular Weight 329,82 Molecular Weight 438,53
Molecular Weight 663,81
Compound S-22 was synthesized in analogy to a previously published procedure
by
Weineisen et al. (EJNMMI Research. 2014, 4(1), 63) with some minor
modifications. Resin-
bound S-21 (0.86 mmol, 1.00 eq.) was dissolved in 7.81 mL DCE and cooled to 0
C. H-
L-Glu(OBz1)-0tBu*HCI (S-11) (425 mg, 1.29 mmol, 1.50 eq.) and triethylamine
(298 pL,
2.15 mmol, 2.50 eq.) were added and stirred for further five minutes at 0 C.
The reaction
mixture was warmed to 40 C and stirred for 4.3 h under argon atmosphere. The
resin was
transferred to a syringe for peptide synthesis (equipped with a frit, pore
size 25 pm) and
washed with DCM (4x). Some resin beads were taken according to GP7 and
analyzed via
RP-HPLC, which indicated nearly complete conversion to S-22. The dried resin
was treated
with a mixture of HFIP/DCM (1/4, v/v) at room temperature for 4h in total (4 x
30 min,
2 x 1 h). Thereby, all acid-labile protective groups were retained. The major
portion of
solvent was removed under a stream of nitrogen and the residual crude product
additionally
dried by lyophilization. The resulting yellow oil was used in the next step
without further
purification (81.8 mg, 14.3%).
Chemical formula: C34H53N3010;
Molecular weight: 663.81 g/mol;
Exact mass: 663.37 g/mol;
tR-value: 15.7 min (10- 90% B in 15 min, Method A)
Capacity factor k: 9.5
ESI-MS: calculated monoisotopic mass (C301-145N010): 663.37;
found: ESI (positive ion mode): m/z = 552.4 [M(S-22)-2tBu+H], 608.5 [M(S-22)-
tBu+H],
664.6 [M(S-22)+H].
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
5-benzyl 1-(tert-butyl) (((S)-1-(tert-butoxy)-5-(((S)-1-(tert-butoxy)-1-
oxooctan-2-yl)amino)-1,5-
dioxo-pentan-2-yl)carbamoy1)-L-glutamate (S-23)
0 (s) H H (s) 0 (s) H H (s)
N 2(:) N
0 0 NH 0 0 DCM 0 NH 0 0
n reflux, 46 h
0 (S) Argon 0 (S)
OH >ro
S-22 S-8 S-23
Exact Mass: 663,37 Exact Mass: 200,19 Exact Mass: 719,44
Molecular Weight 663,81 Molecular Weight 200,33 Molecular Weight
719,92
Compound S-23 was synthesized in analogy to a previously published procedure
by
5 Bergmeier et al. (J Org Chem. 1993, 58(9), 2369-76) with some minor
modifications.
Glassware and reagents were handled under air- and moisture-free conditions
(GP9).
Lyophilized educt S-22 (crude product, -81.8 mg, 0.12 mmol, 1.00 eq.) was
dissolved in
2 mL dry DCM and the first portion of 0-tert-butyl-N,N'-diisopropylisourea (S-
8) (40.1 pL,
0.18 mmol, 1.50 eq.) was added. The reaction mixture was stirred under reflux
(-42 C) and
10 argon atmosphere for 22 h. A second portion of S-8 (200 pL, 0.90 mmol,
7.49 eq.) was
added and also DCM, in order to keep the solvent amount constantly between 2
and 3 mL.
After stirring for further 24 h at reflux temperature and under argon
atmosphere, the reaction
was terminated by diluting the suspension with DCM. Solid by-products were
removed by
filtration and the organic layer was washed once with H20. The aqueous phase
was
15 extracted twice with DCM. The combined organic phases were transferred
into a round
bottom flask and the solvent removed under reduced pressure. Purification by
preparative
RP-HPLC (70- 90% B in 20 min, Method C, 5 mL/min) provided 41.4 mg (48%) of
compound S-23 as a colorless solid.
Chemical formula: C38H61N3010;
20 Molecular weight: 719.92 g/mol;
Exact mass: 719.44 g/mol;
tR-value: 19.2 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 11.8
ESI-MS: calculated monoisotopic mass (C38H6iN3010): 719.44;
25 found: ESI (positive ion mode): m/z = 720.6 [M(S-23)+H], 742.6 [M(S-
23)+Na],
758.6 [M (S-23)+ K].
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
71
(5S, 10S, 14S)-10, 14-bis(tert-butoxycarbony1)-5-hexy1-2 ,2-dimethy1-4,7, 12-
trioxo-3-oxa-
6,11,13-triazaheptadecan-17-oic acid (21)
(s) 0 0
.õ1<
y
H2, Pd/C
DCM 8
0 NH (:).0 0 NH 0 OH
0
rst r.t. 24 h 0 rst
401
,r0 ,r0
S-23 21
Exact Mass: 719,44 Exact Mass: 629,39
Molecular Weight 719,92 Molecular Weight 629,79
Compound S-23 (41.4 mg, 57.5 pmol, 1.00 eq.) was dissolved in 6 mL DCM and the
solution
was flushed five minutes with argon to remove dissolved oxygen. 6.12 mg of
palladium on
carbon (10% wt) (corresponds to 0.61 mg palladium, 5.75 pmol, 0.10 eq.) were
added and
the flask was sealed with a rubber septum. Remaining air was displaced with
argon and
subsequently replaced by hydrogen gas. The mixture was stirred under hydrogen
atmosphere at room temperature for 24 h. Palladium on carbon was filtered off,
and the
solvent was evaporated in vacuo. This afforded 35.5 mg (98.1%) of compound 21
as a
colorless clear oil, which was used in the next step without further
purification.
Chemical formula: C31H55N3010;
Molecular weight: 629.79 g/mol;
Exact mass: 629.39 g/mol;
tR-value: 15.8 min (10- 90% B in 15 min, Method A)
Capacity factor k: 9.5
ESI-MS: calculated monoisotopic mass (C31H55N3010): 629.39;
found: ESI (positive ion mode): m/z = 630.5 [M(21)+H], 652.5 [M(21)+Na].
L-Glu(L-2-Aoc-OtBu)-0tBu-(carbonyl)-L-Glu[D-Orn(Dde)-2-CT]-0tBu (S-24)
0 0 0
(s) H H (s)
L
>Lo (s) y 40J< TBTU 0 y 0
HOAt
0
NH2 õ
õ11 sym-collidine
DMF 0
0 NH 0 OH 0 NH 0 NH
rst rst
0 0 0
40 0
,r0
21 18 S-24
Exact Mass: 629,39 Exact Mass: 296,17 Exact Mass:
907,55
Molecular Weight: 629,79 Molecular Weight: 296,37 Molecular Weight:
908,14
According to GP2, fragment 21(35.5 mg, 56.4 pmol, 1.00 eq.) was coupled to
resin-bound
H-D-Orn(Dde) (18) (81.2 pmol 1.44 eq.), with TBTU (36.2 mg, 0.11 mmol, 2.00
eq.) and
HOAt (15.0 mg, 0.11 mmol, 2.00 eq.) as coupling reagents and sym-collidine
(67.7 pL,
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
72
0.51 mmol, 9.00 eq.) as base. After shaking for 23.5 h at room temperature,
formation of
product S-24 could be confirmed (GP7), as only one major peak with the
expected m/z-
ratio of 908.4 occurred.
Chemical formula: C46H77N5013;
Molecular weight: 908.14 g/mol;
Exact mass: 907.55 g/mol;
tR-value: 12.7 min (40 - 95% B in 15 min, Method A)
Capacity factor k: 7.5
ESI-MS: calculated monoisotopic mass (C46H77N5013): 907.55;
found: ESI (positive ion mode): m/z = 454.8 [M(S-24)+2H]2+, 908.4 [M(S-24)+H].
Proinhibitor 11 (6)
H0)52-N-TrN0H
0 0
HO-S
0 NH 0 NH
H o 0
o
OH OH 0
HN'
HO, / Ho 0
6 io 0 r
Exact Mass: 1539,75 F SI \
Molecular Weight: 1540,78 A
Further reactions on resin-bound compound S-24 were performed according to
standard
Fmoc-SPPS on 2-CT resin, applying the above-mentioned methods (GP2 - GP8). In
brief,
the Dde protective group was removed (GP4) and succinic anhydride (56.7 mg,
0.57 mmol,
7.00 eq.) was coupled (GP2) over a period of at least 2.5 h, only using DIPEA
(96.4 pL,
0.57 mmol, 7.00 eq.) and no further coupling reagents. The peptide was
elongated with
Fmoc-D-Lys-OtBu*HCI (74.7 mg, 0.16 mmol, 2.00 eq.). Therefore, the resin-bound
acid was
preactivated for five minutes using TBTU (52.0 mg, 0.16 mmol, 2.00 eq.), HOAt
(22.0 mg,
0.16 mmol, 2.00 eq.) and DIPEA (82.7 pL, 0.49 mmol, 6.00 eq.). The amino acid
was
dissolved in DMF, added to the preactivated resin and shaken for at least 2.5
h. Fmoc-
removal was conducted (GP3) and Fmoc-D-Dap(Dde)-OH (79.5 mg, 0.16 mmol, 2.00
eq.)
was coupled for at least 2.5 h using TBTU (52.0 mg, 0.16 mmol, 2.00 eq.), HOAt
(22.0 mg,
0.16 mmol, 2.00 eq.) and sym-collidine (75.2 pL, 0.57 mmol, 7.00 eq.) as
coupling reagents.
Afterwards, Dde-removal was performed according to GP5. The SiFA-BA moiety
(12.0 mg,
42.5 pmol, 0.53 eq.) was attached using TBTU (52.0 mg, 0.16 mmol, 2.00 eq.),
HOAt
(22.0 mg, 0.16 mmol, 2.00 eq.) and sym-collidine (75.2 pL, 0.57 mmol, 7.00
eq.) as coupling
reagents. After an incubation time of at least 2 h, the Fmoc protective group
was removed
(GP3) and the DOTA chelator moiety was added to the resin. Therefore, DOTA-NHS
(67.8 mg, 89.6 pmol, 1.10 eq.) and DIPEA (118 pL, 8.52 mmol, 7.00 eq.) were
each
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
73
dissolved in DMF. First, DIPEA in DMF was added to the resin for
preactivation. After five
minutes, DOTA-NHS in DMF was added and incubated with the resin-bound amine
for
23.2 h. An adequate conversion (RP-HPLC/MS analysis after GP6) was achieved
and the
peptide was cleaved off the resin with TFA/TIPS/DCM (95/2.5/2.5, GP8) and
purified
afterwards by preparative RP-HPLC (40 - 70% C(A) in 20 min). Subsequent
lyophilization
afforded 20.0 mg (16.0% yield, chemical purity >99%) of pure product 6 as a
colorless
powder.
Chemical formula: C68Hii0FN13024Si;
Molecular weight: 1540.78 g/mol;
Exact mass: 1539.75 g/mol;
tR-value: 9.44 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 5.5
ESI-MS: calculated monoisotopic mass (C68H1i0FN13024SO: 1539.75;
found: ESI (positive ion mode): m/z =
770.5 [M(6)+2H]2+, 1539.9 [M(6)+H],
1924.9 [M5(6)+4H]4.
natLu-proinhibitor II (natLu-6)
0 0
HO s2-. EN'y'N0H 0 -....,. 0
0 NH 0NH H 0 91
H
oy..11...1õ. 0.(!...J,) ==,,.....".õ-N Ir-,...,--11,N "--.''..-----
-------N,11,Uf.- ,,,r\,N.....-,,,,,..D)_-,,
OH OH 0 / 0-- - \--- ---------
\
natLU-6
Exact Mass: 1711,67 FsIX 0
Molecular Weight: 1712,72
100 pL of the precursor (6) (2.00 mM in DMSO, 0.20 pmol, 1.00 eq.) were added
to 60.0 pL
of LuCI3 (20 mM in Tracepur -H20, 1.20 pmol, 6.00 eq.) and 40.0 pL Tracepur -
H20. The
reaction mixture was heated for 30 min at 95 C and afforded natLu-5 in >99%
chemical
purity (>99% yield), determined by RP-HPLC (220 nm). This natLu-6 solution
(now 1.00 mM)
was directly used as stock solution for affinity determination.
Chemical formula: C68H107FLuNi3024Si;
Molecular weight: 1712.72 g/mol;
Exact mass: 1711.67 g/mol;
tR-value: 9.48 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 5.3
ESI-MS: calculated monoisotopic mass (C68H107FLuNi3024SO: 1711.67;
found: ESI (positive ion mode): m/z = 856.4 [M(natLu-6)+2H]2+, 1711.6 [M(natLu-
6)+H].
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
74
[177Lu]Lu-proinhibitor II ([177Lu]Lu-6)
0 0
HO)lH H
ys =N .."(4.'0H
0 0
0NH 0NH 0 C) 0
0
N N N
OH OH 0 .1>i 0
HN
177Lu-6 y o
Exact Mass: 1713,67 F Six 0
Molecular Weight: 1714,70
5.00 pL of the precursor (6) (0.20 mM in DMSO, 1.00 nmol, 1.00 eq.) were added
to 10.0 pL
of 1 M Na0Ac buffer (aq.) (pH = 5.5). Subsequently, 28.0 or 32.5 MBq
[177Lu]LuCI3 (As >
3000 GBq/mg, 740 MBq/mL, 0.04 M HCI, ITG, Garching, Germany) were added and
the
mixture was filled up to 100 pL with 0.04 M HCI (in Tracepur -H20). 10.0 pL of
0.1 M sodium
ascorbate (aq.) (in Tracepur -H20) were added and the reaction mixture was
heated for
25 min at 95 C. Removal of free [177Lu]Lu3+ via HLB cartridge (30 mg) was
required, which
afforded [177Lu]Lu-6 in 81.4 6.9% (n = 2) isolated ROY (d.c. to the start of
synthesis). The
apparent A, were 24.1 and 24.8 GBq/pmol at the end of synthesis. RCP as
determined by
radio-RP-HPLC and radio-TLC was 98.2 0.1%.
Chemical formula: C68H107F177LuNi3024Si;
Molecular weight: 1714.70 g/mol;
Exact mass: 1713.67 g/mol;
tR-value: 11.1 min (10 - 90% B in 15 min, Method A)
tR-value of co-injected cold standard: 11.0 min (10- 90% B in 15 min, Method
A)
Capacity factor k: 6.4.
Proinhibitor III (7)
(S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-5-(tert-butoxy)-5-
oxopentanamido)octanoic acid
(S-25)
1) Fmoc-removal (GP3)
o
2) Cbz-Glu(OtBu)-OH (s)
TBTU, HOAt, DIPEA.. H
HO,Tor_41
O1tFmoc 3) HFIP/DCM
8 "1
00
S-20 S-25
Exact Mass: 381,19 Exact Mass: 478,27
Molecular Weight 381,47 Molecular Weight 478,59
Fmoc-L-2-Aminooctanoic acid was coupled to 2-CTC resin according to GP1.
Further
reactions on compound S-20 (load: 0.59 mmol/g, 0.63 mmol, 1.00 eq., n = 3)
were
performed according to standard Fmoc-SPPS on 2-CT resin, applying the above-
mentioned
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
methods (GP2 & GP3). In brief, the Fmoc protective group was removed (GP3) and
Cbz-L-
Glu(OtBu)-OH (321 mg, 0.95 mmol, 1.50 eq.) was coupled (GP2) over a period of
2 h, using
TBTU (405 mg, 1.26 mmol, 2.00 eq.), HOAt (171 mg, 1.26 mmol, 2.00 eq.) and
DIPEA
(582 pL, 3.42 mmol, 5.43 eq.). Some resin beads were taken and treated with
TFA
5 according to GP6. RP-HPLC/MS analysis revealed nearly complete conversion
to product S-
25. The protected dipeptide was cleaved off the resin by incubation with
HFIP/DCM (1/4) for
4 h in total (4 x 30 min, 2 x 1 h). Flash chromatography purification (40 -
90% B in 10 min,
Method D, 12 mL/min) of the crude product provided 649 mg (72.0%) of compound
S-25 as
a colorless, viscous oil.
10 Chemical formula: C25H38N207;
Molecular weight: 478.59 g/mol;
Exact mass: 478.27 g/mol;
tR-value: 14.8 min (10- 90% B in 15 min, Method A)
Capacity factor k: 8.9
15 ESI-MS: calculated monoisotopic mass (C25H38N207): 478.27;
found: ESI (positive ion mode): m/z = 422.8 [M(S-25)-tBu+H], 478.8 [M(S-
25)+H],
500.7 [M(S-25)+Na], 956.8 [M2(S-25)+H], 978.8 [M2(S-25)+Na], 994.7 [M2(S-
25)+K].
Tert-butyl (S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-5-(tert-butoxy)-5-
20 (S-26)
r 0 >L
_ 0
Hoo = H
kl,[0r0
N DCM
reflux, 46 h
Argon
0 0 0 0
S-25 S-8 S-26
Exact Mass: 478,27 Exact Mass: 200,19 Exact Mass: 534,33
Molecular Weight: 478,59 Molecular Weight: 200,33 Molecular Weight:
534,69
Compound S-26 was synthesized in analogy to a previously published procedure
by
Bergmeier et al. (J Org Chem. 1993, 58(9), 2369-76) with some minor
modifications.
Glassware and reagents were handled under air- and moisture-free conditions
(GP9).
25 Lyophilized educt S-25 (649 mg, 1.36 mmol, 1.00 eq.) was dissolved in 2
mL dry DCM and
the first portion of 0-tert-butyl-N,N'-diisopropylisourea (S-8) (454 pL, 2.04
mmol, 1.50 eq.)
was added. The reaction mixture was stirred under reflux (-42 C) and argon
atmosphere for
22 h. A second portion of S-8 (454 pL, 2.04 mmol, 1.50 eq.) was added and also
DCM, in
order to keep the solvent amount constantly between 2 and 3 mL. After stirring
for further
30 24 h at reflux temperature and under argon atmosphere, the reaction was
terminated by
diluting the suspension with DCM. Solid by-products were removed by filtration
and the
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
76
organic layer washed once with H20. The aqueous phase was extracted twice with
DCM.
The combined organic phases were transferred into a round bottom flask and the
solvent
removed under reduced pressure. Purification by flash chromatography (40 - 90%
B
in 10 min, Method D, 12 mL/min) provided 481 mg (66.2%) of compound S-26 as a
colorless
solid.
Chemical formula: C29H4.6N207;
Molecular weight: 534.69 g/mol;
Exact mass: 534.33 g/mol;
tR-value: 16.7 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 10.1
ESI-MS: calculated monoisotopic mass (C29H46N207): 534.33;
found: ESI (positive ion mode): m/z = 423.0 [M(S-26)-2tBu+H], 479.1 [M(S-26)-
tBu+H],
535.2 [M(S-26)+H], 557.0 [M(S-26)+Na], 579.2 [M(S-26)+K].
Tert-butyl (S)-2-((S)-2-amino-5-(tert-butoxy)-5-oxopentanamido)octanoate (S-
27)
r 0 0
(s) N 0 N " HD2c,mpd,c >ron (s)NH2
1 lof
r t 26 h
0 0 0 0
S-26 S-27
Exact Mass 534,33 Exact Mass 400,29
Molecular Weight 534,69 Molecular Weight 400,56
Compound S-26 (481 mg, 0.89 mmol, 1.00 eq.) was dissolved in 10 mL DCM and the
solution was flushed 5 minutes with argon to remove dissolved oxygen. 94.2 mg
of palladium
on carbon (10% wt) (corresponds to 9.42 mg palladium, 89.0 pmol, 0.10 eq.)
were added
and the flask was sealed with a rubber septum. Remaining air was displaced
with argon and
subsequently replaced by hydrogen gas. The mixture was stirred under hydrogen
atmosphere at room temperature for 26 h. Palladium on carbon was filtered off,
and the
solvent was evaporated in vacuo. This afforded 162 mg (45.3%) of compound S-27
as a
slightly brown viscous oil, which was used in the next step without further
purification.
Chemical formula: C21 H401\1206;
Molecular weight: 400.56 g/mol;
Exact mass: 400.29 g/mol;
tR-value: 7.07 min (40 - 95% B in 15 min, Method A)
Capacity factor k: 3.7
ESI-MS: calculated monoisotopic mass (C21H40N205): 400.29;
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
77
found: ESI (positive ion mode): m/z = 401.0 [M(S-27)+H], 422.9 [M(S-27)+Na],
438.9 [M(S-27)+K], 801.0 [M2(S-27)+H], 822.9 [M2(S-27)+Na].
5-Benzyl 1-(tert-butyl) (1H-imidazole-1-carbony1)-L-glutamate (S-28)
0 0 0 0
0
TEA
A
N N DMAP=
0
DC M
, ,0 r A
>"*.a.'irrgNH2 r.t. 42 h
' HCI yrs.)..N N
Argon H
0 0
S-11 S-9 S-28
Exact Mass: 295,16 Exact Mass: 162,05 Exact Mass: 387,18
Molecular Weight: 295,81 Molecular Weight: 162,15 Molecular Weight:
387,44
5 Compound S-11 (396 mg, 1.20 mmol, 1.00 eq.) was dissolved in 10 mL DOE
and cooled
to 0 C. Triethylamine (416 pL, 3.00 mmol, 2.50 eq.), DMAP on polystyrene
(3.00 mmol/g,
16.0 mg, 48.0 pmol, 0.04 eq.) and 1,1'-carbonyldiimidazole (S-9) (214 mg, 1.32
mmol,
1.10 eq.) were added and the mixture was stirred for further 5 min at 0 C.
Afterwards, it was
warmed to room temperature and stirred for 42 h under argon atmosphere. DMAP
was
10 filtered off and the solution was washed once with saturated NaHCO3,
brine and H20. The
combined organic phases were dried over Na2SO4, filtered and the solvent was
removed
under reduced pressure. The obtained crude product (439 mg, 94.5%) was
analyzed via
RP-HPLC/MS and revealed almost exclusively product S-28, which was used in the
next
step without further purification.
15 Chemical formula: 0201-125N305;
Molecular weight: 387.44 g/mol;
Exact mass: 387.18 g/mol;
tR-value: 10.1 min (10- 90% B in 15 min, Method A)
Capacity factor k: 5.7
20 ESI-MS: calculated monoisotopic mass (C201-125N305): 387.18;
found: ESI (positive ion mode): m/z = 388.2 [M(S-28)+H].
5-Benzyl 1-(tert-butyl) (((S)-5-(tert-butoxy)-1-(((S)-1-(tert-butoxy)-1-
oxooctan-2-yl)amino)-1,5-
dioxopentan-2-yl)carbamoy1)-L-glutamate (S-29)
- 0 õ
N 0 r (s) H HOL (s) NH2
, 0 TEA
DCE T -1 8 0 ...;õ
0 oc _> 40 C, 21 h
Argon
0 0 0 0 0 0 0 0
101
S-27 S-28 S-29
Exact Mass: 400,29 Exact Mass: 387,18 Exact Mass:
719,44
25 Molecular Weight: 400,56 Molecular Weight: 387,44
Molecular Weight: 719,92
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
78
Compound S-29 was synthesized in analogy to a previously published procedure
by
Weineisen et al. (EJNMMI Research. 2014, 4(1), 63) with some minor
modifications. The H-
L-Glu(OtBu)-L-2-Aoc-OtBu dipeptide S-27 (162 mg, 0.40 mmol, 1.10 eq.) was
dissolved in
mL DCE and compound S-28 (141 mg, 0.36 mmol, 1.00 eq.) was added. At 0 C,
5 triethylamine (139 pL, 1.00 mmol, 2.78 eq.) was added and the mixture was
stirred for
further five minutes at 0 C. The solution was warmed to 40 C and stirred for
21 h under
argon atmosphere. The reaction mixture was washed once with H20 and brine. The
combined aqueous phases were extracted once with DCM. The entire organic layer
was
dried over Na2SO4, filtered and the solvent removed in vacuo. Purification of
the crude
10 product by preparative RP-HPLC (45 - 90% B in 20 min, Method B, 5
mL/min) afforded
128 mg (49%) of compound S-29 as a colorless clear viscous oil.
Chemical formula: C38H61N3010;
Molecular weight: 719.92 g/mol;
Exact mass: 719.44 g/mol;
tR-value: 17.5 min (40 - 95% B in 15 min, Method A)
Capacity factor k: 10.7
ESI-MS: calculated monoisotopic mass (C38H6iN3010): 719.44;
found: ESI (positive ion mode): m/z = 720.0 [M(S-29)+H], 742.0 [M(S-
29)+MeCN+H].
(5S,8S,12S)-8-(3-(tert-butoxy)-3-oxopropyI)-12-(tert-butoxycarbony1)-5-hexyl-
2,2-dimethyl-
4,7,10-trioxo-3-oxa-6,9,11-triazapentadecan-15-oic acid (22)
r o W o 0
H H H
H2, Pd/C
crN 1-or _ 0
DCM
r t 23 h
0 0 0 0 0 0 0 OH
S-29 22
Exact Mass 719,44 Exact Mass 629,39
Molecular Weight 719,92 Molecular Weight
629,79
Compound S-29 (128 mg, 0.18 mmol, 1.00 eq.) was dissolved in 6 mL DCM and the
solution
was flushed 5 minutes with argon to remove dissolved oxygen. 19.2 mg of
palladium on
carbon (10% wt) (corresponds to 1.92 mg palladium, 18.0 pmol, 0.10 eq.) were
added and
the flask was sealed with a rubber septum. Remaining air was displaced with
argon and
subsequently replaced by hydrogen gas. The mixture was stirred under hydrogen
atmosphere at room temperature for 23 h. Palladium on carbon was filtered off,
and the
solvent was evaporated in vacuo. This afforded 102 mg (89.9%) of compound 22
as a
colorless solid, which was used in the next step without further purification.
Chemical formula: C31H55N3010;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
79
Molecular weight: 629.79 g/mol;
Exact mass: 629.39 g/mol;
tR-value: 13.1 min (40 - 95% B in 15 min, Method A)
Capacity factor k: 7.7
ESI-MS: calculated monoisotopic mass (C31H55N3010): 629.39;
found: ESI (positive ion mode): m/z = 630.0
[M(22)+H], 651.9 [M(22)+Na],
667.9 [M(22)+K].
L-Glu(L-2-Aoc-OtBu)-0tBu-(carbonyl)-L-Glu[D-Orn(Dde)-2-CT]-0tBu (S-30)
0 0 TBTU 0
HOAt 0 -
0 + racollidine >r crN 0
0 0
0 0 0 NH 1.4 0 0
0 OH
00 0
22 18 S-30
Exact Mass: 629,39 Exact Mass: 296,17 Exact Mass:
907,55
Molecular VVeight: 629,79 Molecular VVeight: 296,37
Molecular VVeight: 908,14
According to GP2, fragment 22 (102 mg, 0.16 mmol, 1.00 eq.) was coupled to
resin-bound
H-D-Orn(Dde) (18) (0.23 mmol 1.44 eq.), with TBTU (104 mg, 0.32 mmol, 2.00
eq.) and
HOAt (44.0 mg, 0.32 mmol, 2.00 eq.) as coupling reagents and sym-collidine
(191 pL,
1.44 mmol, 9.00 eq.) as base. After shaking for 19 h at room temperature,
formation of
product S-30 could be confirmed (GP7), as only one major peak with the
expected m/z-
ratio of 908.0 occurred.
Chemical formula: C46H77N5013;
Molecular weight: 908.14 g/mol;
Exact mass: 907.55 g/mol;
tR-value: 13.7 min (40 - 95% B in 15 min, Method A)
Capacity factor k: 8.1
ESI-MS: calculated monoisotopic mass (C46H77N5013): 907.55;
found: ESI (positive ion mode): m/z = 908.0 [M(S-30)+H], 1814.9 [M2(S-30)+H].
Proinhibitor III (7)
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
HON\ 0
H s Flyc:4)L OH
0 ===;õ. 0
0 OH 0 NH H 0 (:)r 0 ti HOI
OH 0
HOJ
7 101 0 Ho 0
Exact Mass: 1539,75 ,Six_
Molecular Weight: 1540,78
Further reactions on resin-bound compound S-30 (0.23 mmol, 1.00 eq.) were
performed
according to standard Fmoc-SPPS on 2-CT resin, applying the above-mentioned
methods
(GP2 - GP8). In brief, the Dde protective group was removed (GP4) and succinic
anhydride
5 (161 mg, 1.61 mmol, 7.00 eq.) was coupled (GP2) over a period of at least
2.5 h, only using
DIPEA (374 pL, 2.20 mmol, 9.56 eq.) and no further coupling reagents. The
peptide was
elongated with Fmoc-D-LysOtBu*HCI (212 mg, 0.46 mmol, 2.00 eq.). Therefore,
the
resin-bound acid was preactivated for five minutes by using TBTU (148 mg, 0.46
mmol,
2.00 eq.), HOAt (63.0 mg, 0.46 mmol, 2.00 eq.) and DIPEA (335 pL, 1.97 mmol,
8.56 eq.).
10 The amino acid was dissolved in DMF, added to the preactivated resin and
shaken for at
least 2.5 h. Fmoc-removal was conducted (GP3) and Fmoc-D-Dap(Dde)-OH (226 mg,
0.46 mmol, 2.00 eq.) was coupled for at least 2.5 h using TBTU (148 mg, 0.46
mmol,
2.00 eq.), HOAt (63.0 mg, 0.46 mmol, 2.00 eq.) and sym-collidine (213 pL, 1.61
mmol,
7.00 eq.) as coupling reagents. Afterwards, Dde-removal was performed
according to GP5.
15 The SiFA-BA moiety (64.9 mg, 0.23 mmol, 1.00 eq.) was attached using
TBTU (148 mg,
0.46 mmol, 2.00 eq.), HOAt (63.0 mg, 0.46 mmol, 2.00 eq.) and sym-collidine
(213 pL,
1.61 mmol, 7.00 eq.) as coupling reagents and incubation for at least 2 h.
Fmoc protective
group removal (GP3) was performed followed by coupling of the DOTA moiety.
Therefore,
DOTA-NHS (175 mg, 0.23 mmol, 1.00 eq.) and DIPEA (324 pL, 1.91 mmol, 8.28 eq.)
were
20 each dissolved in DMF. First, DIPEA in DMF was added to the resin for
preactivation. After
five minutes, DOTA-NHS in DMF was added and incubated with the resin-bound
amine for
16 h. An adequate conversion (RP-HPLC/MS analysis after GP6) was reached and
the
peptide was cleaved off the resin with TFA/TIPS/DCM (95/2.5/2.5/, GP8) and
purified
afterwards by preparative RP-HPLC (40 - 65% B in 20 min, Method B, 5 mlimin).
25 Subsequent lyophilization afforded 16.6 mg (4.68% yield, chemical purity
>99%) of pure
product 7 as a colorless powder.
Chemical formula: C68Hii0FN13024Si;
Molecular weight: 1540.78 g/mol;
Exact mass: 1539.75 g/mol;
30 tR-value: 9.15 min (10- 90% B in 15 min, Method A)
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
81
Capacity factor k: 5.1
ESI-MS: calculated monoisotopic mass (C68H1i0FN13024SO: 1539.75;
found: ESI (positive ion mode): m/z = 770.5 [M(7)+2H]2+, 1539.9 [M(7)+H].
.. nat. ¨_
LU proinhibitor III (natLu-7)
HON\ 0
H s F'(s)L OH
0 0
gni0 OH (:).-NH 0 (:)e 0
_0
OH 0
HN/ Cr
nat Lu_7 _y 0
Exact Mass: 1711,67 F 0
Molecular Weight: 1712,72
100 pL of the precursor (7) (2.00 mM in DMSO, 0.20 pmol, 1.00 eq.) were added
to 60.0 pL
of LuCI3 (20 mM in Tracepur -H20, 1.20 pmol, 6.00 eq.) and 40.0 pL Tracepur -
H20. The
reaction mixture was heated for 30 min at 95 C and afforded natLu-7 in >99%
chemical
purity (>99% yield), determined by RP-HPLC (220 nm). This natLu-7 solution
(now 1.00 mM)
was directly used as stock solution for affinity determination.
Chemical formula: C68H107FLuNi3024Si;
Molecular weight: 1712.72 g/mol;
Exact mass: 1711.67 g/mol;
.. tR-value: 9.29 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 5.2
ESI-MS: calculated monoisotopic mass (C68H107FLuNi3024SO: 1711.67;
ri¶ mat
found: ESI (positive ion mode): m/z = 856.1 LivR Lu-7)+2H]2+, 1711.1
[mcatak7)+Hr.
[177Lu]Lu-proinhibitor III ([177Lu]Lu-7)
HONA\ 0
H s tlyo 4)1 ad
o
HO 0 0
CYS
0 OH 0 NH 0 0 H
01>..õ;1\11()LN: J=L&N .0
,N-17;q
HN
177Lu-7 soi 0
Exact Mass: 1713,67 ,Sik 0
Molecular Weight: 1714,70
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
82
5.00 pL of the precursor (7) (0.20 mM in DMSO, 1.00 nmol, 1.00 eq.) were added
to 10.0 pL
of 1 M Na0Ac buffer (aq.) (pH = 5.5). Subsequently, 27.4 MBq [177Lu]LuCI3 (As
> 3000
GBq/mg, 740 MBq/mL, 0.04 M HCI, ITG, Garching, Germany) were added and the
mixture
was filled up to 100 pL with 0.04 M HCI (in Tracepur -H20). 10.0 pL of 0.1 M
sodium
ascorbate (aq.) (in Tracepur -H20) were added and the reaction mixture was
heated for
25 min at 95 C. This afforded [177Lu]Lu-7 in >99% (n = 1) isolated ROY (d.c.
to the start of
synthesis). The apparent A, was 27.4 GBq/pmol at the end of synthesis. RCP as
determined by radio-RP-HPLC and radio-TLC was 94.7%.
Chemical formula: C68H107F177LuNi3024Si;
Molecular weight: 1714.70 g/mol;
Exact mass: 1713.67 g/mol;
tR-value: 11.0 min (10 - 90% B in 15 min, Method A)
tR-value of co-injected cold standard: 10.9 min (10 - 90% B in 15 min, Method
A)
Capacity factor k: 6.3.
Synthesis of PSMA-binding motifs with substituents & bioisosteres of the
PI'-y-carboxylic acid 2-Aminoheptanoic acid derivative 8
Tert-butyl (S)-2-aminoheptanoate (23)
0
HO
y
.,...
(s) NH2
(s) NH2
+ >L0.1, HC104 .
r.t., 22 h
S-31 S-32 23
Exact Mass: 145,11 Exact Mass: 116,08 Exact Mass: 201,17
Molecular Weight: 145,20 Molecular Weight: 116,16 Molecular Weight:
201,31
Compound 23 was synthesized in analogy to a previously published procedure by
Hyun et al. (J Am Chem Soc. 2010, 132(48), 17053-5) with some minor
modifications. (S)-2-
Aminoheptanoic acid (S-31) (300 mg, 2.07 mmol, 1.00 eq.) was dissolved in 7.13
mL of
tert-butyl acetate (S-32) and 70% (v/v) perchloric acid (aq.) (384 pL, 4.74
mmol, 2.29 eq.)
was added slowly. The reaction mixture was stirred for 22 h at room
temperature. H20 and
some drops of 0.3 M HCI were added for quenching. The pH value of the aqueous
phase
was adjusted to 9 with 10% (w/v) Na2CO3(aq.) and extracted three times with
DCM. The
combined organic phases were dried over Na2SO4, filtered and the solvent was
removed
under reduced pressure. Purification
by .. column .. chromatography
(DCM/Me0H/acetone = 5/1/1) yielded 446 mg (>99%) of pure product 23 as a
slightly yellow
ViSCOUS oil.
Chemical formula: Ci 1 H23NO2;
Molecular weight: 201.31 g/mol;
Exact mass: 201.17 g/mol;
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
83
tR-value: not detectable at 220/254 nm
Rrvalue: 0.76 (DCM/Me0H/acetone = 5/1/1)
ESI-MS: calculated monoisotopic mass (CiiH23NO2): 201.17;
found: ESI (positive ion mode): m/z = 202.0 [M(23)+H], 243.0 [M(23)+MeCN+H];
1H-NMR (300 MHz, CDCI3) O(ppm): 3.75 (t, 3J = 6.2 Hz, 1H, H(1)), 2.04 (s, 2H,
H(2)), 1.91 ¨
1.70 (m, 2H, H(3)), 1.48 (s, 9H, H(4, 4', 4")), 1.31 (virt. td, 6H, H(5, 6,
7)), 0.93 ¨ 0.78 (m,
3H, H(8)).
13C-NMR (75 MHz, CDCI3) O(ppm): 171.02 (s, 10, 0(1)), 83.45 (s, 10, 0(2)),
54.35 (s, 10,
0(3)), 32.18 (s, 10, 0(4)), 31.41 (s, 10, C(5)), 28.09 (s, 30, 0(6,6', 6")),
24.56 (s, 10, 0(7)),
22.43 (s, 10, 0(8)), 14.03 (s, 10, 0(9)).
6 0
6' I it
j 0.1 2 6" "." **".0"."1't rd IF1u
2
NH2
4
3
7(6
a 2 3
L-2-Aha-OtBu-(carbonyl)-L-Glu[D-Orn(Dde)-2-C-1]-0tBu (S-33)
0
õNõior. 0
0 o
TEA
DCE
0 NH C ->40 C, 16.3 h 6
0NH 0
Argon
04)R) 04)1')
0 0 0 0 0 0
23 20 S-33
Exact Mass: 201,17 Exact Mass: 575,30 Exact Mass:
708,43
Molecular Weight: 201,31 Molecular Weight: 575,66 Molecular
Weight: 708,89
Compound 20 (0.24 mmol, 1.00 eq.) was transferred into a round bottom flask
and dissolved
in 2.50 mL DOE. At 0 C, triethylamine (83.2 pL, 0.60 mmol, 2.50 eq.) and tert-
butyl (S)-2-
aminoheptanoate (23) (60.9 mg, 0.30 mmol, 1.25 eq.) were added and the mixture
was
stirred for further 5 min at 0 C. Afterwards, it was warmed to 40 C and
stirred for 16.3 h
under argon atmosphere. The resin was washed with DCM (4x), some resin beads
were
taken and treated with HFIP/DCM (1/4) according to GP7. RP-HPLC/MS analysis
revealed
nearly complete conversion to product S-33.
Chemical formula: 036H60N4010;
Molecular weight: 708.89 g/mol;
Exact mass: 708.43 g/mol;
tR-value: 14.2 min (10- 90% B in 15 min)
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
84
Capacity factor k: 8.5
ESI-MS: calculated monoisotopic mass (C36H60N4010): 708.43;
found: ESI (positive ion mode): m/z = 709.1 [M(S-33)+H], 731.1 [M(S-33)+Na].
2-Aminoheptanoic acid derivative 8
0 H H 0
Ho-j-NyN=q-)1*-0H
0 0
0NH HO
HN NJ
0 ti
OH 0
8 y o 0
HO)rf Ho 0
Exact Mass: 1396,70 FSIX
Molecular Weight: 1397,64
Further reactions on resin-bound compound S-33 (0.24 mmol, 1.00 eq.) were
performed
according to standard Fmoc-SPPS on 2-CT resin, applying the above-mentioned
methods
(GP2 - GP8). In brief, the Dde protective group was removed (GP4) and succinic
anhydride
.. (170 mg, 1.68 mmol, 7.00 eq.) was coupled (GP2) over a period of at least
2.5 h, only using
DIPEA (286 pL, 1.68 mmol, 7.00 eq.) and no further coupling reagents. The
peptide was
elongated with Fmoc-D-LysOtBu*HCI (221 mg, 0.48 mmol, 2.00 eq.). Therefore,
the
resin-bound acid was preactivated for five minutes using TBTU (154 mg, 0.48
mmol,
2.00 eq.), HOAt (65.3 mg, 0.48 mmol, 2.00 eq.) and DIPEA (245 pL, 1.44 mmol,
6.00 eq.).
.. The amino acid was dissolved in DMF, added to the preactivated resin and
shaken for at
least 2.5 h. Fmoc-removal was conducted (GP3) and Fmoc-D-Dap(Dde)-OH (235 mg,
0.48 mmol, 2.00 eq.) was coupled for at least 2.5 h using TBTU (154 mg, 0.48
mmol,
2.00 eq.), HOAt (65.3 mg, 0.48 mmol, 2.00 eq.) and sym-collidine (223 pL, 1.68
mmol,
7.00 eq.) as coupling reagents. Afterwards, Dde-removal was performed
according to GP5.
.. The SiFA-BA moiety (67.7 mg, 0.24 mmol, 1.00 eq.) was attached using TBTU
(154 mg,
0.48 mmol, 2.00 eq.), HOAt (65.3 mg, 0.48 mmol, 2.00 eq.) and sym-collidine
(223 pL,
1.68 mmol, 7.00 eq.) as coupling reagents and incubation for at least 2 h.
Removal of the
Fmoc protective group (GP3) was followed by coupling of the DOTA moiety.
Therefore,
DOTA-NHS (91.4 mg, 0.12 mmol, 0.50 eq.) and DIPEA (286 pL, 1.68 mmol, 7.00
eq.) were
each dissolved in DMF. First, DIPEA in DMF was added to the resin for
preactivation. After
five minutes, DOTA-NHS in DMF was added and incubated with the resin-bound
amine for
70.5 h. An adequate conversion (RP-HPLC/MS analysis after GP6) was reached and
the
peptide was cleaved off the resin with TFA/TIPS/DCM (95/2.5/2.5, GP8) and
purified
afterwards by preparative RP-HPLC (30 - 80% B in 20 min, Method B, 5 mL/min
and 25 -
.. 70% B in 15 min, Method B, 1 mL/min). Subsequent lyophilization afforded
3.17 mg (0.95%
yield, chemical purity 95.5%) of pure product 8 as a colorless powder.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
Chemical formula: C62H101FN1202iSi;
Molecular weight: 1397.64 g/mol;
Exact mass: 1396.70 g/mol;
tR-value: 11.8 min (10 - 90% B in 15 min, Method A)
5 Capacity factor k: 6.9
ESI-MS: calculated monoisotopic mass (C62H101FN12021SO: 1396.70;
found: ESI (positive ion mode): m/z = 699.4 [M(8)+2H]2+, 1398.9 [M(8)+H].
_
natLu-2-Aminoheptanoic acid derivative 8 (natLu-8)
0 0
HO)jH H
ys NyN4 AOH
/ 0==== NH 0 H 0 H R
nµl
0(1>=,,,/,ENIy)L A&N, r Ni-\õ0
(RT1 i TI 2\1:-7.1n2'L¨_--10
OH 0 / 0-
HN \ \---N õ.1
natLu-8 y 101 0
0
Exact Mass: 1568,61 FSX
10 Molecular Weight: 1569,58
100 pL of the precursor (8) (2.00 mM in DMSO, 0.20 pmol, 1.00 eq.) were added
to 60.0 pL
of LuCI3 (20 mM in Tracepur -H20, 1.20 pmol, 6.00 eq.) and 40.0 pL Tracepur -
H20. The
reaction mixture was heated for 30 min at 95 C and afforded natLu-8 in 94.9%
chemical
purity (>99% yield), determined by RP-HPLC (220 nm). This natLu-8 solution
(now 1.00 mM)
15 was directly used as stock solution for affinity determination.
Chemical formula: C62H98FLuNi202iSi;
Molecular weight: 1569.58 g/mol;
Exact mass: 1568.61 g/mol;
tR-value: 11.7 min (10 - 90% B in 15 min, Method A)
20 Capacity factor k: 6.8
ESI-MS: calculated monoisotopic mass (C62H98FLuNi2021SO: 1568.61;
found: ESI (positive ion mode): m/z = 784.5 [m cat Lu-8)+2H]2+, 1568.0 [mcatLu-
8)+H].
Fury! derivative 9
25 Tert-butyl (S)-2-amino-3-(furan-2-yl)propanoate (24*TFA)
0 0
HO
\ 0 P NH2 TFA
c....r)--
0
>I0 HC104 ,
r.t., 22 h >,-0 P NH2 =
\ 0
S-34 S-32 24*TFA
Exact Mass: 155,06 Exact Mass: 116,08 Exact Mass: 325,14
Molecular Weight: 155,15 Molecular Weight: 116,16 Molecular Weight:
325,28
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
86
Compound 24 was synthesized in analogy to a previously published procedure by
Hyun et al. (J Am Chem Soc. 2010, 132(48), 17053-5) with some minor
modifications. 3-(2-
Fury1)-L-alanine (S-34) (300 mg, 2.93 mmol, 1.00 eq.) was dissolved in 6.65 mL
of tert-butyl
acetate (S-32) and 70% (v/v) perchloric acid (aq.) (359 pL, 4.42 mmol, 2.29
eq.) was added
slowly. The reaction mixture was stirred for 22 h at room temperature. H20 and
some drops
of 0.3 M HCI were added for quenching. The pH value of the aqueous phase was
adjusted to
9 with 10% (w/v) Na2CO3 (aq.) and extracted three times with DCM. The combined
organic
phases were dried over Na2SO4, filtered and the solvent was removed under
reduced
pressure. Purification by column chromatography (DCM/Me0H/acetone = 5/1/1) and
preparative RP-HPLC (30 - 75% B in 20 min, Method B, 9 mL/min) yielded 65.5 mg
(10.4%)
of pure product 24*TFA as a colorless solid.
Chemical formula (w/o TFA): C11H17NO3;
Molecular weight (w/o TFA): 211.26 g/mol;
Exact mass (w/o TFA): 211.12 g/mol;
tR-value: 6.93 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 3.6
Rrvalue: 0.69 (DCM/Me0H/acetone = 5/1/1)
ESI-MS: calculated monoisotopic mass (CiiHi7NO3): 211.12;
found: ESI (positive ion mode): m/z = 212.1 [M(24)+H], 253.1 [M(24)+MeCN+H].
3-(2-Fury1)-L-alanine-OtBu-(carbonyl)- L-Glu[D-Orn(Dde)-2-C-1]-0tBu (S-35)
0 0
TFA N 0,4L, >L0 (s)
0
0 TEA 8
DCE
0 C -> 40 C, 17h -0 0
0 NH õ 0 NH
õ
04,J Argon
0 0 a 0 a 0
24*TFA 20 S-35
Exact Mass 325,14 Exact Mass 575,30 Exact Mass
718,38
Molecular Weight 325,28 Molecular Weight 575,66
Molecular Weight 718,85
Compound 20 (0.29 mmol, 1.45 eq.) was transferred into a round bottom flask
and dissolved
in 8.00 mL DCE. At 0 C, triethylamine (69.8 pL, 0.50 mmol, 2.50 eq.) and
24*TFA (65.5 mg,
0.20 mmol, 1.00 eq.) were added and the mixture was stirred for further 5 min
at 0 C.
Afterwards, it was warmed to 40 C and stirred for 17 h under argon
atmosphere. The resin
was washed with DCM (4x), some resin beads were taken and treated with
HFIP/DCM (1/4)
according to GP7. RP-HPLC/MS analysis revealed nearly complete conversion to
product S-35.
Chemical formula: C36H54N4011;
Molecular weight: 718.85 g/mol;
Exact mass: 718.38 g/mol;
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
87
tR-value: 12.4 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 7.3
ESI-MS: calculated monoisotopic mass (C36H54N4011): 718.38;
found: ESI (positive ion mode): m/z = 718.8 [M(S-35)+H], 740.7 [M(S-35+Nar,
756.8 [M(S-35)+K].
Furyl derivative 9
OHHO
HO s
0 0
\ 0
HO
0NH -S
0
H = H
OH 0
9 y o 0
HO,./ Ho 0
Exact Mass: 1406,64 FSI
Molecular Weight: 1407,59 X
Further reactions on resin-bound compound S-35 (0.29 mmol, 1.00 eq.) were
performed
.. according to standard Fmoc-SPPS on 2-CT resin, applying the above-mentioned
methods
(GP2 - GP8). In brief, the Dde protective group was removed (GP4) and succinic
anhydride
(203 mg, 2.03 mmol, 7.00 eq.) was coupled (GP2) over a period of at least 2.5
h, only using
DIPEA (345 pL, 2.03 mmol, 7.00 eq.) and no further coupling reagents. The
peptide was
elongated with Fmoc-D-Lys-OtBu*HCI (267 mg, 0.58 mmol, 2.00 eq.). Therefore,
the
resin-bound acid was preactivated for five minutes using TBTU (186 mg, 0.58
mmol,
2.00 eq.), HOAt (78.9 mg, 0.58 mmol, 2.00 eq.) and DIPEA (296 pL, 1.74 mmol,
6.00 eq.).
The amino acid was dissolved in DMF, added to the preactivated resin and
shaken for at
least 2.5 h. Fmoc-removal was conducted (GP3) and Fmoc-D-Dap(Dde)-OH (285 mg,
0.58 mmol, 2.00 eq.) was coupled for at least 2.5 h using TBTU (186 mg, 0.58
mmol,
.. 2.00 eq.), HOAt (78.9 mg, 0.58 mmol, 2.00 eq.) and sym-collidine (269 pL,
2.03 mmol,
7.00 eq.) as coupling reagents. Afterwards, Dde-removal was performed
according to GP5.
The SiFA-BA moiety (81.8 mg, 0.29 mmol, 1.00 eq.) was attached using TBTU (186
mg,
0.58 mmol, 2.00 eq.), HOAt (78.9 mg, 0.58 mmol, 2.00 eq.) and sym-collidine
(269 pL,
2.03 mmol, 7.00 eq.) as coupling reagents and incubation for at least 2 h.
Removal of the
Fmoc protective group (GP3) was followed by coupling of the DOTA moiety.
Therefore,
DOTA-NHS (110 mg, 0.15 mmol, 0.50 eq.) and DIPEA (345 pL, 2.03 mmol, 7.00 eq.)
were
each dissolved in DMF. First, DIPEA in DMF was added to the resin for
preactivation. After
five minutes, DOTA-NHS in DMF was added and incubated with the resin-bound
amine for
13 h. An adequate conversion (RP-HPLC/MS analysis after GP6) was reached and
the
peptide was cleaved off the resin with TFA/TIPS/DCM (95/2.5/2.5, GP8) and
purified
afterwards by preparative RP-HPLC (35 - 80% B in 20 min, Method B, 5 mlimin).
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
88
Subsequent lyophilization afforded 8.72 mg (2.14%, yield, chemical purity
>99%) of pure
product 9 as a colorless powder.
Chemical formula: C62H95FN12022Si;
Molecular weight: 1407.59 g/mol;
Exact mass: 1406.64 g/mol;
tR-value: 11.3 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 6.5
ESI-MS: calculated monoisotopic mass (C62H95FN12022SO: 1406.64;
found: ESI (positive ion mode): m/z = 703.8 [M(9)+2H]2+, 1406.6 [M(9)+H].
natLu-Furyl derivative 9 (natLu-9)
0 H H. 0
HO s NyNOH
0 0
\ 0
0NH 0 H 0 qµl
H
r\).L
HN
natLu_9 y = o
Exact Mass: 1578,56 FSI
0
Molecular Weight: 1579,53
100 pL of the precursor (9) (2.00 mM in DMSO, 0.20 pmol, 1.00 eq.) were added
to 60.0 pL
of LuCI3 (20 mM in Tracepur -H20, 1.20 pmol, 6.00 eq.) and 40.0 pL Tracepur -
H20. The
reaction mixture was heated for 30 min at 95 C and afforded natLu-9 in 98.1%
chemical
purity (>99% yield), determined by RP-HPLC (220 nm). This natLu-9 solution
(now 1.00 mM)
was directly used as stock solution for affinity determination.
Chemical formula: C62H92FLuNi2022Si;
Molecular weight: 1579.53 g/mol;
Exact mass: 1578.56 g/mol;
tR-value: 11.2 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 6.5
ESI-MS: calculated monoisotopic mass (C62H92FLuNi2022SO: 1578.56;
found: ESI (positive ion mode): m/z = 789.7 [M(natLu-9)+2H]2+, 1579.3 [M(natLu-
9)+H].
Alkyne derivative 10
(25)-2-Amino-4-pentynoate-OtBu-(carbonyl)-L-Glu[D-Orn(Dde)-2-C-1]-0tBu (S-36)
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
89
NH2 = HCI
/ +
0 TEA
0 0 NH . 0
0
1:01)C._> 40 oc, 20 h ,NH
Argon
0 0 0 o 0 o
25*HCI 20 S-36
Exact Mass: 205,09 Exact Mass: 575,30 Exact Mass:
676,37
Molecular Weight: 205,68 Molecular Weight: 575,66 Molecular
Weight: 676,81
Compound 20 (0.24 mmol, 1.00 eq.) was transferred into a round bottom flask
and dissolved
in 2.18 mL DCE. At 0 C, triethylamine (83.2 pL, 0.60 mmol, 2.50 eq.) and tert-
butyl (2S)-2-
amino-4-pentynoate (25)*HCI (59.6 mg, 0.29 mmol, 1.20 eq.) were added and the
mixture
was stirred for further 5 min at 0 C. Afterwards, it was warmed to 40 C and
stirred for 20 h
under argon atmosphere. The resin was washed with DCM (4x), some resin beads
were
taken and treated with HFIP/DCM (1/4) according to GP7. RP-HPLC/MS analysis
revealed
nearly complete conversion to product S-36.
Chemical formula: C34.H52N4.010;
Molecular weight: 676.81 g/mol;
Exact mass: 676.37 g/mol;
tR-value: 6.05 min (40 - 95% B in 15 min, Method A)
Capacity factor k: 3.0
ESI-MS: calculated monoisotopic mass (C34H52N4010): 676.37;
found: ESI (positive ion mode): m/z = 677.0 [M(S-36)+H], 699.0 [M(S-36)+Na].
Alkyne derivative 10
0 0
y HO
/
/ s NH.õTr.NH OH..t..........11
0 NH 0 HO 0 HO
0 H
H = N H
OH 0 N
HN7 C--.N
10 I ----
HO,J ss--"9
HO
y io 0
s
Exact Mass: 1364,63 F SXi
Molecular Weight: 1365,55
Further reactions on resin-bound compound S-36 (0.24 mmol, 1.00 eq.) were
performed
according to standard Fmoc-SPPS on 2-CT resin, applying the above-mentioned
methods
(GP2 - GP8). In brief, the Dde protective group was removed (GP4) and succinic
anhydride
(170 mg, 1.68 mmol, 7.00 eq.) was coupled (GP2) over a period of at least 2.5
h, only using
DIPEA (286 pL, 1.68 mmol, 7.00 eq.) and no further coupling reagents. The
peptide was
elongated with Fmoc-D-Lys-OtBu*HCI (221 mg, 0.48 mmol, 2.00 eq.). Therefore,
the
resin-bound acid was preactivated for five minutes with TBTU (154 mg, 0.48
mmol,
2.00 eq.), HOAt (65.3 mg, 0.48 mmol, 2.00 eq.) and DIPEA (245 pL, 1.44 mmol,
6.00 eq.).
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
The amino acid was dissolved in DMF, added to the preactivated resin and
shaken for at
least 2.5 h. Fmoc-removal was conducted (GP3) and Fmoc-D-Dap(Dde)-OH (235 mg,
0.48 mmol, 2.00 eq.) was coupled for at least 2.5 h using TBTU (154 mg, 0.48
mmol,
2.00 eq.), HOAt (65.3 mg, 0.48 mmol, 2.00 eq.) and sym-collidine (223 pL, 1.68
mmol,
5 7.00 eq.) as coupling reagents. Afterwards, Dde-removal was performed
according to GP5.
The SiFA-BA moiety (67.7 mg, 0.24 mmol, 1.00 eq.) was attached using TBTU (154
mg,
0.48 mmol, 2.00 eq.), HOAt (65.3 mg, 0.48 mmol, 2.00 eq.) and sym-collidine
(223 pL,
1.68 mmol, 7.00 eq.) as coupling reagents and incubation for at least 2 h.
Removal of the
Fmoc protective group (GP3) was followed by coupling of the DOTA moiety.
Therefore,
10 DOTA-NHS (91.4 mg, 0.12 mmol, 0.50 eq.) and DIPEA (286 pL, 1.68 mmol,
7.00 eq.) were
each dissolved in DMF. First, DIPEA in DMF was added to the resin for
preactivation. After
five minutes, DOTA-NHS in DMF was added and incubated with the resin-bound
amine for
71 h. An adequate conversion (RP-HPLC/MS analysis after GP6) was reached and
the
peptide was cleaved off the resin with TFA/TIPS/DCM (95/2.5/2.5, GP8) and
purified
15 afterwards by preparative RP-HPLC (30 - 80% B in 20 min, Method B, 5
mlimin).
Subsequent lyophilization afforded 10.9 mg (3.33% yield, chemical purity
98.5%) of pure
product 10 as a colorless powder.
Chemical formula: C601-193FN1202iSi;
Molecular weight: 1365.55 g/mol;
20 Exact mass: 1364.63 g/mol;
tR-value: 11.1 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 6.4
ESI-MS: calculated monoisotopic mass (C601-193FN12021SO: 1364.63;
found: ESI (positive ion mode): m/z = 682.7 [M(10)+2H]2+, 1364.4 [M(1 0)+H].
natLu-Alkyne derivative 10 (natLu-10)
0 0
H s ENtlf-ENI..(0..-OH Oy
/ ql
/
0NH H 0 H
HN
natLU-10 y io
Exact Mass: 1536,55 F Six 0
Molecular Weight: 1537,49
100 pL of the precursor (10) (2.00 mM in DMSO, 0.20 pmol, 1.00 eq.) were added
to 60.0 pL
of LuCI3 (20 mM in Tracepur -H20, 1.20 pmol, 6.00 eq.) and 40.0 pL Tracepur -
H20. The
reaction mixture was heated for 30 min at 95 C and afforded natLu-10 in 99.1%
chemical
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
91
purity (>99% yield), determined by RP-HPLC (220 nm). This natLu-10 solution
(now 1.00 mM)
was directly used as stock solution for affinity determination.
Chemical formula: C601-190FLuNi202iSi;
Molecular weight: 1537.49 g/mol;
Exact mass: 1536.55 g/mol;
tR-value: 10.9 min (10- 90% B in 15 min, Method A)
Capacity factor k: 6.3
ESI-MS: calculated monoisotopic mass (C601-190FLuNi2021SO: 1536.55;
found: ESI (positive ion mode): m/z = 769.6 [M(natLu-10)+21-1]2+, 1538.4
[M(natLu-10)+H].
[177Lu]Lu-Alkyne derivative 10 ([177Lu]Lu-10)
0 0
HO s ENtir4OH y
0 7.,.. 0
/ 1
/
0NH 0 H 0 .1.
H
HN
177Lu-10 y = 0 flb
Exact Mass: 1538,55 F Six 0
Molecular Weight: 1539,47
5.00 pL of the precursor (10) (0.20 mM in DMSO, 1.00 nmol, 1.00 eq.) were
added to 10.0
pL of 1 M Na0Ac buffer (aq.) (pH = 5.5). Subsequently, 37.5 to 62.0 MBq
[177Lu]LuCI3 (As >
3000 GBq/mg, 740 MBq/mL, 0.04 M HCI, ITG, Garching, Germany) were added and
the
mixture was filled up to 100 pL with 0.04 M HCI (in Tracepur -H20). 10.0 pL of
0.1 M sodium
ascorbate (aq.) (in Tracepur -H20) were added and the reaction mixture was
heated for
min at 95 C. Occasionally, removal of free [177Lu]Lu3+ via HLB cartridge (30
mg) was
required, which afforded [177Lu]Lu-10 in 70.3 or >99% (n = 3) isolated RCY
(d.c. to the start
20 of synthesis). The apparent A, were 26.3 to 62.0 GBq/pmol at the end of
synthesis. RCP as
determined by radio-RP-HPLC and radio-TLC was 93.6 2.5%.
Chemical formula: C601-190F177LuNi202iSi;
Molecular weight: 1539.47 g/mol;
Exact mass: 1538.55 g/mol;
25 tR-value: 10.3 min (10- 90% B in 15 min, Method A)
tR-value of co-injected cold standard: 10.2 min (10 - 90% B in 15 min, Method
A)
Capacity factor k: 5.9.
Tetrazole derivative 11
Tert-butyl N5-benzyl-N2-((benzyloxy)carbonyI)-L-glutaminate (S-39)
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
92
410
HOTC: HN
_ BOP
H2N TEA
>rani% so 0 C ¨> r.t., 66 h >10r1i.
S-37 S-38 S-39
Exact Mass: 295,16 Exact Mass: 107,07 Exact Mass: 426,22
Molecular Weight: 295,81 Molecular Weight: 107,16 Molecular Weight:
426,51
Compound S-39 was synthesized in analogy to a previously published procedure
by
Kozikowski et al. (Journal of Medicinal Chemistry. 2004, 47(7), 1729-38)
Benzyl amine (S-
38) (305 pL, 2.80 mmol, 1.40 eq.) and BOP (1.06 g, 2.40 mmol, 1.20 eq.) were
added to a
solution of N-Cbz-L-Glu-OtBu (S-37) (675 mg, 2.00 mmol, 1.00 eq.) in 18.0 mL
DMF. The
resulting solution was cooled to 0 C and triethylamine (638 pL, 4.60 mmol,
2.30 eq.) was
added. After stirring for 66 h at room temperature the reaction mixture was
poured into
ice-cold water (100 mL) and extracted four times with Et0Ac. The organic layer
was washed
successively with 1 M HCI, H20, saturated NaHCO3 and brine. The organic phase
was dried
over Na2SO4, filtered and the solvent was removed in vacuo. Purification by
column
chromatography (Et0Ac/n-hexane = 1/1) yielded 876 mg (2.05 mmol, >99%) of
N-Cbz-L-Gln(Bn)-0tBu (S-39) as a colorless solid.
Chemical formula: C24.H30N205;
Molecular weight: 426.51 g/mol;
Exact mass: 426.22 g/mol;
tR-value: n.d.
Capacity factor k: n.d.
Rrvalue: 0.54 (Et0Ac/n-hexane = 1/1)
ESI-MS: n.d.
1H-NMR (400 MHz, CDCI3) O(ppm): 7.38 ¨ 7.26 (m, 10H, H(1, 1', 2,2', 3, 4, 4',
5, 6, 6'), 6.27
(s, 1H, H(7)), 5.56 (d, 3J = 8.1 Hz, 1H, H(8)), 5.08 (s, 2H, H(9)), 4.42
(virt. t, 2H, H(10)), 4.23
(td, 3J = 8.8, 3.8 Hz, 1H, H(11)), 2.26 (virt. ddt, 3H, H(12, 13)), 2.02 ¨
1.86 (m, 1H, H(14)),
1.45 (s, 9H, H(15, 15', 15")).
13C-NMR (101 MHz, CDCI3) O(ppm): 171.92 (s, 1C, C(1)), 171.15 (s, 1C, C(2)),
156.51 (s,
1C, C(3)), 138.37 (s, 1C, C(4)), 136.37 (s, 1C, C(5)), 128.82 (s, 2C, C(6,
6')), 128.65 (s, 2C,
C(7, 7')), 128.33 (s, 1C, C(8)), 128.26 (s, 2C, C(9, 9')), 127.95 (s, 2C,
C(10, 10')), 127.61 (s,
1C, C(11)), 82.68 (s, 1C, C(12)), 67.16 (s, 1C, C(13)), 54.13 (s, 1C, C(14)),
43.84 (s, 1C,
C(15)), 32.72 (s, 1C, C(16)), 29.42 (s, 1C, C(17)), 28.11 (s, 3C, C(18, 18',
18")).
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
93
11_ 10'
1 11
7:zz. A.
15
HN 0
4 41:1 10 1
16
6
HN -0 17 0
7 11
13.14 \ 12
_ 0
15 0 11: 9 1' 2, 18" 0 9 .."8
>e= yo-1 0
15' 0 58 1* 3
1"
2 S-39
Tert-butyl (S)-4-(1-benzy1-1H-tetrazol-5-y1)-2-
(((benzyloxy)carbonyl)amino)butanoate (S-40)
40 PPh3
DIAD N
140=N
HN TMSN3 N N
NaNO2
0 CAN - 0
mAn MeCN 0 0 = - A
II H 1101 oc, r.t., 15 h yr'H
0 0
Argon
S-39 S-40
Exact Mass: 426,22 Exact Mass: 451,22
Molecular Weight: 426,51 Molecular Weight: 451,53
5 Compound S-40 was synthesized in analogy to a previously published
procedure by
Kozikowski et al. (Journal of Medicinal Chemistry. 2004, 47(7), 1729-38)
Diisopropyl
azodicarboxylate (530 pL, 2.70 mmol, 1.35 eq.) was added to a solution of PPh3
(683 mg,
2.60 mmol, 1.30 eq.) and N-Cbz-L-Gln(Bn)-0tBu (S-39) (853 mg, 2.00 mmol, 1.00
eq.) in
10 mL ice-cold, anhydrous MeCN over two minutes. Trimethylsilyl azide (372 pL,
2.80 mmol,
10 1.40 eq.) was added over five minutes, and the solution was allowed to
stir for 15 h at room
temperature. Afterwards, the solution was cooled to 0 C and 726 pL of a 3 M
NaNO2
solution (aq.) (152 mg, 2.20 mmol, 1.10 eq.) was added. The mixture was
allowed to stir for
30 min at room temperature and 3.30 mL of cerium(IV) ammonium nitrate (1.21 g,
2.20 mmol, 1.10 eq.) in H20 was added. The solution was stirred for further 20
min and
subsequently poured into ice-cold H20. The mixture was extracted three times
with DCM
and the combined organic phases were washed once with water, then dried over
Na2SO4,
filtered and the solvent removed in vacuo. Purification by column
chromatography (Et0Ac/n-
hexane = 1/2) yielded 222 mg (24.6%) of product S-40 as a colorless solid.
Chemical formula: C24H29N504;
Molecular weight: 451.53 g/mol;
Exact mass: 451.22 g/mol;
tR-value: 14.5 min (10- 90% B in 15 min, Method A)
Capacity factor k: 8.7
Rrvalue: 0.28 (Et0Ac/n-hexane = 1/2)
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
94
ESI-MS: calculated monoisotopic mass (C9Hi7N502): 451.22;
found: ESI (positive ion mode): m/z = 395.7 [M(S-40)-tBu+H], 451.7 [M(S-
40)+H];
1H-NMR (400 MHz, CDCI3) O(ppm): 7.43 ¨ 7.28 (m, 8H, H(1, 1', 2,2', 3,3',
4,4')), 7.14 (virt.
dd, 2H, H(5, 6)), 5.56 ¨ 5.30 (m, 2H, H(7)), 5.24 ¨4.99 (m, 2H, H(8)), 4.26
(td, 3J = 8.2,
4.4 Hz, 1H, H(9)), 2.75 (virt. tq, 2H, H(10)), 2.34 (virt. dq, 1H, H(11)),
2.01 (virt. dddd, 1H,
H(12)), 1.42 (s, 9H, H(13, 13', 13")).
13C-NMR (101 MHz, CDCI3) O(ppm): 170.51 (s, 10, 0(1)), 156.19 (s, 10, 0(2)),
154.26 (s,
10, 0(3)), 136.31 (s, 10, 0(4)), 133.33 (s, 10, C(5)), 129.40 (s, 20,
0(6,6')), 129.11 (s, 10,
0(7)), 128.73 (s, 20, 0(8, 8')), 128.45 (s, 10, 0(9)), 128.30 (s, 20, 0(10,
10')), 127.67 (s,
20,0(11, 11')), 83.11 (s, 10,0(12)), 67.23 (s, 10,0(13)), 53.93 (s, 10,
0(14)), 50.90 (s, 10,
0(15)), 30.29 (s, 10, 0(16)), 28.06 (s, 30, 0(17, 17', 17")), 19.98 (s, 10,
0(18)).
.LY N=N
.10 15" 3,
-N
6 grib 2' N_
1 Mil N ,N
18
16 0
2 7
17, 0 14õ2 õAl!
13 o A B 3' 17 0 11 <,--7
4 O
13'>
0 13" 3 5
4 S-40
Tert-butyl (S)-2-amino-4-(1H-tetrazol-5-yl)butanoate (S-41)
NIN1 11 N=N,
HNI,e1
0
0 )( H2, Pd/C
= Me0H
r.t. 24 h >ihrM'NH2
0
S-40 S-41
Exact Mass: 451,22 Exact Mass: 227,14
Molecular Weight: 451,53 Molecular Weight: 227,27
Compound S-40 (120 mg, 0.27 mmol, 1.00 eq.) was dissolved in 15.0 mL Me0H and
the
solution was flushed 5 minutes with argon to remove dissolved oxygen. 12.0 mg
of palladium
on carbon (10% wt) (corresponds to 1.20 mg palladium, 11.3 pmol, 0.04 eq.)
were added
and the flask was sealed with a rubber septum. Remaining air was displaced
with argon and
subsequently replaced by hydrogen gas. The mixture was stirred under hydrogen
atmosphere at room temperature for 23 h. Palladium on carbon was filtered off,
and the
solvent was evaporated in vacuo. This afforded a mixture of product S-41
(minor portion)
and reactant S-40 with free a-amine, still bearing the Bn-protective group at
the tetrazole
moiety (major portion). However, as a certain conversion to product S-41 could
be observed
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
by RP-HPLC/MS analysis and the N-Cbz-protective group was cleaved off
efficiently, the
crude product was used in the next step without further purification.
Chemical formula: C9H17N502;
Molecular weight: 227.27 g/mol;
5 Exact mass: 227.14 g/mol;
tR-value: 4.6 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 2.1
ESI-MS: calculated monoisotopic mass (C9Hi7N502): 227.14;
found: ESI (positive ion mode): m/z = 228.0 [M(S-41)+H], 268.7 [M(S-
41)+MeCN+H].
5-Benzyl 1-(tert-butyl) (((S)-1-(tert-butoxy)-1-oxo-4-(1H-tetrazol-5-yl)butan-
2-y1)carbamoy1)-L-
g I utamate (S-42)
N=e>11, j 0 (s)n ts)
'11 0 TEA
DCE
0
0 C ¨> 40 C, 20h
Argon 0
N 0 0 IHN N 0 0
N=N
40 N=N
S-41 S-28 S-42
Exact Mass 227,14 Exact Mass 387,18 Exact Mass 546,28
Molecular Weight 227,27 Molecular Weight 387,44 Molecular Weight
546,63
Compound S-42 was synthesized in analogy to a previously published procedure
by
Weineisen et al. (EJNMMI Research. 2014, 4(1), 63) with some minor
modifications. Tert-
butyl (S)-2-amino-4-(1H-tetrazol-5-yl)butanoate (S-41) (-100 mg crude product,
-266 pmol,
1.20 eq.) was dissolved in 2.00 mL DCE and compound S-28 (86.0 mg, 222 pmol,
1.00 eq.)
was added. At 0 C, triethylamine (76.9 pL, 555 pmol, 2.50 eq.) was added and
the mixture
was stirred for further five minutes at 0 C. The solution was warmed to 40 C
and stirred for
20 h under argon atmosphere. The solvent was removed in vacuo and the crude
product
was purified via flash chromatography (10 - 90% B in 15 min, Method D, 12
mL/min), which
afforded 39.6 mg (32.7%) of compound S-42 as a colorless solid.
Chemical formula: C26H38N607;
Molecular weight: 546.63 g/mol;
Exact mass: 546.28 g/mol;
tR-value: 11.3 min (30 - 90% B in 15 min, Method A)
Capacity factor k: 6.5
ESI-MS: calculated monoisotopic mass (C26H38N607): 546.28;
found: ESI (positive ion mode): m/z = 490.4 [M(S-42)-tBu+H], 546.7 [M(S-
42)+H],
568.8 [M(S-42)+Na].
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
96
(S)-5-(tert-butoxy)-4-(3-((S)-1-(tert-butoxy)-1-oxo-4-(1H-tetrazol-5-yl)butan-
2-y1)ureido)-5-
oxopentanoic acid (26)
y 0-
H2, Pd/C y 0
Me0H
0 0
r.t. 69.5 h
"====.,
HN 'N 0 0 HN 'N 0 OH
1\1=1\I 1\1=1\I
S-42 26
Exact Mass: 546,28 Exact Mass: 456,23
Molecular Weight: 546,63 Molecular
Weight: 456,50
Compound S-42 (17.0 mg, 31.2 pmol, 1.00 eq.) was dissolved in 6.00 mL Me0H and
the
solution was flushed 5 minutes with argon to remove dissolved oxygen. 3.30 mg
of palladium
on carbon (10% wt) (corresponds to 330 pg palladium, 3.12 pmol, 0.10 eq.) were
added and
the flask was sealed with a rubber septum. Remaining air was displaced with
argon and
subsequently replaced by hydrogen gas. The mixture was stirred under hydrogen
atmosphere at room temperature for 69.5 h. Palladium on carbon was filtered
off, and the
solvent was evaporated in vacuo. This afforded 44.0 mg of crude product as a
colorless oil,
with some minor by-products and remaining reactant S-42. As the main component
could be
identified as product 26 by RP-HPLC/MS analysis, the crude product was used in
the next
step without further purification.
Chemical formula: C19H32N607;
Molecular weight: 456.50 g/mol;
Exact mass: 456.23 g/mol;
tR-value: 8.94 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 5.0
ESI-MS: calculated monoisotopic mass (C19H32N607): 456.23;
found: ESI (positive ion mode): m/z = 345.9 [M(26)-2tBu+H], 456.7 [M(26)+H],
478.7 [M(26)+Na], 912.5 [M2(26)+H], 934.7 [M2(26)+Na], 950.3 [M2(26)+K].
(S)-2-amino-4-(1H-tetrazol-5-yl)butanoic acid-OtBu-(carbonyl)-L-Glu[D-Orn(Dde)-
2-C-1]-
0tBu (S-43)
0 0 1, TBTU 0
H H HOAt >L0 (s) EdyEd&L) 0j< (s)
NyN&L,)
NH2 OJ sym-collidine
HN OH DMF of r.t., 14 h 0
0
0 0.0
HN 0 NH
N=N N=N
0 0
26 18 S-43
Exact Mass: 456,23 Exact Mass: 296,17 Exact Mass:
734,40
Molecular Weight 456,50 Molecular Weight 296,37
Molecular Weight 734,85
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
97
According to GP2, fragment 26 (28.5 mg, -62.4 pmol, 1.00 eq.) was coupled to
resin-bound
H-D-Orn(Dde) (18) (89.0 pmol 1.43 eq.) with TBTU (40.1 mg, 125 pmol, 2.00 eq.)
and HOAt
(17.0 mg, 125 pmol, 2.00 eq.) as coupling reagents and sym-collidine (74.5 pL,
562 pmol,
9.00 eq.) as base. After shaking for 14 h at room temperature, formation of
product S-43
could be confirmed (GP7), as only one major peak with the expected m/z-ratio
of 734.9
occurred.
Chemical formula: C34H54N8010;
Molecular weight: 734.85 g/mol;
Exact mass: 734.40 g/mol;
tR-value: 9.91 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 5.6
ESI-MS: calculated monoisotopic mass (C34H54N8010): 734.40;
found: ESI (positive ion mode): m/z = 734.9 [M(S-43)+H].
Tetrazole derivative 11
0 0
HO s [ly[l'q)LOH
0 ---,. 0
HO/HN N 0 NH H H 0 0 ti
H
OH 0
HN' C---Nj-----,
11 y 101 o 0
HO)rr j Ho 0
Exact Mass: 1422,66 FsIX
Molecular Weight: 1423,59
Further reactions on resin-bound compound S-43 (89.0 pmol, 1.00 eq.) were
performed
according to standard Fmoc-SPPS on 2-CT resin, applying the above-mentioned
methods
(GP2 - GP8). In brief, the Dde protective group was removed (GP4) and succinic
anhydride
(62.3 mg, 0.62 mmol, 7.00 eq.) was coupled (GP2) over a period of at least 2.5
h, only using
DIPEA (106 pL, 0.62 mmol, 7.00 eq.) and no further coupling reagents. The
peptide was
elongated with Fmoc-D-Lys-OtBu*HCI (82.1 mg, 0.18 mmol, 2.00 eq.). Therefore,
the
resin-bound acid was preactivated for five minutes with TBTU (57.2 mg, 0.18
mmol,
2.00 eq.), HOAt (24.2 mg, 0.18 mmol, 2.00 eq.) and DIPEA (91.0 pL, 0.53 mmol,
6.00 eq.).
The amino acid was dissolved in DMF, added to the preactivated resin and
shaken for at
least 2.5 h. Fmoc-removal was conducted (GP3) and Fmoc-D-Dap(Dde)-OH (88.3 mg,
0.18 mmol, 2.00 eq.) was coupled for at least 2.5 h using TBTU (57.2 mg, 0.18
mmol,
2.00 eq.), HOAt (24.2 mg, 0.18 mmol, 2.00 eq.) and sym-collidine (83.5 pL,
0.62 mmol,
7.00 eq.) as coupling reagents. Afterwards, Dde-removal was performed
according to GP5.
The SiFA-BA moiety (25.1 mg, 89.0 pmol, 1.00 eq.) was attached using TBTU
(57.2 mg,
0.18 mmol, 2.00 eq.), HOAt (24.2 mg, 0.18 mmol, 2.00 eq.) and sym-collidine
(83.5 pL,
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
98
0.62 mmol, 7.00 eq.) as coupling reagents and incubation for at least 2 h.
Removal of the
Fmoc protective group (GP3) was followed by coupling of the DOTA moiety.
Therefore,
DOTA-NHS (33.9 mg, 44.5 pmol, 0.50 eq.) and DIPEA (106 pL, 0.62 mmol, 7.00
eq.) were
each dissolved in DMF. First, DIPEA in DMF was added to the resin for
preactivation. After
five minutes, DOTA-NHS in DMF was added and incubated with the resin-bound
amine for
h. As only low conversion (RP-HPLC/MS analysis after GP7) was reached, further
DOTA-
NHS (33.9 mg, 44.5 pmol, 0.50 eq.) and DIPEA (106 pL, 0.62 mmol, 7.00 eq.) was
added
and again incubated for 71 h. Again, no increased conversion could be observed
and hence,
HOAt (24.2 mg, 0.18 mmol, 2.00 eq.) and DIPEA (212 pL, 1.24 mmol, 14.0 eq.)
were added
10 to the reaction mixture. RP-HPLC/MS analysis after 20 h revealed no
further significant
increase of product signal and hence, the peptide was cleaved off the resin
with
TFA/TIPS/DCM (95/2.5/2.5, GP8) and purified afterwards by preparative RP-HPLC
(25 -
80% B in 20 min, Method B, 5 mL/min and 25 - 70% B in 15 min, Method B, 1
mlimin).
Subsequent lyophilization afforded 3.55 mg (2.80% yield, chemical purity >99%)
of pure
15 product 11 as a colorless powder.
Chemical formula: C601-195FN1602iSi;
Molecular weight: 1423.59 g/mol;
Exact mass: 1422.66 g/mol;
tR-value: 10.8 min (10- 90% B in 15 min, Method A)
Capacity factor k: 6.2
ESI-MS: calculated monoisotopic mass (C601-195FN16021SO: 1422.66;
found: ESI (positive ion mode): m/z = 711.6 [M(11)+2H]2+, 1422.5 [M(11)+H].
natLu-Tetrazole derivative 11 (natLu-11)
0 0
HO s ENlyENI..P)..-OH
..i".
0
HN '''N 0 NH H H 0 0 H. qµl
1\1=1\1 Ofi>.=,,..----,N.ir---....)-N----------NAP-Ny"--, Nr)cn:',NI----
OH 0 / 0 -- \ j=, 'N ,-)
HN
natLU-1 1 y I.
o
Exact Mass: 1594,58 FsIX 0
Molecular Weight: 1595,54
100 pL of the precursor (11) (2.00 mM in DMSO, 0.20 pmol, 1.00 eq.) were added
to 60.0 pL
of LuCI3 (20 mM in Tracepur -H20, 1.20 pmol, 6.00 eq.) and 40.0 pL Tracepur -
H20. The
reaction mixture was heated for 30 min at 95 C and afforded 1atLu-11 in 92.9%
chemical
purity (>99% yield), determined by RP-HPLC (220 nm). This natLu-11 solution
(now 1.00 mM)
was directly used as stock solution for affinity determination.
Chemical formula: C601-192FLuNi602iSi;
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
99
Molecular weight: 1595.54 g/mol;
Exact mass: 1594.58 g/mol;
tR-value: 10.6 min (10 - 90% B in 15 min, Method A)
Capacity factor k: 6.1
ESI-MS: calculated monoisotopic mass (C601-192FLuNi6021SO: 1594.58;
found: ESI (positive ion mode): m/z = 797.5 [M(natLu-11)+2H]2+, 816.6 [M(natLu-
11)+K+H]2+,
1595.0 [M(natLu-11)+Hr.
FLuiLu-Tetrazole derivative 11 ([177Lu]Lu-11)
0 H H. 0
Ho)Lys=Nli-N11*-0H
0 0
HN N 0 NH H 0 0 H.
1\1=1\1
OH 0
HN
177LU-11 y = 0
Exact Mass: 1596,58 F Si 0x
Molecular Weight: 1597,51
5.00 pL of the precursor (11) (0.20 mM in DMSO, 1.00 nmol, 1.00 eq.) were
added to 10.0
pL of 1 M Na0Ac buffer (aq.) (pH = 5.5). Subsequently, 42.2 to 63.5 MBq
[177Lu]LuCI3 (As >
3000 GBq/mg, 740 MBq/mL, 0.04 M HCI, ITG, Garching, Germany) were added and
the
mixture was filled up to 100 pL with 0.04 M HCI (in Tracepur -H20). 10.0 pL of
0.1 M sodium
ascorbate (aq.) (in Tracepur -H20) were added and the reaction mixture was
heated for
min at 95 C. This afforded [177Lu]Lu-11 in >99% (n = 4) isolated RCY (d.c. to
the start of
synthesis). The apparent A, ranged from 42.2 to 63.5 GBq/pmol at the end of
synthesis. RCP as determined by radio-RP-HPLC and radio-TLC was 97.2 1.2%.
20 Chemical formula: C601-192F177LuNi602iSi;
Molecular weight: 1597.51 g/mol;
Exact mass: 1596.58 g/mol;
tR-value: 10.0 min (10- 90% B in 15 min, Method A)
tR-value of co-injected cold standard: 9.9 min (10 - 90% B in 15 min, Method
A)
25 Capacity factor k: 5.7.
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
100
Cold complexation and radiolabeling reaction conditions and results
Table 1: Reaction conditions, chemical purity and yield of the investigated
natGa- and
natLu-PSMA ligands.
PSMA inhibitor Reaction Chemical purity Yielda
conditions
natGa-2 75 C, 30 min 93.0%
3.35%
natGa-3 75 C. 30 min 97.2%
26.5%
natLu-3 70 C, 25 min 92.3%
>99%
natGa-4 75 C, 30 min 97.6%
15.7%
natLu-5 70 C, 30 min >99%
>99%
natLu-6 95 C, 25 min >99%
>99%
natLu-7 95 C, 25 min >99%
>99%
nal Lu-8 95 C, 25 min 94.9%
>99%
nal Lu-9 95 C, 25 min 98.1%
>99%
natLu-10 95 C, 25 min 99.1%
>99%
natLu-11 95 C, 25 min 92.9%
>99%
acalculated relative to the uncomplexed precursor. Number of experiments is n
= 1.
Table 2: Reaction conditions, ROY, apparent Am, used activities and RCP of the
investigated
[1771_u]Lu-PSMA ligands.
used
No. of
PSMA Reaction apparent Am
RCYa activities RCP
experi-
inhibitor conditions [GBq/prnol]
[MBq]
ments
70 C, 25 96.9
[1771_u]Lu-3 69.7 18.2% 12.5 - 21.9 22.3
- 62.2 6
min 2.1%
_
80 C, 25 89.3
[1771_u]Lu-5 44.0 7.6% 4.64 - 14.5 14.0
- 35.9 4
min 1.9%
95 C, 98.2 0.1
[1771_u]Lu-6 81.4 6.9% 24.1 & 24.8 28.0
& 32.5 2
25 min %
95 C,
[1771_u]Lu-7 >99% 27.4 27.4 94.7% 1
25 min
95 C, 93.6
[177Lu]Lu-10 70.3 to >99% 26.3 - 62.0 37.5
- 62.0 3
25 min 2.5%
95 C, 97.2
[177Lu]Lu-11 >99% 42.2 - 63.5 42.2
- 63.5 4
25 min 1.2%
adecay corrected to the start of synthesis. Data for isolated RCY and RCP are
expressed as mean SD.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
101
In vitro experiments
Cell culture
PSMA-positive LNCaP cells (300265; Cell Lines Service, Eppelheim, Germany)
were
cultivated in Dulbecco's modified Eagle medium/Nutrition Mixture F-12 with
GlutaMAX (1/1,
.. DMEM-F12, Thermo Fisher Scientific, Darmstadt, Germany) supplemented with
10% fetal
bovine serum (Merck KGaA, Darmstadt, Germany) and kept at 37 C in a
humidified
5% CO2 atmosphere. One day (24 2 h) prior to all in vitro experiments, the
cultivated
LNCaP cells were harvested using a mixture of
trypsin/ethylenediaminetetraacetic acid
(0.05%/0.02%) in phosphate-buffered saline (PBS) (Thermo Fisher Scientific,
Darmstadt,
.. Germany) and centrifuged at 1,300 rpm (ca. 190 x g) for 3 min at room
temperature
(Heraeus Megafuge 16, Thermo Fisher Scientific, Darmstadt, Germany). After
centrifugation,
the supernatant was disposed and the cell pellet was resuspended in culture
medium. Cells
were counted with a Neubauer hemocytometer (Paul Marienfeld GmbH & Co. KG,
Lauda-KOnigshofen, Germany) and seeded in 24-well plates (Greiner Bio-One,
.. Kremsmunster, Austria). ICso values were determined by transferring 1.50 x
105 cells/mL per
well into 24-well plates, whereas internalization was assessed by transferring
1.25 x 105 cells/mL per well into poly-L-lysine (PLL)-coated 24-well plates
(Greiner Bio-One,
Kremsmunster, Austria).
Affinity determinations (ICH)
The culture medium was removed and the cells were washed with 500 pL of Hank's
balanced salt solution (HBSS) (Merck KGaA, Darmstadt, Germany), containing 1%
bovine
serum albumin (BSA) (Merck KGaA, Darmstadt, Germany). Afterwards, 200 pL of
HBSS
(1% BSA) were added to each well and equilibrated on ice (4 C) for 15 min. 25
pL/well of
either HBSS (1% BSA) (= control) or of solutions, containing the respective
unlabeled ligand
in increasing concentrations (10-10- 10-4 M in HBSS) were added, followed by
the addition of
25 pL of ([1251]I-BA)KuE in HBSS (1 %BSA) to each well. Experiments were
carried out in
triplicates for each concentration. The final concentrations of unlabeled
ligand ranged from
10-11- 10-5 M and the final radioligand concentration was 0.2 nM in all
binding assays. The
cells were incubated for one hour at 4 C. Incubation was terminated by
removal of the
incubation medium. The cells were washed with 250 pL of HBSS (1% BSA) and the
wash
medium was combined with the respective supernatant. This fraction represents
the amount
of free radioligand. The cells were lysed by addition of 250 pL of 1 M aqueous
NaOH. The
lysate of each well was transferred to the respective vial as well as 250 pL
of 1 M NaOH
used for rinsing the well. Quantification of the amount of free and bound
activity was
performed in a y-counter. The corresponding ICso values were calculated using
the
GraphPad PRISM7 software.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
102
Binding to PSMA was determined using LNCaP human prostate cancer cells in a
competitive binding assay with natGa or natLu complexes of compounds 2 to 11.
For
comparison, ICso values of natLu-PSMA-10 (natLu-1) (7.2 3.7 nM) were also
determined.
The results show loss of affinity to a varying extent for all modifications
differing from
glutamate at P1' position (Table 3).
Only natLu-3 (carbamate I) and
nati
LU
(tetrazole derivative) still exhibited high affinity (7.1 0.7 nM and 16.4
3.8 nM,
respectively) towards PSMA-expressing LNCaP cells.
Internalization studies
The culture medium was removed and the cells were washed with 500 pL of DMEM-
F12
containing 5% BSA. Afterwards, 200 pL of DMEM-F12 (5% BSA) were added to each
well
and left to equilibrate at 37 C for 15 min. 25 pL of DMEM-F12 (5% BSA) were
added to
each well, followed by the addition of 25 pL of the respective 177Ludabeled
ligand (10.0 nM in
DMEM-F12 (5% BSA)). For blocking PSMA-specific binding and uptake, 25 pL of
2-(phosphonomethyl)pentane-1,5-dioic acid (2-PMPA) (100 pM in DMEM (5% BSA))
instead
of DMEM-F12 (5% BSA) were added prior to radiotracer addition. The same
procedure was
conducted with ([1251]I-BA)KuE (2.0 nM in DMEM-F12 (5% BSA)) which served as
the
reference. Each experiment (control and blockade) was performed in triplicate.
The final
concentration of the 177Ludabeled ligand was 1.0 nM and that of ([1251]I-
BA)KuE was 0.2 nM
in all internalization assays. The cells were incubated for one hour at 37 C.
Incubation was
terminated by placing the plate on ice (4 C, 1 min) and removal of the
incubation medium.
The cells were washed with 250 pL of ice-cold PBS and the wash medium was
combined
with the respective supernatant. This fraction represents the amount of free
radioligand.
250 pL of ice-cold 2-PMPA (10 pM in PBS) were added and the cells were
incubated for
10 min at 4 C. Afterwards, the cells were rinsed again with 250 pL of ice-
cold PBS and the
wash medium was combined with the respective supernatant. This fraction
represents the
amount of cell surface-bound ligand. In the last step, the cells were lysed by
addition of
250 pL of 1 M aqueous NaOH. After 20 min, the lysate of each well was
transferred to the
respective vial as well as 250 pL of 1 M NaOH used for rinsing the well. This
fraction
represents the amount of internalized radioligand. Quantification of the
amount of free, cell
surface-bound and internalized activity was performed in a y-counter. The
corresponding
internalization values were corrected for non-specific binding and normalized
to the specific
binding observed for the reference ([1251]I-BA)KuE.
LNCaP cells were used to investigate internalization of the 177Ludabeled
compounds 1, 3, 5,
6, 7, 10 and 11. No internalization studies were performed on thioureate 2,
carbamate 11(4),
L-2-aminoheptanoic acid derivative 8 and furyl derivative 9, as these
candidates were
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
103
excluded due to poor 1050 data. Normalized to the uptake of ([1251]I-BA)KuE,
the results in
Table 3 show that all modified compounds exhibited significantly lower values
in comparison
to [1771_u]Lu-PSMA-10 ([1771_u]Lu-1) (177 15%). natLu-3 (carbamate I)
displayed an
internalization of 67.8 0.5% compared to ([1251]I-BA)KuE and hence, showed
highest
.. internalization of all modified inhibitor derivatives. For [1771_u]Lu-10
(alkyne) and [1771_u]Lu-11
(tetrazole), both lacking a glutamate moiety at the P1' position, only weak
internalization was
detected (1.2 0.4% and 9.9 3.2% compared to the reference, respectively).
For all
proinhibitor motifs internalization studies were conducted prior to any
affinity determination,
in order to investigate possible substrate cleavage kinetics. Internalization
at 37 C was
determined at several time points of 0.5 h, 1 h, 2 h and 4 h. All in all, no
internalization at any
time point could be detected.
Lipophilicity
In analogy to internalization studies, log D values were determined for
177Ludabeled
.. compounds 1, 3, 5, 6, 7, 10 and 11 (Table 3). Within the proinhibitor
subgroup,
methionine-functionalized derivative 5 displayed the most hydrophilic
character with a log D
value of -2.89 0.18. Moreover, [1771_u]Lu-3 (carbamate I) represents the
most hydrophilic
compound of all examined and modified PSMA inhibitors (log D = -3.40 0.45),
comparable
to [1771_u]Lu-1 (log D = -3.15 0.01).
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
104
Table 3. PSMA-binding affinities (1050), internalization (%) and lipophilicity
(log D) of the
investigated compounds.a
%Internalization
PSMA inhibitor IC50 compared to the log D
referenceb
nalLui[177Lu]Lu-1 2.76 0.51 nM 1 h: 177 15 -3.78
0.01
natGa > 3 pM-2 n.d. n.d.
(n = 2)
natGa-3 21.3 1.7 nM n.d. n.d.
nalLui[177Lu]Lu-3 7.1 0.7 nM 1 h: 67.8 0.5 -3.40
0.45
natGa > 1 pM-4 n.d. n.d.
(n = 2)
0.5 h: 0.00 0.00
1 h: 0.00 0.00
nalLui[177Lu]Lu-5 26 16 pM -2.89
0.18
4 h: 0.01 0.05
0.5 h: 0.00 0.00
1 h: 0.00 0.10
nalLui[177Lu]Lu-6 2.5 1.2 pM -2.52
0.22
4 h: 0.01 0.06
0.5 h: 0.00 0.00
1 h: 0.00 0.00
nalLui[177Lu]Lu-7 6.3 3.6 pM -2.37
0.22
4 h: 0.00 0.00
nalLu-8 > 2 pM
n.d. n.d.
(n = 2)
> 440 nM
nalLu-9 (n = 2) n.d. n.d.
nalLui[177Lu]Lu-10 138 53 nM 1 h: 1.2 0.4 -2.83
0.08
nalLui[177Lu]Lu-11 16.4 3.8 nM 1 h: 9.9 3.2 -2.91
0.05
aBinding assays (IC50) were performed using LNCaP cells (150,000 cells/well)
and ([1251]lBA)KuE (c = 0.2 nM) as radioligand. Cells were incubated in HBSS
(1% BSA) at 4 C for 1 h.
blnternalization values were corrected for unspecific binding and normalized
to the external
reference ([1251]l-BA)KuE (13.0 2.5% internalization at 1 h (n = 21), c= 0.2
nM; 1.0 nM for
177Lu-compounds; 37 C, 1 h, 125,000 cells/well, PLL-coated plates). Data for
binding (IC50)
and internalization are expressed as mean SD (n = 3) unless otherwise
stated. Data are
expressed as mean SD (n = 6) for log D.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
105
In vivo experiments
All animal experiments were conducted in accordance with general animal
welfare
regulations in Germany (German animal protection act, as amended on
18.05.2018, Art. 141
G v. 29.3.2017 1 626, approval no. 55.2-1-54-2532-71-13) and the institutional
guidelines for
the care and use of animals. To establish tumor xenografts, LNCaP cells
(approx. 107 cells)
were suspended in 200 pL of a 1/1 mixture (v/v) of DMEM F-12 and Matrigel (BD
Biosciences, Heidelberg, Germany) and inoculated subcutaneously onto the right
shoulder
of 6 - 8 weeks old CB17-SCID mice (Charles River Laboratories, Sulzfeld,
Germany). Mice
were used for experiments when tumor size reached 5 - 10 mm in diameter (3 - 6
weeks
after inoculation).
Biodistribution
Approximately 2 - 10 MBq (0.20 nmol) of the 177Ludabeled PSMA inhibitors were
injected
into the tail vein of LNCaP tumor xenograft-bearing male CB17-SCID mice (n = 3
to 5). They
were sacrificed by CO2 asphyxiation and cervical dislocation either 1 h or 24
h post injection
(p.i.) (n = 3 for [177Lu]Lu-5, -6 & -7 (proinhibitor compounds 1-111), n = 4
for [177Lu]Lu-10
(alkyne) and n = 5 for [177Lu]Lu-3 (carbamate 1) and n = 5 for [177Lu]Lu-11
(tetrazole)).
Selected organs were removed, weighed and organ activities measured in a y-
counter.
[177Lu]Lu-5, -6 and -7 (proinhibitors 1-111) were evaluated (n = 3) in tumor-
bearing CB-17
SCID mice prior to any affinity measurement. However, in vivo data in general
reflected the
low internalization values for all proinhibitors, with a maximum tumor
accumulation of
0.33 0.11% ID/g for [177Lu]Lu-6 (proinhibitor II) and a minimum tumor
accumulation of
0.09 0.02% ID/g for [177Lu]Lu-5 (proinhibitor 1) as depicted in Figure 6.
Furthermore, non-
target tissue uptake was on the scale of [177Lu]Lu-PSMA-10 ([177Lu]Lu-1) or
even higher.
For further in vivo studies, derivatives with medium to high affinity were
chosen (i.e.
[177Lu]Lu-3, -10 and -11) (Figure 7). For all modified peptides, a distinctly
lower tumor
accumulation (0.10 to 1.20% ID/g) at 24 h p.i. in comparison to the original
[177Lu]Lu-PSMA-
10 compound (9.82 0.33% ID/g) could be observed with unchanging salivary
gland uptake
(Figure 8). Apparently, tumor-to-submandibular gland and tumor-to-parotid
gland ratios
declined by a factor of 8 for [177Lu]Lu-11 (tetrazole) up to a factor of 45
for [177Lu]Lu-10
(alkyne). However, salivary gland uptake in general stayed at an equally low
level for all
EuE- and non-EuE-based inhibitor motifs (between 0.02 0.00% ID/g and 0.09
0.03% ID/g). Residual tumor-to-tissue ratios observed for [177Lu]Lu-3, -10 and
-11 were also
markedly lower than for [177Lu]Lu-PSMA-10 (Figure 8). Tumor-to-tissue ratios
of proinhibitors
were not determined, as uptake in tumor xenografts was very low
0.33 0.11% ID/g)
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
106
(Error! Reference source not found.6), with no significant change in kidney
accumulation
or other non-target tissues.
Tumor uptake for [177Lu]Lu-3 (carbamate I) and -11 (tetrazole) was also
analyzed 1 h p.i. and
compared to [177Lu]Lu-1 (Table 5). At this early time point, tumor
accumulation of [177Lu]Lu-3
was already only about half of the uptake obtained for [177Lu]Lu-1 (5.31
0.94% ID/g for
[177Lu]Lu-3 vs. 12.2 1.8% ID/g for [177Lu]Lu-1). [177Lu]Lu-1 1 showed even
lower tumor
uptake (3.40 0.63% ID/g). Kidney uptake was distinctly lower for both
substances
(61.8 25.9% ID/g for [177Lu]Lu-3 and 33.2 3.8% ID/g for [177Lu]Lu-1 1 vs.
173 56% ID/g
for [177Lu]Lu-1) but activity accumulation in all other non-target tissues
stayed in the same
range. Interestingly, salivary gland uptake of both peptides was found to be
distinctly higher
at 1 h p.i. (between 0.37 0.08% ID/g and 0.62 0.20% ID/g) than at 24 h
p.i. (Table 5 and
6). This resulted in two-fold lower tumor-to-submandibularis and -parotidea
ratios of
[177Lu]Lu-3 and -11 at 1 h p.i. compared to their respective values at 24 h
p.i. (Table 4 and
5).
For visualization of the biodistribution data, maximum intensity projections
(MIPs) of
pSPECT/CT scans in LNCaP xenograft-bearing mice, acquired 24 h p.i. of
[177Lu]Lu-3,
[177Lu]Lu-6, [177Lu]Lu-7, [177Lu]Lu-1 0, [177Lu]Lu-1 1 and [177Lu]Lu-1
([177Lu]Lu-PSMA-1 0) are
depicted in Figure 9. All images were scaled to the same maximum uptake value
(2.5% ID/mL), enabling a clear visual comparison. Arrows indicate apparent
tumor uptake in
[177Lu]Lu-3, [177Lu]Lu-1 1 and [177Lu]Lu-1.
In vivo data of PSMA inhibitors
0
Table 4: Biodistribution of [177Lu]Lu-PSMA-10 ([177Lu]Lu-1) and related
derivatives with modified inhibitor motifs at 24 h p.i. in male LNCaP
tumor xenograft-bearing CB17-SCID mice. Data are expressed as a percentage of
the injected dose per gram (% ID/g), mean standard
deviation (n = 2 for [177Lu]Lu-5*, n = 3 for [177Lu]Lu-6 and [177Lu]Lu-7, n =
4 for [177Lu]Lu-10 and n = 5 for [177Lu]Lu-1, [177Lu]Lu-3 and [177Lu]Lu- 42
11. *Ingestion of radioactively contaminated animal feed led to putative high
activities in stomach and intestine, therefore excluding all values of t,
mouse 3).
[177Lu]Lu-1 ; [177Lu]Lu-3
[177Lu]Lu-5 [177Lu]Lu-6 [177Lu]Lu-7
[177Lu]Lu-10 [177Lu]Lu-11
Organ ,
([177Lu]Lu-PSMA-10) 1 (carbamate I) (proinhibitor I)
(proinhibitor II) (proinhibitor III) (alkyne)
(tetrazole)
Blood 0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.00
Heart 0.02 0.00 0.02 0.01 0.01 0.00
0.03 0.01 0.03 0.01 0.01 0.00 0.02 0.00
P
Lung 0.03 0.00 0.03 0.01 0.33 0.30
0.10 0.08 0.04 0.01 0.03 0.03 0.05 0.02 .
Liver 0.18 0.06 0.13 0.05 0.05 0.00
0.14 0.02 0.17 0.05 0.09 0.04 0.18 0.04 ,..
o
k;
Spleen 0.17 0.03 0.09 0.01 0.05 0.01
0.11 0.03 0.08 0.02 0.04 0.00 0.11 0.03
T
Pancreas 0.01 0.00 0.02 0.01 0.01 0.00
0.03 0.01 0.02 0.00 0.01 0.01 0.02 0.00 .
,
,
Stomach 0.06 0.01 0.06 0.04 0.14 0.07
0.05 0.01 0.04 0.01 0.12 0.11 0.12 0.11 .
Intestine 0.11 0.05 0.12 0.06 0.55 0.04
0.18 0.06 0.10 0.05 0.32 0.29 0.52 0.68
Kidneys 1.97 0.78 0.31 0.05 0.48 0.02
2.36 0.39 2.04 0.75 1.29 0.28 3.23 0.77
Adrenals 0.06 0.04 0.04 0.01 0.00 0.00
0.04 0.00 0.03 0.01 0.02 0.02 0.17 0.19
Muscle 0.00 0.00 0.01 0.01 0.00 0.00
0.02 0.00 0.01 0.00 0.00 0.00 0.02 0.01
od
Bone 0.02 0.01 0.02 0.01 0.00 0.00
0.02 0.01 0.04 0.01 0.03 0.01 0.18 0.04 n
1-i
Tumor 9.82 0.30 1.20 0.55 0.09 0.02
0.33 0.11 0.14 0.05 0.10 0.03 0.68 0.16 m
od
t..)
Submandibular
=
t..)
0.04 0.01 , 0.03 0.01 0.02
0.01 0.07 0.01 0.05 0.02 0.02 0.00 0.04 0.01 t..)
gland ,
O-
u,
=
Parotid gland 0.04 0.01 0.04 0.02 0.02 0.00
0.09 0.03 0.06 0.01 0.02 0.00 0.06 0.02 o
=
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
108
Table 5: Biodistribution of [177Lu]Lu-PSMA-10 ([177Lu]Lu-1) and related
derivatives with
modified inhibitor motifs at 1 h p.i. in male LNCaP tumor xenograft-bearing
CB17-SCID mice.
Data are expressed as a percentage of the injected dose per gram (% !Dig),
mean standard deviation (n = 5 for [177Lu]Lu-1, [177Lu]Lu-3 and [177Lu]Lu-
11).
[177Lu]Lu-1 a [177Lu]Lu-3 [177Lu]Lu-1 1
Organ
([177Lu]Lu-PSMA-10) (carbamate I) (tetrazole)
Blood 0.48 0.15 0.97 0.18
1.09 0.30
Heart 0.42 0.15 0.36 0.04
0.41 0.04
Lung 0.80 0.16 2.88 2.96
1.23 0.27
Liver 0.40 0.13 0.87 0.28
0.74 0.17
Spleen 10.7 2.9 2.51 0.95 1.04 0.15
Pancreas 0.31 0.12 0.25 0.06
0.33 0.11
Stomach 0.26 0.08 0.30 0.09
1.55 1.67
Intestine 0.28 0.10 0.36 0.17
0.67 0.21
Kidneys 173 56 61.8 25.9 33.2 3.8
Adrenals 1.30 0.37 1.46 0.70
0.61 0.42
Muscle 0.36 0.10 0.13 0.04
0.15 0.03
Bone 0.37 0.24 0.18 0.02
0.47 0.44
Tumor 12.2 1.8 5.31 0.94
3.40 0.63
Submandibular 0.37 0.08
n.d. 0.40 0.05
gland
Parotid gland n.d. 0.62 0.20 0.56 0.08
aValues for [177Lu]Lu-PSMA-10 ([177Lu]Lu-1) at 1 h p.i. taken from
W02019/020831.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
109
Table 6: Tumor-to-tissue ratios of [177Lu]Lu-PSMA-10 ([177Lu]Lu-1) and related
derivatives
with modified inhibitor motifs at 24 h p.i. in male LNCaP tumor xenograft-
bearing CB17-SCID
mice. Data are expressed as mean ratios standard deviation (n = 4 for
[177Lu]Lu-10 and
n = 5 for [177Lu]Lu-1, [177Lu]Lu-3 and [177Lu]Lu-11).
[177Lu]Lu-1
Ratio
([177Lu]Lu- [177Lu]Lu-3 [177Lu]Lu-10
[177Lu]Lu-1 1
Tumor-to-
PSMA-10) ' (carbamate I) (alkyne)
(tetrazole)
blood 11498 1953 947 652 26.8 16.9 227 50
kidney 5.66 1.99 3.80 1.36 0.08 0.01 0.22 0.06
muscle 2441 373 127 92 27.7 10.9
55.9 24.3
liver 57.5 13.1 8.94 2.94 1.46 0.88 3.74 0.50
submandibular 275 49 34.5 9.2
6.11 1.78
16.9 2.2
gland
parotid gland 250 64 31.8 9.3 6.38 3.06
12.2 1.7
Table 7: Tumor-to-tissue ratios of [177Lu]Lu-3 (carbamate I) and [177Lu]Lu-11
(tetrazole) at 1 h
pJ in male LNCaP tumor xenograft-bearing CB17-SCID mice. Data are expressed as
mean
ratios standard deviation (n = 5 for [177Lu]Lu-3 and [177Lu]Lu-1 1).
Ratio [177Lu]_u-3 [177Lu]_u-1 1
Tumor-to- (carbamate I) (tetrazole)
blood 5.57 1.18 3.46 1.62
kidney 0.09 0.03 0.10 0.03
muscle 44.1 9.0 24.9 10.2
liver 6.61 2.19 5.00 2.11
submandibular
14.7 3.5 8.74 2.52
gland
parotid gland 9.09 3.13 6.20 1.74
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
110
Metabolite analysis
[177Lu]Lu-11 (9.64 MBq) was injected into the tail vein of a LNCaP tumor
xenograft-bearing
CB17-SCID mouse. The animal was sacrificed 1 h p.i. and subjected to the
standard
procedure for biodistribution studies. In addition, urine was taken from all
mice that were
investigated in this experiment (8.4 - 9.0 MBq) and pooled (n = 5). Relevant
dissected
organs (tumor, kidneys, liver) and body fluids (blood and urine) were
collected, homogenized
if necessary and subjected to mechanochemical as well as solid phase
extraction (SPE).
Four 2 mL LoBind tubes were equipped with steel and ceramic beads from Lysis
Tubes W
(analytikjena, Jena, Germany) for kidneys, tumor and liver (bisected). 1 mL
radioimmunoprecipitation assay (RIPA) buffer containing 2.0 pmol of 2-PM PA
was added to
each tube and the organs were homogenized with a MM-400 ball mill (Retsch
GmbH, Haan,
Germany) at 30 Hz for 20 min. Afterwards, the homogenates were transferred to
LoBind
tubes free from steel and ceramic beads and centrifuged (15,200 rpm, 10 min,
21 C). The
first supernatants were stored, and the precipitates were again subjected to
mechanochemical extraction with 1 mL RIPA buffer (2.0 pmol PMPA) at 30 Hz for
20 min.
After centrifugation (15,200 rpm, 10 min, 21 C), also the second supernatants
were kept for
SPE.
After cardiac puncture, 1 mL Tracepur -H20 was directly added to the collected
blood
sample and centrifuged twice (13,000 rpm, 5 min) to separate the plasma from
the blood
cells. The precipitate was dissolved in 500 pL Tracepur -H20 and together with
the first
supernatant again centrifuged (13,000 rpm, 5 min). Both supernatants were kept
for SPE.
Pooled urine samples were centrifuged (13,000 rpm, 5 min) and the supernatant
was directly
analyzed via radio-RP-HPLC.
For solid phase extraction, the supernatants were loaded onto Strata-X
cartridges (200 mg),
which were preconditioned with 5 mL Me0H and 5 mL H20 (eight cartridges in
total, for all
organ and blood supernatants). The cartridges were washed with 1 mL Tracepur -
H20 and
dried prior to elution. For each cartridge, 750 pL of MeCN/H20 (6/4, 0.1% TFA)
were used
for elution and the extracts were analyzed via radio-RP-HPLC. The extraction
efficiencies
were calculated before and after SPE and the results are given in
Table 8.
Besides biodistribution and pSPECT/CT studies, [177Lu]Lu-11 (tetrazole) was
analyzed
according to its metabolic stability 1 h p.i. Relevant dissected organs
(tumor, kidney, liver)
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
111
and body fluids (blood and urine) were collected, homogenized if necessary and
subjected to
extraction of the incorporated activity. Tissue extracts were analyzed by
radio-RP-HPLC at a
predefined gradient (25 - 40% MeCN (0.1% TFA) in 20 min), for which the
retention time
(18.3 min) of the intact cold standard (natLu-11) was previously determined
and hence,
served as a reference. Only one metabolite with higher hydrophilicity was
detected in tumor
(7.1%), blood (8.5%) and kidney (11.7%), with the maximum percentage of
metabolite
amount found in the urine (18.7%). This metabolite was not detectable in the
liver
homogenate, instead a more lipophilic metabolite was observed at tR = 20.5 min
(28.0%).
The respective radio-RP-HPLC analyses of extracts from homogenized organs and
body
fluids are depicted in Figure 10.
Table 8: Extraction efficiencies of [177Lu]Lu-11 from liver, tumor, kidneys
and blood using a
MM-400 ball mill. The percentage of activity after sample extraction and after
SPE
purification was quantified, decay corrected and the overall extracted
activity was calculated.
Organs and body efficiency [% extracted radioactivity]
fluids
sample extraction SPE purification overall
liver 96.1 67.2 64.5
tumor 97.3 76.1 74.0
kidneys 96.0 74.8 71.8
blood 94.8 78.9 74.8
pSPECT/CT imaging
Imaging experiments were conducted using a MILabs VECTor4 small-animal
SPECT/PET/01/CT.
The resulting data were analyzed by the associated PMOD (version 4.0)
software. Mice were
anaesthetized with isoflurane and the 177Lu-labeled PSMA compounds were
injected via the tail
vein. Mice were euthanized 1 h or 24 h p.i. and blood samples for later
biodistribution or
metabolite analysis were taken by cardiac puncture before image acquisition.
Static images were
acquired with 45 min acquisition time using the HE-GP-RM collimator and a step-
wise
multi-planar bed movement. All images were reconstructed using the MILabs-Rec
software
(version 10.02) and a pixel-based Similarity-Regulated Ordered Subsets
Expectation
Maximization (SROSEM) algorithm with a window-based scatter correction (20%
below and 20%
above the photopeak, respectively). Voxel size CT: 80 pm, voxel size SPECT:
0.8 mm, 1.6 mm
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
112
(FWHM) Gaussian blurring post processing filter, with calibration factor in
kBq/mL and decay
correction, no attenuation correction.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1: Schematic representation of PSMA inhibitors containing (A)
modifications within
the central Zn2+-binding unit (B) proinhibitor motifs (expected cleavage sites
are indicated as
red dotted lines) and (C) substituents & bioisosteres of the P1'-y-carboxylic
acid. All
compounds were derived from the EuE-based ligand PSMA-1O (1) (D) which served
as a
reference for all obtained in vitro and in vivo data. (E) The reference ligand
for 1050
determinations was ([1251]I-BA)KuE.
Figure 2: Detailed structures of the modified PSMA inhibitors, with (A)
thioureate 2,
carbamate I & II (3 & 4) (B) proinhibitors I, II and III (5, 6 & 7) and (C) L-
2-aminoheptanoic
acid (8), furyl (9), alkyne (10) and tetrazole (11) derivatives. All compounds
are depicted in
their free chelator form and represent PSMA ligands containing modifications
within the
central Zn2+-binding unit (A), proinhibitor motifs (B) and substituents &
bioisosteres of the
P1'-y-carboxylic acid (C).
Figure 3: General, simplified synthetic routes for the preparation of
thioureate 2, carbamate I
(3) and carbamate 11 (4). Synthesis of the binding motif of thioureate 2 was
conducted by a
solid phase procedure, whereas binding motifs 15 (carbamate I) and 17
(carbamate II) were
obtained by solution phase synthesis prior to coupling to compound 18.
Figure 4: General, simplified synthetic routes for the preparation of
proinhibitors I, II & III (5,
6 & 7). Synthesis of the binding motif of proinhibitor I (5) was conducted by
a solid phase
procedure, whereas binding motif 21 was obtained by a mixed solid/solution
phase synthesis
prior to coupling to compound 18. Compound 22 (proinhibitor Ill) could only be
obtained by
solution phase synthesis.
Figure 5: General, simplified synthetic routes for the preparation of L-2-aha
(8), furyl (9),
alkyne (10) and tetrazole (11) derivatives. Syntheses of the binding motifs of
compounds 8
(L-2-aha), 9 (furyl) and 10 (alkyne) were conducted by a solid phase
procedure, whereas
binding motif 26 (tetrazole) was obtained by solution phase synthesis prior to
coupling to
compound 18.
CA 03207132 2023-07-04
WO 2022/144467
PCT/EP2022/050090
113
Figure 6: Biodistribution data (% ID/g) of [177Lu]Lu-PSMA-10 ([177Lu]Lu-1),
[177Lu]Lu-5,
[177Lu]Lu-6 and [177Lu]Lu-7 in tumor xenograft-bearing CB17-SCID mice at 24 h
p.i. (n = 2 for
[177Lu]Lu-5*, n = 3 for [177Lu]Lu-6 and [177Lu]Lu-7 and n = 5 for [177Lu]Lu-
PSMA-10
([177Lu]Lu-1)). Submandibular and parotid glands were dissected separately and
their values
are depicted in the columns ,GL. SUBMAND.` and ,GL. PAROTIDEAr, respectively.
*Ingestion of radioactively contaminated animal feed led to putative high
activities in stomach
and intestine, therefore excluding all values of mouse 3.
Figure 7: Biodistribution data (% ID/g) of [177Lu]Lu-PSMA-10 ([177Lu]Lu-1),
[177Lu]Lu-3,
[177Lu]Lu-10 and [177Lu]Lu-11 in tumor xenograft-bearing CB17-SCID mice at 24
h p.i. (n = 4
for [177Lu]Lu-10 and n = 5 for all other experiments). Submandibular and
parotid glands were
dissected separately and their values are depicted in the columns ,GL.
SUBMAND.` and ,GL.
PAROTIDEAr, respectively.
Figure 8: Tumor-to-tissue ratios of [177Lu]Lu-PSMA-10 ([177Lu]Lu-1), [177Lu]Lu-
3, [177Lu]Lu-10
and [177Lu]Lu-11 in selected organs at 24 h p.i. (n = 4 for [177Lu]Lu-10 and n
= 5 for all other
experiments).
Figure 9: Maximum intensity projections (MIPs) of pSPECT/CT scans in LNCaP
xenograft-
bearing mice, acquired 24 h p.i. of (A) [177Lu]Lu-3 (carbamate I) (3.2 MBq)
(B) [177Lu]Lu-6
(proinhibitor II) (5.3 MBq) (C) [177Lu]Lu-7 (proinhibitor III) (4.5 MBq) (D)
[177Lu]Lu-10 (alkyne)
(9.7 MBq) (E) [177Lu]Lu-11 (tetrazole) (7.0 MBq) (F) [177Lu]Lu-PSMA-10 (1)
(2.8 MBq). For
clear comparison, all images were scaled to the same maximum uptake value
(2.5% ID/mL).
Arrows indicate apparent tumor uptake in (A), (E) and (F). No pSPECT/CT image
is
displayed for [177Lu]Lu-5 (proinhibitor l), as ingestion of radioactive animal
feed led to
putative high activities in stomach and intestine. Therefore, all values of
this mouse (=
mouse 3) from the respective biodistribution study and also its pSPECT/CT
image were
excluded. Static images were acquired post mortem (002 asphyxiation and
cervical
dislocation) and after cardiac puncture with an acquisition time of 45 min.
Further
biodistribution studies were performed after the scan and included in the
calculation of
% ID/g values provided by Figure 6 and 7 and Table 4.
Figure 10: Radio-RP-HPLC analyses of extracts from homogenized organs and body
fluids
of tumor xenograft-bearing CB17-SCID mice, 1 h p.i. of [177Lu]Lu-11 (9.64 MBq,
gradient:
25- 40% MeCN (0.1% TFA) in 20 min, flow rate: 1 mL/min). The retention time
(18.3 min) of
the intact cold standard (nat-Lu-11) was previously determined and hence,
served as a
CA 03207132 2023-07-04
WO 2022/144467 PCT/EP2022/050090
114
reference. The radioactivity detector was placed downstream of the UV-detector
causing for
a slight time delay of the radioactivity signals.
